Delaware |
7374 |
88-0950636 | ||
(State or other jurisdiction of incorporation or organization) |
(Primary Standard Industrial Classification Code Number) |
(I.R.S. Employer Identification No.) |
Large accelerated filer |
☐ | Accelerated filer |
☐ | |||
Non-accelerated filer |
☒ | Smaller reporting company |
☒ | |||
Emerging growth company |
☒ |
Page |
||||
6 | ||||
13 | ||||
49 | ||||
51 | ||||
52 | ||||
66 | ||||
75 | ||||
96 | ||||
103 | ||||
127 | ||||
130 | ||||
132 | ||||
138 | ||||
151 | ||||
157 | ||||
160 | ||||
160 | ||||
160 | ||||
161 | ||||
F-1 |
• | our ability to achieve milestones, technological advancements, including with respect to executing on our technology roadmap and developing practical applications; |
• | the potential of quantum computing and estimated market size and market growth; |
• | the success of our partnerships and collaborations; |
• | our ability to accelerate our development of multiple generations of quantum processors; |
• | the outcome of any legal proceedings that may be instituted against us or others with respect to the Business Combination or other matters; |
• | our ability to execute on our business strategy, including monetization of our products; |
• | our financial performance, growth rate and market opportunity; |
• | our ability to maintain the listing of our common stock and public warrants on the Nasdaq Capital Market (“Nasdaq”), and the potential liquidity and trading of such securities; |
• | the risk that the Business Combination disrupts current plans and operations of Rigetti; |
• | the ability to recognize the anticipated benefits of the Business Combination, which may be affected by, among other things, competition, our ability to grow and manage growth profitably, maintain relationships with customers and suppliers and retain our management and key employees; |
• | costs related to the Business Combination and operating as a public company; |
• | changes in applicable laws or regulations; |
• | the possibility that we may be adversely affected by other economic, business, or competitive factors; |
• | our estimates of expenses and profitability; |
• | the evolution of the markets in which we compete; |
• | our ability to implement our strategic initiatives, expansion plans and continue to innovate our existing services; |
• | the expected use of proceeds of the Business Combination; |
• | the sufficiency of our cash resources; |
• | unfavorable conditions in our industry, the global economy or global supply chain (including any supply chain impacts from the conflict involving Russia and Ukraine), including financial and credit market fluctuations; |
• | changes in applicable laws or regulations; |
• | our success in retaining or recruiting, or changes required in, our officers, key employees or directors following the completion of the business combination; |
• | our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; |
• | our ability to expand or maintain our existing customer base; and |
• | the effect of COVID-19 on the foregoing. |
• | We are in our early stages and have a limited operating history, which makes it difficult to forecast our future results of operations. |
• | We have a history of operating losses and expects to incur significant expenses and continuing losses for the foreseeable future. |
• | Even if the market in which we compete achieves the forecasted growth, our business could fail to grow at similar rates, if at all. |
• | We may need additional capital to pursue our business objectives and respond to business opportunities, challenges or unforeseen circumstances, and we cannot be sure that additional financing will be available. |
• | Our ability to use net operating loss carryforwards and other tax attributes may be limited in connection with the Business Combination or other ownership changes. |
• | We have not produced quantum computers with high qubit counts or at volume and faces significant barriers in our attempts to produce quantum computers, including the need to invent and develop new technology. If we cannot successfully overcome those barriers, our business will be negatively impacted and could fail. |
• | Our future generations of hardware developed to demonstrate narrow quantum advantage and broad quantum advantage, and the release of a 1,000+ qubit system and 4,000+ qubit system, each of which is an important milestone for our technical roadmap and commercialization, may not occur on our anticipated timeline or at all. |
• | The quantum computing industry is competitive on a global scale and we may not be successful in competing in this industry or establishing and maintaining confidence in our long-term business prospects among current and future partners and customers. |
• | Our business is currently dependent upon our relationship with our cloud providers. There are no assurances that we will be able to commercialize quantum computers from our relationships with cloud providers. |
• | We rely on access to high performance third party classical computing through public clouds, high performance computing centers and on-premises computing infrastructure to deliver performant quantum solutions to customers. We may not be able to maintain high quality relationships and |
connectivity with these resources which could make it harder for us to reach customers or deliver solutions in a cost-effective manner. |
• | Our system depends on the use of certain development tools, supplies, equipment and production methods. If we are unable to procure the necessary tools, supplies and equipment to build our quantum systems, or are unable to do so on a timely and cost-effective basis, and in sufficient quantities, we may incur significant costs or delays which could negatively affect our operations and business. |
• | Even if we are successful in developing quantum computing systems and executing on our strategy, competitors in the industry may achieve technological breakthroughs which render our quantum computing systems obsolete or inferior to other products. |
• | We may be unable to reduce the cost of developing our quantum computers, which may prevent us from pricing our quantum systems competitively. |
• | The quantum computing industry is in its early stages and volatile, and if it does not develop, if it develops slower than we expect, if it develops in a manner that does not require use of our quantum computing solutions, if we encounter negative publicity or if our solution does not drive commercial engagement, the growth of our business will be harmed. |
• | If our computers fail to achieve quantum advantage, our business, financial condition and future prospects may be harmed. |
• | We could suffer disruptions, outages, defects and other performance and quality problems with our quantum computing systems, our production technology partners or with the public cloud, data centers and internet infrastructure on which we rely. |
• | We have identified a material weakness in our internal control over financial reporting and may identify additional material weaknesses in the future. If we fail to remediate the material weakness or if we otherwise fail to establish and maintain effective control over financial reporting, it may adversely affect our ability to accurately and timely report our financial results, and may adversely affect investor confidence and business operations. |
• | System security and data protection breaches, as well as cyber-attacks, including state-sponsored attacks, could disrupt our operations, which may damage our reputation and adversely affect our business. |
• | Our failure to obtain, maintain and protect our intellectual property rights could impair our ability to protect and commercialize our proprietary products and technology and cause us to lose our competitive advantage. |
• | Delaware law, the Certificate of Incorporation and Bylaws contain certain provisions, including anti-takeover provisions, that limit the ability of stockholders to take certain actions and could delay or discourage takeover attempts that stockholders may consider favorable. |
• | Our business will require significant amounts of capital to sustain operations. |
• | Our warrants are accounted for as liabilities. |
• | Future issuances of debt securities and equity securities may adversely affect us, our common stock and may be dilutive to existing stockholders. |
• | Our failure to meet the continued listing requirements of Nasdaq. |
• | Our warrants may be out of the money at the time they become exercisable and they may expire worthless. |
• | With the approval by the holders of at least 50% of the then-outstanding public warrants, we may amend the terms of the warrants in a manner that may be adverse to holders. |
Issuer |
Rigetti Computing, Inc. (f/k/a Supernova Partners Acquisition Company II, Ltd.). |
Shares of common stock offered by us |
Up to 19,354,059 shares of our common stock consisting of (i) 4,450,000 shares of common stock issuable upon exercise of the private placement warrants by holders thereof, (ii) 8,624,972 shares of common stock issuable upon exercise of the public warrants by holders thereof, and (iii) 6,279,087 shares of common stock issuable upon exercise of the Rigetti assumed warrants by holders thereof. |
Shares of common stock outstanding prior to exercise of all warrants and Rigetti assumed warrants |
113,810,285 shares (as of March 18, 2022). |
Shares of common stock outstanding assuming exercise of all warrants and Rigetti assumed warrants |
133,164,344 shares (based on total number of outstanding shares of common stock as of March 18, 2022). |
Exercise price of public warrants and private placement warrants |
$11.50 per share, with respect to the private placement warrants and public warrants, subject to adjustment as described herein. |
Exercise price of Rigetti assumed warrants |
The weighted average exercise price of the Rigetti assumed warrants is $0.6628 per share. |
Use of proceeds |
We will receive up to an aggregate of approximately $155 million from the exercise of the warrants and Rigetti assumed warrants, assuming the exercise in full of all of the warrants and Rigetti assumed warrants for cash. We expect to use the net proceeds from the exercise of the warrants and Rigetti assumed warrants for general corporate purposes. See the section entitled “Use of Proceeds.” |
Shares of common stock offered by the selling securityholders |
We are registering the resale by the selling securityholders named in this prospectus, or their permitted transferees, and aggregate of up to 96,941,181 shares of common stock, consisting of: |
• | 14,641,244 shares of common stock issued in the PIPE Financing; |
• | 8,625,000 Founder Shares (including 3,059,273 Sponsor Vesting Shares subject to vesting and forfeiture); |
• | 4,450,000 shares of common stock issuable upon the exercise of the private placement warrants; |
• | 2,446,716 shares of common stock issuable upon the exercise of Rigetti assumed warrants; |
• | 6,226,065 shares of common stock issuable upon the exercise of outstanding options; |
• | 6,288,369 shares of common stock issuable in connection with the vesting and settlement of outstanding restricted stock units; and |
• | 54,263,787 shares of common stock issued in connection with the Business Combination to certain of the selling securityholders. |
Warrants offered by the selling security holders |
Up to 4,450,000 private placement warrants. |
Redemption |
The public warrants and private placement warrants are redeemable in certain circumstances. See the section entitled “Description of Securities—Warrants” for further discussion. |
Use of proceeds |
We will not receive any of the proceeds from the sale of the shares of common stock or warrants by the selling securityholders. |
Lock-up agreements |
Certain of our securityholders are subject to certain restrictions on transfer until the termination of applicable lock-up periods. See the sections entitled “ Certain Relationships and Related Party Transactions—Sponsor Support Agreement Description of Our Securities—Lock-Up Provisions in Bylaws |
Market for common stock and public warrants |
Our common stock and public warrants are currently traded on Nasdaq under the symbols “RGTI” and “RGTIW,” respectively. |
Risk factors |
Before investing in our securities, you should carefully read and consider the information set forth in “ Risk Factors |
• | attract new customers and grow our customer base; |
• | maintain and increase the rates at which existing customers use our platform, sell additional products and services to our existing customers, and reduce customer churn; |
• | invest in our platform and product offerings; |
• | effectively manage organizational change; |
• | accelerate and/or refocus research and development activities; |
• | expand manufacturing and supply chain capacity; |
• | increase sales and marketing efforts; |
• | broaden customer-support and services capabilities; |
• | maintain or increase operational efficiencies; |
• | implement appropriate operational and financial systems; and |
• | maintain effective financial disclosure controls and procedures. |
• | limit our ability to borrow additional funds for working capital, capital expenditures, acquisitions, or other general business purposes; |
• | require us to use a portion of our cash flow from operations to make debt service payments instead of other purposes, thereby reducing the amount of cash flow available for future working capital, capital expenditures, acquisitions, or other general business purposes; |
• | expose us to the risk of increased interest rates as following the consummation of our initial public offering borrowings under the Loan Agreement are subject to interest at the greater of (i) a floating per annum rate equal to 7.5% above the prime rate, or (ii) a fixed per annum rate equal to 11.0%, also paid on a monthly basis; |
• | limit our flexibility to plan for, or react to, changes in our business and industry; |
• | increase our vulnerability to the impact of adverse economic, competitive and industry conditions; and |
• | increase our cost of borrowing. |
• | large, well-established tech companies that generally compete across our products, including Quantinuum, Google, Microsoft, Amazon, Intel and IBM; |
• | large research organizations funded by sovereign nations such as China, Russia, Canada, Australia and the United Kingdom, and those in the European Union as of the date of this prospectus and we believe additional countries in the future; |
• | less-established public and private companies with competing technology, including companies located outside the United States; and |
• | new or emerging entrants seeking to develop competing technologies. |
• | our inability to enter into agreements with suppliers on commercially reasonable terms, or at all; |
• | difficulties of suppliers ramping up their supply of materials to meet our requirements; |
• | a significant increase in the price of one or more components, including due to industry consolidation occurring within one or more component supplier markets or as a result of decreased production capacity at manufacturers; |
• | any reductions or interruption in supply, including disruptions on our global supply chain as a result of the COVID-19 pandemic, which we have experienced, and may in the future experience; |
• | financial problems of either manufacturers or component suppliers; |
• | significantly increased freight charges, or raw material costs and other expenses associated with our business; |
• | other factors beyond our control or which we do not presently anticipate, could also affect our suppliers’ ability to deliver components to us on a timely basis; |
• | a failure to develop our supply chain management capabilities and recruit and retain qualified professionals; |
• | a failure to adequately authorize procurement of inventory by our contract manufacturers; or |
• | a failure to appropriately cancel, reschedule or adjust our requirements based on our business needs. |
• | unexpected costs and errors in the localization of our platform and solutions, including translation into foreign languages and adaptation for local culture, practices and regulatory requirements; |
• | lack of familiarity and burdens of complying with foreign laws, legal standards, privacy and cybersecurity standards, regulatory requirements, tariffs and other barriers, and the risk of penalties to our customers and individual members of management or employees if our practices are deemed to not be in compliance; |
• | practical difficulties of enforcing intellectual property rights in countries with varying laws and standards and reduced or varied protection for intellectual property rights in some countries; |
• | an evolving legal framework and additional legal or regulatory requirements for data privacy and cybersecurity, which may necessitate the establishment of systems to maintain data in local markets, requiring us to invest in additional data centers and network infrastructure, and the implementation of additional employee data privacy documentation (including locally-compliant data privacy notice and policies), all of which may involve substantial expense and may cause us to need to divert resources from other aspects of our business, all of which may adversely affect our business; |
• | unexpected changes in regulatory requirements, taxes, trade laws, tariffs, export quotas, custom duties or other trade restrictions; |
• | difficulties in managing systems integrators and technology partners; |
• | differing technology standards; |
• | different pricing environments, longer sales cycles, longer accounts receivable payment cycles and difficulties in collecting accounts receivable; |
• | increased financial accounting and reporting burdens and complexities; |
• | difficulties in managing and staffing international operations including the proper classification of independent contractors and other contingent workers, differing employer/employee relationships and local employment laws; |
• | increased costs involved with recruiting and retaining an expanded employee population outside the United States through cash and equity-based incentive programs and unexpected legal costs and regulatory restrictions in issuing our shares to employees outside the United States; |
• | global political and regulatory changes that may lead to restrictions on immigration and travel for our employees; |
• | fluctuations in exchange rates that may decrease the value of our foreign-based revenue; |
• | potentially adverse tax consequences, including the complexities of foreign value added tax (or other tax) systems, restrictions on the repatriation of earnings, and transfer pricing requirements; and |
• | permanent establishment risks and complexities in connection with international payroll, tax and social security requirements for international employees. |
• | obtain expertise; |
• | obtain sales and marketing services or support; |
• | obtain equipment and facilities; |
• | develop relationships with potential future customers; and |
• | generate revenue. |
• | specialized disclosure and accounting requirements unique to government contracts; |
• | financial and compliance audits that may result in potential liability for price adjustments, recoupment of government funds after such funds have been spent, civil and criminal penalties, or administrative sanctions such as suspension or debarment from doing business with the U.S. government; |
• | public disclosures of certain contract and company information; and |
• | mandatory socioeconomic compliance requirements, including labor requirements, non-discrimination and affirmative action programs and environmental compliance requirements. |
• | Any intellectual property litigation to which we might become a party, or for which we are required to provide indemnification, regardless of the merit of the claim or our defenses, may require us to do one or more of the following: |
• | cease selling or using solutions or services that incorporate the intellectual property rights that allegedly infringe, misappropriate or violate the intellectual property of a third party; |
• | make substantial payments for legal fees, settlement payments or other costs or damages; |
• | obtain a license, which may not be available on reasonable terms or at all, to sell or use the relevant technology; |
• | redesign the allegedly infringing solutions to avoid infringement, misappropriation or violation, which could be costly, time-consuming or impossible; or |
• | indemnify third parties using our products or services. |
• | our ability to meet our technological milestones; |
• | changes in the industries in which we and our customers operate; |
• | variations in our operating performance and the performance of our competitors in general; |
• | material and adverse impact of the COVID-19 pandemic on the markets and the broader global economy; |
• | actual or anticipated fluctuations in our quarterly or annual operating results; |
• | publication of research reports by securities analysts about us or our competitors or our industry; |
• | the public’s reaction to our press releases, our other public announcements and our filings with the SEC; |
• | our failure or the failure of our competitors to meet analysts’ projections or guidance that we or our competitors may give to the market; |
• | additions and departures of key personnel; |
• | changes in laws and regulations affecting our business; |
• | commencement of, or involvement in, litigation involving the Company; |
• | changes in our capital structure, such as future issuances of securities or the incurrence of additional debt; |
• | the volume of shares of common stock available for public sale; and |
• | general economic and political conditions such as recessions, interest rates, foreign currency fluctuations, international tariffs, social, political and economic risks and acts of war or terrorism. |
• | labor availability and costs for hourly and management personnel; |
• | profitability of our products, especially in new markets and due to seasonal fluctuations; |
• | changes in interest rates; |
• | impairment of long-lived assets; |
• | macroeconomic conditions, both nationally and locally; |
• | negative publicity relating to products we serve; |
• | changes in consumer preferences and competitive conditions; and |
• | expansion to new markets. |
• | may significantly dilute the equity interests of our investors; |
• | may subordinate the rights of holders of common stock if preferred stock is issued with rights senior to those afforded our common stock; |
• | could cause a change in control if a substantial number of shares of our common stock are issued, which may affect, among other things, our ability to use our net operating loss carry forwards, if any, and could result in the resignation or removal of our present officers and directors; and |
• | may adversely affect prevailing market prices for our common stock. |
• | providing for a classified board of directors with staggered, three-year terms; |
• | the ability of the Board to issue up to 10,000,000 shares of preferred stock, including “blank check” preferred stock, with any rights, preferences and privileges as they may designate, including the right to approve an acquisition or other change of control; |
• | provide that the authorized number of directors may be changed only by resolution of the Board; |
• | provide that, subject to the rights of the holders of any series of preferred stock, any individual director or directors may be removed only with cause by the affirmative vote of the holders of at least 66 2/3% of the voting power of all of the then-outstanding shares of our capital stock entitled to vote generally in the election of directors, voting together as a single class; |
• | provide that all vacancies, including newly created directorships, may, except as otherwise required by law, be filled by the affirmative vote of a majority of directors then in office, even if less than a quorum; |
• | require that any action to be taken by our stockholders must be effected at a duly called annual or special meeting of stockholders and not be taken by written consent or electronic transmission; |
• | provide that stockholders seeking to present proposals before a meeting of stockholders or to nominate candidates for election as directors at a meeting of stockholders must provide advance notice in writing, and also specify requirements as to the form and content of a stockholder’s notice; |
• | provide that special meetings of our stockholders may be called by the chairperson of the Board, the chief executive officer or by the Board pursuant to a resolution adopted by a majority of the total number of authorized directors; and |
• | not provide for cumulative voting rights, therefore allowing the holders of a majority of the shares of common stock entitled to vote in any election of directors to elect all of the directors standing for election, if they should so choose. |
• | result in us incurring substantial costs; |
• | affect our ability to timely file our periodic reports until the restatement is completed; |
• | divert the attention of our management and employees from managing our business; |
• | result in material changes to our historical and future financial results; |
• | result in investors losing confidence in our operating results; |
• | subject us to securities class action litigation; and |
• | cause our stock price to decline. |
11 Months Ended |
Year Ended |
|||||||||||||||
December 31, |
January 31, |
|||||||||||||||
2021 |
2021 |
$Change |
% Change |
|||||||||||||
( In thousands) |
||||||||||||||||
Revenue |
$ | 8,196 | $ | 5,543 | $ | 2,653 | 48 | % | ||||||||
Cost of revenue |
1,623 | 1,492 | 131 | 9 | % | |||||||||||
|
|
|
|
|
|
|||||||||||
Total gross profit |
6,573 | 4,051 | 2,522 | 62 | % | |||||||||||
Operating expenses: |
||||||||||||||||
Research and development |
26,928 | 24,099 | 2,829 | 12 | % | |||||||||||
General and administrative |
11,299 | 13,158 | (1,859 | ) | -14 | % | ||||||||||
Sales and marketing |
2,475 | 1,886 | 589 | 31 | % | |||||||||||
|
|
|
|
|
|
|||||||||||
Total operating expenses |
40,702 | 39,143 | 1,559 | 4 | % | |||||||||||
|
|
|
|
|
|
|||||||||||
Loss from operations |
$ | (34,129 | ) | $ | (35,092 | ) | $ | 963 | -3 | % | ||||||
|
|
|
|
|
|
|||||||||||
Other (expense) income, net: |
||||||||||||||||
Gain on extinguishment of debt |
— | 8,914 | (8,914 | ) | nm | |||||||||||
Change in fair value of warrant liability |
(1,664 | ) | — | (1,664 | ) | nm | ||||||||||
Interest expense |
(2,465 | ) | (52 | ) | (2,413 | ) | nm | |||||||||
Interest income |
10 | 60 | (50 | ) | -83 | % | ||||||||||
Other income |
7 | 42 | (35 | ) | -83 | % | ||||||||||
|
|
|
|
|
|
|||||||||||
Total other (expense) income, net |
(4,112 | ) | 8,964 | (13,076 | ) | |||||||||||
Net loss before provision for income taxes |
(38,241 | ) | (26,128 | ) | (12,113 | ) | ||||||||||
Provision for income taxes |
— | — | — | |||||||||||||
|
|
|
|
|
|
|||||||||||
Net loss |
$ | (38,241 | ) | $ | (26,128 | ) | $ | (12,113 | ) | |||||||
|
|
|
|
|
|
Total |
Short-Term |
Long-Term |
||||||||||
Financing obligations |
$ | 24,791,032 | $ | 1,290,538 | $ | 23,500,494 | ||||||
Operating lease obligations |
4,674,898 | 1,807,759 | 2,867,139 | |||||||||
|
|
|
|
|
|
|||||||
Total |
$ | 29,465,930 | $ | 3,098,297 | $ | 26,367,633 | ||||||
|
|
|
|
|
|
11 Months Ended |
Year Ended |
|||||||
December 31, |
January 31, |
|||||||
2021 |
2021 |
|||||||
Net cash used in operating activities |
$ | (29,043 | ) | $ | (30,067 | ) | ||
Net cash used in investing activities |
(7,008 | ) | (4,400 | ) | ||||
Net cash provided by financing activities |
25,582 | 56,289 |
• | On October 6, 2021, Supernova entered into the Merger Agreement, by and among First Merger Sub, Second Merger Sub, and Legacy Rigetti. |
• | On March 1, 2022, pursuant to the Merger Agreement, Supernova filed a notice of deregistration with the Cayman Islands Registrar of Companies, together with the necessary accompanying documents, and filed a certificate of incorporation and a certificate of corporate domestication with the Secretary of State of the State of Delaware, under which Supernova was domesticated and continues as a Delaware corporation, changing its name to “Rigetti Computing, Inc.” |
• | As a result of and upon the effective time of the Domestication, among other things, (1) each then issued and outstanding Supernova Class A ordinary share converted automatically, on a one-for-one one-for-one one-fourth of one warrant to purchase common stock. No fractional shares were issued upon exercise of the Warrants. |
• | On the Closing Date, pursuant to the Merger Agreement, the Company consummated the merger transaction contemplated by the Merger Agreement, following approval at the Extraordinary General Meeting on February 28, 2022, whereby (i) the First Merger occurred and (ii) immediately following the consummation of the First Merger, the Second Merger occurred. |
• | Immediately prior to the effective time of the First Merger, all shares of Legacy Rigetti Preferred Stock converted into shares of Legacy Rigetti common stock in accordance with the Amended and Restated Certificate of Incorporation of Legacy Rigetti pursuant to the Legacy Rigetti Preferred Stock Conversion. |
• | Each share of Legacy Rigetti common stock (including Legacy Rigetti common stock resulting from the Legacy Rigetti Preferred Stock Conversion) that was issued and outstanding immediately prior to the First Merger was cancelled and converted into 78,959,579 shares of common stock. |
• | Each warrant to purchase Legacy Rigetti common stock converted into a Rigetti assumed warrant to purchase shares of common stock subject to the same terms and conditions as were applicable to the original Legacy Rigetti warrants, and with an exercise price and number of shares of common stock purchasable based on the Exchange Ratio and other terms contained in the Merger Agreement. |
• | Each option to purchase Legacy Rigetti common stock converted into a Rigetti assumed option to purchase shares of common stock subject to the same terms and conditions as were applicable to the original Legacy Rigetti options, and with an exercise price and number of shares of common stock purchasable based on the Exchange Ratio and other terms contained in the Merger Agreement. |
• | Each restricted share of Legacy Rigetti common stock was exchanged for restricted shares of common stock subject to the same terms and conditions as were applicable to the original Legacy restricted shares, and with the number of shares of common stock based on the Exchange Ratio and other terms contained in the Merger Agreement. |
• | Each Legacy Rigetti restricted stock unit award converted into a Rigetti assumed RSU to receive shares of common stock subject to the same terms and conditions as were applicable to the original Legacy restricted stock unit awards, and with the number of shares of common stock to which the Rigetti assumed RSU relates based on the Exchange Ratio and other terms contained in the Merger Agreement. |
• | The issuance and sale of (i) 10,251,000 shares of common stock for a purchase price of $10.00 per share and (ii) 4,390,244 shares of common stock for a purchase price of $10.25 per share, generated aggregate gross proceeds of $147.5 million in PIPE Financing pursuant to the Subscription Agreements. |
• | Pursuant to the Sponsor Support Agreement, at the Closing (i) 2,479,000 shares of common stock held by the Sponsor (the “Promote Sponsor Vesting Shares”) became subject to vesting and are considered unvested and will only vest if, during the five year period following the Closing, the volume weighted average price of our common stock equals or exceeds $12.50 for any twenty trading days within a period of thirty consecutive trading days, and (ii) 580,273 shares of our common stock held by the Sponsor (“Sponsor Redemption-Based Vesting Shares”) became subject to vesting and considered unvested and will only vest if, during the five year period following the Closing, the volume weighted average price of our common stock equals or exceeds $15.00 for any twenty trading days within a period of thirty consecutive trading days (collectively, the Promote Sponsor Vesting Shares and Sponsor Redemption-Based Vesting Shares, “Sponsor Vesting Shares”). Any Sponsor Vesting Shares that remain unvested after the fifth anniversary of the Closing will be forfeited. |
• | In connection with the execution of the Merger Agreement, Legacy Rigetti entered into a warrant subscription agreement with a strategic partner, Ampere, for the purchase of a warrant for an aggregate purchase price (including amounts from exercise) of $10,000,000. At the Closing, the warrant agreement was assumed by Rigetti as a result of the Merger. The warrant provides for the purchase of an aggregate of 1,000,000 shares of common stock at an exercise price of $0.0001. Ampere is required to pay $5.0 million no later than (i) the Closing or (ii) June 30, 2022, and upon such payment the warrant will vest and be exercisable by Ampere with respect to 500,000 shares of common stock pursuant to the terms of the warrant. No such purchase or payment has been made as of the Closing Date regarding this first $5.0 million. Ampere is required to pay an additional $5.0 million no later than the second anniversary of the date of the warrant subscription agreement, and upon such payment, the warrant will vest and be exercisable by Ampere with respect to the remaining 500,000 shares of common stock pursuant to the terms of the warrant. No pro forma adjustments have been made for the purchase of the warrants as the purchase of such warrants are contingent upon future events not tied to the Closing and are not expected to be purchased until June 30, 2022. Further, shares of common stock underlying the warrant subscription agreement are not reflected in the post-Business Combination capitalization tables. |
• | Former Legacy Rigetti stockholders have a controlling voting interest in Rigetti; |
• | The Rigetti board of directors as of immediately after the closing is comprised of eight board members, seven seats occupied by previous Legacy Rigetti board members and one seat being occupied by a previous Supernova director; |
• | Legacy Rigetti management continues to hold executive management roles for the post-combination company and be responsible for the day-to-day |
• | the post-combination company assumes the Rigetti name; |
• | Rigetti maintains the Legacy Rigetti headquarters; and |
• | the intended strategy of Rigetti is to continue Legacy Rigetti’s strategy. |
SNII (Historical) |
Legacy Rigetti (Historical) |
Transaction Accounting Adjustments |
Pro Forma Condensed Combined |
|||||||||||||||
ASSETS |
||||||||||||||||||
Current assets |
||||||||||||||||||
Cash |
$ | 533 | $ | 11,728 | $ | 345,019 | (2A) |
$ | 216,717 | |||||||||
(12,075 | ) | (2C) |
||||||||||||||||
147,510 | (2B) |
|||||||||||||||||
(44,843 | ) | (2D) |
||||||||||||||||
(2,000 | ) | (2L) |
||||||||||||||||
(229,155 | ) | (2I) |
||||||||||||||||
Accounts receivable |
— | 1,543 | — | 1,543 | ||||||||||||||
Prepaid expenses and other current assets |
235 | 1,351 | — | 1,586 | ||||||||||||||
Deferred offering costs |
— | 3,448 | (3,448 | ) | (2D) |
— | ||||||||||||
|
|
|
|
|
|
|
|
|||||||||||
Total Current Assets |
768 | 18,070 | 201,008 | 219,846 | ||||||||||||||
Property and equipment, net |
— | 22,498 | — | 22,498 | ||||||||||||||
Restricted cash |
— | 317 | — | 317 | ||||||||||||||
Marketable securities held in Trust Account |
345,019 | — | (345,019 | ) | (2A) |
— | ||||||||||||
Other assets |
36 | 164 | — | 200 | ||||||||||||||
Goodwill |
— | 5,377 | — | 5,377 | ||||||||||||||
|
|
|
|
|
|
|
|
|||||||||||
TOTAL ASSETS |
$ |
345,823 |
$ |
46,426 |
$ |
(144,011 |
) |
$ |
248,238 |
|||||||||
|
|
|
|
|
|
|
|
|||||||||||
Current liabilities |
||||||||||||||||||
Accounts payable |
314 | 1,971 | (1,252 | ) | (2D) |
1,033 | ||||||||||||
Accrued expenses and other current liabilities |
3,923 | 4,036 | (4,530 | ) | (2D) |
3,429 | ||||||||||||
Deferred revenue - current |
— | 985 | — | 985 | ||||||||||||||
Debt - current portion |
— | 1,290 | — | 1,290 | ||||||||||||||
|
|
|
|
|
|
|
|
|||||||||||
Total Current Liabilities |
4,237 | 8,282 | (5,782 | ) | 6,737 | |||||||||||||
Other liabilities |
— | 295 | 29,958 | (2J) |
30,253 | |||||||||||||
Derivative warrant liabilities |
30,988 | 4,355 | — | 35,343 | ||||||||||||||
Deferred underwriting commissions |
12,075 | — | (12,075 | ) | (2C) |
— | ||||||||||||
Debt - net of current portion |
— | 23,500 | — | 23,500 | ||||||||||||||
|
|
|
|
|
|
|
|
|||||||||||
Total Liabilities |
47,300 |
36,432 |
12,101 |
95,833 |
||||||||||||||
|
|
|
|
|
|
|
|
|||||||||||
Commitments and contingencies |
||||||||||||||||||
Redeemable convertible preferred stock, par value $0.000001 per share |
— | 81,523 | (81,523 | ) | (2F) |
— | ||||||||||||
Class A Ordinary shares, $0.0001 par value |
345,000 | — | (345,000 | ) | (2E) |
— | ||||||||||||
Stockholders’ Equity |
||||||||||||||||||
Class A common stock, par value $0.000001 per share |
— | 1 | (1 | ) | (2F) |
— | ||||||||||||
Class A common stock, par value $0.0001 per share |
— | — | — | — | ||||||||||||||
Class A common stock, par value $0.0001 per share |
— | — | 3 | (2E) |
11 | |||||||||||||
1 | (2B) |
|||||||||||||||||
1 | (2G) |
|||||||||||||||||
8 | (2F) |
|||||||||||||||||
(2 | ) | (2I) |
||||||||||||||||
Class B common stock, par value $0.0001 per share |
1 | — | (1 | ) | (2G) |
— | ||||||||||||
Additional paid-in capital |
— | 135,550 | 344,997 | (2E) |
364,392 | |||||||||||||
(46,478 | ) | (2H) |
||||||||||||||||
147,509 | (2B) |
|||||||||||||||||
81,516 | (2F) |
|||||||||||||||||
(42,509 | ) | (2D) |
||||||||||||||||
(29,958 | ) | (2J) |
||||||||||||||||
2,918 | (2K) |
|||||||||||||||||
(229,153 | ) | (2I) |
||||||||||||||||
Accumulated other comprehensive gain |
— | 52 | — | 52 | ||||||||||||||
Accumulated deficit |
(46,478 | ) | (207,132 | ) | 46,478 | (2H) |
(212,050 | ) | ||||||||||
(2,918 | ) | (2K) |
||||||||||||||||
(2,000 | ) | (2L) |
||||||||||||||||
|
|
|
|
|
|
|
|
|||||||||||
Total Stockholders’ Deficit |
(46,477 | ) | (71,529 | ) | 270,411 | 152,405 | ||||||||||||
|
|
|
|
|
|
|
|
|||||||||||
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY |
$ |
345,823 |
$ |
46,426 |
$ |
(144,011 |
) |
$ |
248,238 |
|||||||||
|
|
|
|
|
|
|
|
SNII (Historical) |
Legacy Rigetti (Pro Forma) |
Transaction Accounting Adjustments |
Pro Forma Condensed Combined |
|||||||||||||||
Revenue |
$ | — | $ | 8,633 | $ | 8,633 | ||||||||||||
Cost of revenues |
— | 1,770 | 1,770 | |||||||||||||||
|
|
|
|
|
|
|
|
|||||||||||
Total gross profit |
— | 6,863 | — | 6,863 | ||||||||||||||
Operating Expenses |
||||||||||||||||||
Research and development |
— | 29,285 | 1,605 | (2CC) |
30,890 | |||||||||||||
General and administrative |
4,905 | 12,597 | 21,703 | (2BB) |
42,518 | |||||||||||||
2,000 | (2DD) |
|||||||||||||||||
1,313 | (2CC) |
|||||||||||||||||
Sales and marketing |
— | 2,557 | — | 2,557 | ||||||||||||||
|
|
|
|
|
|
|
|
|||||||||||
Total operating expenses |
4,905 | 44,439 | 26,621 | 75,965 | ||||||||||||||
|
|
|
|
|
|
|
|
|||||||||||
Operating loss: |
$ |
(4,905 |
) |
$ |
(37,576 |
) |
$ |
(26,621 |
) |
$ |
(69,102 |
) | ||||||
|
|
|
|
|
|
|
|
|||||||||||
Other income (expense), net |
||||||||||||||||||
Change in fair value of warrant liability |
(17,782 | ) | (1,664 | ) | — | (19,446 | ) | |||||||||||
Offering costs associated with warrant liability |
(502 | ) | — | — | (502 | ) | ||||||||||||
Interest income |
19 | 11 | (19 | ) | (2AA) |
11 | ||||||||||||
Interest expense |
— | (2,465 | ) | (2,465 | ) | |||||||||||||
Other expense |
— | (23 | ) | (23 | ) | |||||||||||||
|
|
|
|
|
|
|
|
|||||||||||
Total other income (expense), net |
(18,265 | ) | (4,141 | ) | (19 | ) | (22,425 | ) | ||||||||||
|
|
|
|
|
|
|
|
|||||||||||
Net loss |
$ |
(23,170 |
) |
$ |
(41,717 |
) |
$ |
(26,640 |
) |
$ |
(91,527 |
) | ||||||
|
|
|
|
|
|
|
|
|||||||||||
Loss per Share |
||||||||||||||||||
Weighted-average shares outstanding of common stock |
107,214,031 | |||||||||||||||||
Loss per share (basic and diluted) attributable to common stockholders |
$ | (0.85 | ) |
(A) | Reflects the reclassification of approximately $345.0 million of cash and cash equivalents held in the trust account at the balance sheet date that became available to fund redemptions in connection with the Business Combination or future cash needs of post-combination company. |
(B) | Represents aggregate gross proceeds of $147.5 million from the private placements of (i) 10,251,000 shares of common stock for a purchase price of $10.00 per share and (ii) 4,390,244 shares of common stock for a purchase price of $10.25 per share. |
(C) | Reflects the payment and settlement of approximately $12.0 million of deferred underwriters’ fees related to the Supernova initial public offering that were contingent on the consummation of the Business Combination. |
(D) | Represents the (i) settlement of $46.4 million of estimated transaction costs in consummating the Business Combination and related transactions, of which $44.8 million were not been paid as of December 31, 2021, and (ii) reclassification of Rigetti and Supernova transaction costs of $3.4 million within deferred offering costs and $5.8 million within accrued expenses and accounts payable. In connection with the reverse recapitalization treatment, Legacy Rigetti’s transaction costs are recorded as reductions to additional paid-in capital. Of the total amount shown, approximately $25.6 million is from Supernova, and $20.8 million is from Legacy Rigetti. |
(E) | Reflects the reclassification of Supernova Class A ordinary shares subject to possible redemption to permanent stockholders’ equity. |
(F) | Represents recapitalization of Rigetti equity, both redeemable convertible Preferred Stock and common stock, and issuance of shares of the common stock to Legacy Rigetti equityholders as consideration for the reverse recapitalization. |
(G) | Reflects the conversion of Supernova Class B ordinary shares held by the initial stockholders of Supernova to shares of common stock. Pursuant to the terms of the Supernova’s Memorandum of Association and Articles of Association, all shares of Supernova Class B ordinary shares outstanding prior to the Closing were converted into shares of common stock at the Closing. This adjustment reflects the conversion of such ordinary shares directly into common stock subject to the terms and conditions of the Merger Agreement. |
(H) | Reflects the reclassification of Supernova’s historical accumulated deficit. |
(I) | Reflects the cash disbursement in which 22,915,538 shares of Supernova’s outstanding public shares were redeemed for an aggregate payment of approximately $229.2 million (based on the per share redemption price of $10.00 per share). |
(J) | Reflects the fair value of the Sponsor Vesting Shares contingently releasable to Supernova’s Sponsor to be accounted for as a liability. Fair value was determined based on information available as of the date of the unaudited pro forma condensed combined financial information. Significant assumptions to the valuation include estimated redemption levels of Supernova’s outstanding public shares, a term of five years, volatility of 90.2%, risk-free rate of 1.26%, and a dividend yield of 0.0%. |
(K) | Represents incremental stock-based compensation expense associated with certain Legacy Rigetti RSUs that vest based on both a liquidity and a service condition. The liquidity condition is satisfied upon the occurrence of certain events, including a merger or acquisition or other business combination transaction involving Legacy Rigetti and a publicly traded special purpose acquisition company or other similar entity and, as a result, the liquidity condition for certain of Legacy Rigetti’s RSUs was satisfied upon the completion of the Business Combination. Legacy Rigetti will recognize a total $2.9 million of incremental stock-based compensation expense associated with these restricted stock units, based on the number of Legacy restricted stock units outstanding and the requisite service completed at December 31, 2021, and no forfeitures prior to closing of the Business Combination. |
(L) | Represents the payment of a cash transaction bonus to certain Legacy Rigetti employees as a result of completion of the Business Combination. |
(Amounts in thousands, except share and per share data) |
For the year ended December 31, 2021 |
|||
Pro forma net loss |
$ | (91,527 | ) | |
Weighted average shares calculation, basic and diluted |
||||
Former Rigetti equityholders(a)(b) |
75,422,598 | |||
Sponsor(c) |
5,565,727 | |||
Former Supernova Class A stockholders |
11,584,462 | |||
PIPE Shares(d)(e) |
14,641,244 | |||
|
|
|||
Weighted average Class A shares outstanding |
107,214,031 | |||
|
|
|||
Loss per share attributable to Class A common stockholders (basic and diluted) |
$ | (0.85 | ) | |
|
|
(a) | In accordance with the terms and subject to the conditions of the Merger Agreement, each outstanding share of Legacy Rigetti common stock (including Legacy Rigetti common stock resulting from the Legacy Rigetti Preferred Stock Conversion) was exchanged for shares of common stock and outstanding Legacy Rigetti Options and Legacy Rigetti Warrants (whether vested or unvested) were converted into options and warrants to purchase common stock. |
(b) | Amount excludes 11,617,149 shares underlying options of Legacy Rigetti assumed and converted into Rigetti assumed options to purchase common stock issued to holders of Legacy Rigetti options, as such these options remained unexercised as of the Closing based on Legacy Rigetti options outstanding as of December 31, 2021. In addition, this amount excludes shares of Legacy Rigetti common stock issuable upon exercise of outstanding Legacy Rigetti warrants and Legacy Rigetti restricted stock units which were assumed and converted to Rigetti assumed warrants and Rigetti assumed RSUs with respect to common stock upon Closing. The shares of common stock underlying the Rigetti assumed warrants and Rigetti assumed RSUs are 8,535,739 and 5,390,422, respectively, based on Legacy Rigetti warrants and Legacy Rigetti restricted stock units outstanding as of December 31, 2021. Of the 5,390,422 shares of common stock underlying the Rigetti assumed RSUs based on Legacy Rigetti restricted stock unit awards outstanding as of December 31, 2021, 751,724 shares of common stock became vested at Closing based on meeting both a liquidity and a service condition upon the consummation of the Business Combination. |
(c) | Amount excludes 4,450,000 Supernova Class A ordinary shares underlying the private placement warrants and 8,625,000 Supernova Class A ordinary shares underlying the public warrants that were converted on a one-for-one |
(d) | Amount excludes shares underlying the warrant subscription agreement that provides for the purchase of an aggregate of 1,000,000 shares of common stock issued to a strategic investor. |
(e) | PIPE Investors include affiliates of Supernova investing in 500,000 shares of common stock. |
• | Create high performance quantum computing systems through full-stack product development. Fab-1. |
• | Leverage cloud to provide broad access to our quantum computers. |
• | Develop deep partnerships that accelerate the development and commercialization of quantum computing. |
• | Advance our technology leadership position . |
algorithm and application developers to rapidly innovate, invent, engineer and commercialize our quantum computing technologies. We have also developed numerous proprietary technologies required to create quantum computing chips, quantum computer systems, software and cloud-based services and we rigorously protect our unique intellectual property through a portfolio of 140 patents issued and pending. We intend to continue deeply investing in finding and fostering the talent required to remain at the forefront of quantum computing innovation, while protecting our growing base of intellectual property. |
• | Enabling customers to access Rigetti QPUs through a broad range of quantum application software, development frameworks and algorithm libraries; |
• | Providing software and algorithm developers with the performance and fine-grained control required to expedite a new era of computational breakthroughs; and |
• | Facilitating the implementation of high performance public and private clouds with ultra-low latency connectivity between classical hardware and Rigetti QPUs. |
• | Fermi National Accelerator Laboratory, or Fermilab, and the U.S. DOE’s Superconducting Quantum Materials and Systems Center (“SQMS”), to advance the development of scalable and high performance quantum processors; |
• | DARPA and National Aeronautics and Space Administration (“NASA”) to create quantum computing systems, software and algorithms for optimization applications; and |
• | Innovate UK, as part of the British government’s effort to accelerate commercialization of quantum computing in the United Kingdom and to pursue practical applications in machine learning, molecular simulation and financial optimization. |
• | healthcare – for medical image analysis used to detect and categorize tumors and predict their growth; |
• | drug discovery – for generating molecular structure candidates for medicines to target or cure diseases; |
• | banking – for creating models that can detect financial fraud based upon predictive patterns rather than rules determined by previously observed behaviors; and |
• | defense and intelligence – for reliably converting low resolution satellite imagery into high resolution photography. |
• | enterprise-sized organizations working on quantum-assisted breakthroughs in applications areas like drug discovery, network optimization, financial modeling, weather forecasting and fusion energy with organizations like Astex Pharmaceuticals, Deloitte, NASA, Nasdaq, Standard Chartered Bank, the U.S. DOE and certain military branches within the U.S. Department of Defense; |
• | materials science researchers and quantum algorithm developers at renowned laboratories like Fermilab, Lawrence Livermore National Laboratory, MIT Lincoln Laboratory, NASA Quantum Artificial Intelligence Laboratory and ORNL; |
• | quantum-focused software and algorithm companies like 1Qbit, Phasecraft, Riverlane, Q-CTRL and Zapata; |
• | Cloud service providers like Amazon Web Services, Microsoft, and Strangeworks; and |
• | We also enter into multi-year technology development partnerships with organizations that possess specialized technical expertise and strong interests in advancing the development of quantum computing (as referenced in Business – Key Technology Development Partnerships |
1. | United in our purpose. |
2. | Embrace grand challenges. |
3 . |
Build for tomorrow. |
4. | Act with integrity. |
5. | Evolve and grow. |
6. | Magic through mastery. |
Name |
Age |
Position | ||||
Executive Officers |
||||||
Chad Rigetti | 43 | President, Chief Executive Officer and Director | ||||
Taryn Naidu | 43 | Chief Operating Officer | ||||
Brian Sereda | 61 | Chief Financial Officer | ||||
Rick Danis | 52 | General Counsel and Corporate Secretary | ||||
Mike Harburn | 52 | Chief Technology Officer | ||||
Greg Peters | 62 | Chief Revenue Officer | ||||
Non-Employee Directors |
||||||
Alissa Fitzgerald | 52 | Director | ||||
Gen. Peter Pace | 76 | Director | ||||
Ray Johnson | 66 | Director | ||||
David Cowan | 55 | Director | ||||
Cathy McCarthy | 74 | Director | ||||
Michael Clifton | 42 | Director | ||||
H. Gail Sandford | 58 | Director |
• | the Class I directors are Chad Rigetti, Ray Johnson and H. Gail Sandford, and their terms will expire at the annual meeting of stockholders to be held in 2023; |
• | the Class II directors are Alissa Fitzgerald, Gen. Peter Pace and David Cowan, and their terms will expire at the annual meeting of stockholders to be held in 2024; and |
• | the Class III directors are Cathy McCarthy and Michael Clifton and their terms will expire at the annual meeting of stockholders to be held in 2025. |
• | oversee our accounting and financial reporting processes, systems of internal control, financial statement audits and the integrity of our financial statements; |
• | manage the selection, engagement terms, fees, qualifications, independence, and performance of the registered public accounting firms engaged as our independent outside auditors for the purpose of preparing or issuing an audit report or performing audit services (the “ Auditors |
• | maintain and foster an open avenue of communication with our management, internal audit group (if any) and Auditors; |
• | review any reports or disclosures required by applicable law and stock exchange listing requirements; |
• | oversee the design, implementation, organization and performance of our internal audit function (if any); |
• | help our Board oversee our legal and regulatory compliance, including risk assessment; |
• | oversee our technology security and data privacy programs; |
• | Prepare the audit committee report required by the SEC to be included in our annual proxy statement, and |
• | provide regular reports and information to the Board. |
• | help the Board oversee our compensation policies, plans and programs with a goal to attract, incentivize, retain and reward top quality executive management and employees; |
• | review and determine the compensation to be paid to our executive officers and directors; |
• | when required, review and discuss with management our compensation disclosures in the “Compensation Discussion and Analysis” section of our annual reports, registration statements, proxy statements or information statements filed with the SEC; |
• | when required, prepare and review the Committee report on executive compensation included in our annual proxy statement; and |
• | review and ensure our talent management strategies are aligned to best practices and ensure we attract, retain and develop top talent. |
• | help the Board oversee our corporate governance functions and develop, update as necessary and recommend to the Board the governance principles applicable to Rigetti; |
• | identify, evaluate and recommend and communicate with candidates qualified to become Board members or nominees for directors of the Board consistent with criteria approved by the Board; and |
• | make other recommendations to the Board relating to the directors of Rigetti. |
• | for any transaction from which the director derives an improper personal benefit; |
• | for any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law; |
• | for any unlawful payment of dividends or redemption of shares; or |
• | for any breach of a director’s duty of loyalty to the corporation or our stockholders. |
• | Chad Rigetti, Rigetti’s President and CEO; |
• | Brian Sereda, Rigetti’s Chief Financial Officer; and |
• | Taryn Naidu, Rigetti’s Chief Operating Officer |
Name, Principal Position |
Fiscal Year |
Salary(1) |
Bonus(2) |
Stock Awards(3) |
Option Awards(4) |
Non-Equity Incentive Plan Compensation(5) |
All Other Compensation(6) |
Total |
||||||||||||||||||||||||
Chad Rigetti |
2021 | $ | 320,833 | $ | 1,300 | $ | 3,810,571 | — | $ | 56,000 | $ | 584 | 4,189,288 | |||||||||||||||||||
President and CEO |
2020 | $ | 276,340 | $ | 3,000 | — | $ | 376,059 | — | $ | 608 | $ | 656,007 | |||||||||||||||||||
Brian Sereda(7) |
2021 | $ | 121,875 | $ | 75,000 | $ | 3,825,049 | — | $ | 19,500 | $ | 72 | $ | 4,041,496 | ||||||||||||||||||
Chief Financial Officer |
||||||||||||||||||||||||||||||||
Taryn Naidu |
2021 | $ | 258,098 | — | $ | 1,378,794 | — | $ | 45,540 | $ | 4,343 | $ | 1,686,775 | |||||||||||||||||||
Chief Operating Officer |
2020 | $ | 228,357 | $ | 3,000 | — | $ | 85,798 | — | $ | 10,420 | $ | 327,575 |
(1) | Salary amounts represent actual amounts earned during fiscal year 2021. See “—Narrative Disclosure to Summary Compensation Table—Base Salaries |
(2) | This column reflects amounts awarded as discretionary bonuses in fiscal year 2021 and fiscal year 2020. |
(3) | This column reflects the aggregate grant date fair value of the restricted stock units granted to the named executive officer during fiscal year 2021 under the 2013 Plan (as defined below). The aggregate grant date fair value is computed in accordance with ASC Topic 718 for stock-based compensation transactions. Assumptions used in the calculation of these amounts are included in the notes to our financial statements included elsewhere in this prospectus. In accordance with ASC Topic 718, recognition of compensation expense is deferred until consummation of the Business Combination. This amount does not reflect the actual economic value that may be realized by the named executive officer. |
(4) | This column reflects the aggregate grant date fair value of the option awards granted during fiscal year 2020 and the incremental fair value of option awards modified in fiscal year 2020 computed in accordance with ASC Topic 718 for stock-based compensation transactions. Assumptions used in the calculation of these amounts are included in the notes to our audited financial statements included elsewhere in this prospectus. These amounts do not reflect the actual economic value that will be realized by the named executive officer upon the vesting of the stock options, the exercise of the stock options, or the sale of the common stock underlying such stock options. The amounts reported include the effect of the |
Repricing (as defined below) in May 2020 of stock options held by employees, including the named executive officers, whereby the exercise price per share of each stock option was lowered to $0.214 (our fair market value per share on the date of the Repricing). Please see the description of the Repricing under “Equity-Based Incentive Awards” below. The incremental grant date fair value of the Repricing was $890 and $15,880 for Dr. Rigetti and Mr. Naidu, respectively. |
(5) | See “ —Narrative to Summary Compensation Table—Non-Equity Incentive Plan Compensationnon-equity incentive plan compensation represent amounts earned for the fiscal years presented, whether or not actually paid during such year. |
(6) | This column reflects the aggregate value of other categories of payment, consisting of (i) for Dr. Rigetti, $584 and $608 for life insurance premiums for fiscal year 2021 and fiscal year 2020, respectively; (ii) for Mr. Naidu, $552 for life insurance premiums for each of fiscal year 2021 and fiscal year 2020, $8,305 for temporary housing for fiscal year 2020 and $3,791 and $1,563 for professional membership fees for fiscal year 2021 and fiscal year 2020, respectively; and (iii), for Mr. Sereda, $72 for life insurance premiums for fiscal year 2021. |
(7) | Mr. Sereda joined Rigetti as Chief Financial Officer in August 2021. Mr. Sereda was not a named executive officer for fiscal year 2020. |
Option Awards |
Stock Awards |
|||||||||||||||||||||||||||
Name |
Grant Date |
Number of Securities Underlying Unexercised Options (#) Exercisable |
Number of Securities Underlying Unexercised Options (#) Unexercisable |
Option Exercise Price |
Option Expiration Date |
Equity incentive plan awards: Number of Unearned shares, units or other rights that have not vested(#)(1) |
Equity incentive plan awards: Market or payout value of unearned shares, units or other rights that have not vested($)(2) |
|||||||||||||||||||||
Chad Rigetti |
07/13/2016 | 2,242 | 118 | (3) | $ | 0.272 | 07/12/2026 | — | — | |||||||||||||||||||
05/16/2017 | 1,062 | 354 | (4) | $ | 0.272 | 05/15/2027 | — | — | ||||||||||||||||||||
01/20/2021 | 393 | — | $ | 0.272 | 1/19/2031 | — | — | |||||||||||||||||||||
12/14/2017 | 944 | — | $ | 0.272 | 12/13/2027 | — | — | |||||||||||||||||||||
04/04/2018 | 1,023 | — | $ | 0.272 | 04/03/2028 | — | — | |||||||||||||||||||||
07/11/2018 | 786 | — | $ | 0.272 | 07/10/2028 | — | — | |||||||||||||||||||||
09/26/2018 | 1,495 | — | $ | 0.272 | 09/25/2028 | — | — | |||||||||||||||||||||
01/29/2019 | 708 | — | $ | 0.272 | 01/28/2029 | — | — | |||||||||||||||||||||
01/29/2019 | 629 | — | $ | 0.272 | 01/28/2029 | — | — | |||||||||||||||||||||
10/30/2019 | 393 | — | $ | 0.272 | 10/29/2029 | — | — | |||||||||||||||||||||
10/30/2019 | 472 | — | $ | 0.272 | 10/29/2029 | — | — | |||||||||||||||||||||
10/30/2019 | 865 | — | $ | 0.272 | 10/29/2029 | — | — | |||||||||||||||||||||
05/22/2020 | 2,061,218 | 1,410,308 | (5) | $ | 0.272 | 05/31/2030 | — | — | ||||||||||||||||||||
01/20/2021 | 393 | — | $ | 0.272 | 01/19/2031 | — | — | |||||||||||||||||||||
04/21/2021 | — | — | — | — | 1,044,905 | (6) | $ | 10,752,072 | ||||||||||||||||||||
Taryn Naidu |
04/04/2019 | 86,568 | 70,829 | (7) | $ | 0.272 | 04/03/2019 | — | — | |||||||||||||||||||
05/22/2020 | 321,088 | 325,944 | (8) | $ | 0.272 | 05/01/2030 | — | — | ||||||||||||||||||||
04/21/2021 | — | — | — | — | 378,082 | (9) | $ | 3,890,464 | ||||||||||||||||||||
Brian Sereda |
08/18/2021 | — | — | — | — | 1,048,875 | (10) | $ | 10,792,924 |
(1) | Represents RSUs that vest based on the satisfaction of both a service-based vesting condition and a liquidity-based vesting condition, which is satisfied as described above under “ Narrative Disclosure to Summary Compensation Table— Equity-Based Incentive Awards |
(2) | Represents the market value of RSUs as of December 31, 2021 based on the RSUs that were assumed and converted into a Rigetti assumed RSUs to acquire shares of common stock at the Exchange Ratio and based on the closing price of Supernova Class A ordinary shares of $10.29 per share on December 31, 2021. |
(3) | Twenty percent (20%) of the shares underlying this option vested on April 1, 2017, and the remaining shares underlying this option vest in 60 equal monthly installments on the last calendar day of the month, subject to continued service at each vesting date. Please see “ —Employment Arrangements with Executive Officers |
(4) | Twenty percent (20%) of the shares underlying this option vested on April 1, 2018, and the remaining shares underlying this option vest in 48 equal monthly installments on the last calendar day of the month, subject to continued service at each vesting date. Please see “ —Employment Arrangements with Executive Officers |
(5) | 867,881 of the shares underlying this option were vested as of the vesting commencement date on May 22, 2020, and one forty-eighth (1/48) of the remainder of the shares subject to this option vest each month following the vesting commencement date (February 18, 2020) on the same day of the month as the vesting commencement date (or if there is no corresponding day, on the last day of the month), subject to Dr. Rigetti’s continuing to be a Service Provider (as defined in the 2013 Plan) through each such date, subject to continued service at each vesting date. Please see “— Employment Arrangements with Executive Officers |
(6) | The RSUs have a dual vesting condition whereby vesting monthly over four-year term so long as the employee retains their status with Rigetti. There is an additional liquidity-event vesting requirement that is defined as a change in control, a successful IPO or a successful merger with a SPAC, which was satisfied upon the Closing. Therefore, 28,252 of Dr. Rigetti’s RSU’s vested upon the Closing. |
(7) | Twenty percent (20%) of the shares underlying this option vested on March 18, 2020, and the remaining shares underlying this option vest in 48 equal monthly installments on the last calendar day of the month, subject to continued service at each vesting date. Please see “— Employment Arrangements with Executive Officers |
(8) | 45,292 of the shares underlying this option were vested as of the vesting commencement date on February 18, 2020, and one forty-eighth (1/48) of the remainder of the shares subject to this option vest each month following the vesting commencement date on the same day of the month as the vesting commencement date (or if there is no corresponding day, on the last day of the month), subject to Mr. Naidu’s continuing to be a Service Provider (as defined in the 2013 Plan) through each such date, subject to continued service at each vesting date. Please see “— Employment Arrangements with Executive Officers |
(9) | The RSUs have dual vesting conditions, a time-based vesting requirement and a liquidity-event vesting requirement. The time-based vesting requirement is met monthly over a four-year term so long as the employee retains their status with Rigetti. The liquidity-event vesting requirement that is defined as a change in control, a successful IPO or a successful merger with a SPAC, which was satisfied upon the Closing. Therefore, 78,766 of Mr. Naidu’s RSUs vested upon the Closing. |
(10) | The RSUs have dual vesting conditions, a time-based vesting requirement and a liquidity-event vesting requirement. The time-based vesting requirement is met monthly over a four-year term with a 1-year cliff, so long as the employee retains their status with Rigetti. The liquidity event vesting requirement is defined as a change in control, a successful IPO or a successful merger with a SPAC which was satisfied upon the Closing. However, none of Mr. Sereda’s RSUs vested upon the Closing because the first-year anniversary of the grant date was August 18, 2022. |
Name |
Number of Shares of Rigetti Class A common stock Subject to RSUs |
Grant Date |
Vesting Commencement Date |
Time Based Vesting Schedule |
||||||||||||
Chad T. Rigetti |
2,762,867 | January 25, 2022 | January 25, 2022 | (A | ), (C) | |||||||||||
Taryn Naidu |
429,739 | January 25, 2022 | January 25, 2022 | (A | ), (C) | |||||||||||
Rick Danis |
159,234 | January 25, 2022 | January 25, 2022 | (A | ), (C) | |||||||||||
Brian Sereda |
8,500 | January 25, 2022 | January 25, 2022 | (B | ), (C) | |||||||||||
Michael Harburn |
200,321 | January 25, 2022 | January 25, 2022 | (B | ), (C) | |||||||||||
David Rivas |
128,697 | January 25, 2022 | January 25, 2022 | (A | ), (D) | |||||||||||
Mandy Birch |
193,014 | January 25, 2022 | January 25, 2022 | (A | ), (D) |
(A) | The RSUs are subject to the time-based vesting requirement and liquidity-event vesting requirement described in the summary of material terms of the 2013 Plan under “2013 Plan” below (the Closing of the Business Combination will satisfy the liquidity-event requirement). Time-based vesting will occur in accordance with the following schedule (subject to the individual continuing as a Service Provider (as defined in the 2013 Plan) on each such vesting date): (i) 50% of the total number of RSUs will vest in substantially equal installments (rounded down, except for the final scheduled vesting installment) at the end of each month following the vesting commencement date over a period of 12 months and (ii) the remaining 50% of the total number of RSUs will vest in substantially equal installments (rounded down, except for the final scheduled vesting installment) at the end of each month following the vesting commencement |
date over a period of four years. Prongs (i) and (ii) of the time-based vesting will occur concurrently, such that, at the end of the 12-month period immediately following the vesting commencement date, 62.5% of the total number of RSUs will have vested (subject to Participant continuing as a Service Provider on such vesting date). This vesting schedule will also apply to employees who have served in their roles for at least two years before the grant date. |
(B) | The RSUs are subject to the time-based vesting requirement and liquidity-event vesting requirement described in the summary of material terms of the 2013 Plan under “2013 Plan” below (the Closing of the Business Combination will satisfy the liquidity-event requirement). Time-based vesting will occur in accordance with the following schedule (subject to the individual continuing as a Service Provider (as defined in the 2013 Plan) on each such vesting date): one-forty eighth (1/48th) of the total number of RSUs (rounded down, except for the final scheduled vesting installment) will satisfy time-based vesting each month following the vesting commencement date over a period of four years. This vesting schedule will also apply to employees For individuals who have served in their roles for less than two years as of the grant date. |
(C) | After satisfaction of the liquidity-event vesting requirement, in the event of a Change in Control (as defined in the 2013 Plan), 100% of the then unvested shares subject to the RSU grant shall vest immediately prior to the consummation of the Change in Control. |
(D) | After satisfaction of the liquidity-event vesting requirement, in the event of a Change in Control (as defined in the 2013 Plan), 50% of the then unvested shares subject to the RSU grant shall vest immediately prior to the consummation of the Change in Control, with such acceleration to be applied on a pro-rata basis with respect to each remaining vesting tranche. |
Name |
Transaction Cash Bonus |
|||
Chad Rigetti |
$ | 400,000 | ||
Taryn Naidu |
$ | 400,000 | ||
Rick Danis |
$ | 350,000 | ||
Brian Sereda |
$ | 25,000 |
Name |
Number of Rigetti Stock Awards |
|||
Chad Rigetti |
45,000 | |||
Taryn Naidu |
45,000 | |||
Brian Sereda |
5,000 | |||
Rick Danis |
25,000 |
Name |
Number of Rigetti Alignment RSUs |
Rigetti Alignment RSUs Vesting |
Number of 2022 Rigetti Annual RSUs |
2022 Rigetti Annual RSUs Vesting |
||||||||||||
Chad Rigetti |
2,857,444 | (A | ), (C) | 334,700 | (B | ), (C) | ||||||||||
Taryn Naidu |
444,450 | (A | ), (C) | 161,300 | (B | ), (C) | ||||||||||
Rick Danis |
164,685 | (A | ), (C) | 102,800 | (B | ), (C) | ||||||||||
Brian Sereda |
8,791 | (B | ), (C) | 128,600 | (B | ), (D) | ||||||||||
Michael Harburn |
207,178 | (B | ), (C) | 107,900 | (B | ), (D) |
(A) | Time-based vesting will occur in accordance with the following schedule (subject to the individual’s Continuous Service (as defined in the 2022 Plan) on each such vesting date): (i) 50% of the total number of RSUs will vest in substantially equal installments (rounded down, except for the final scheduled vesting installment) on the last day of each calendar month beginning with the month in which the Vesting Commencement Date occurs and over a period of 12 months and (ii) the remaining 50% of the total number of RSUs will vest in substantially equal installments (rounded down, except for the final scheduled vesting installment) on the last day of each calendar month beginning with the month in which the Vesting Commencement Date occurs and over a period of 48 months. Prongs (i) and (ii) of the time-based vesting will occur concurrently, such that, at the end of the 12-month period immediately following the Vesting Commencement Date, 62.5% of the total number of RSUs will have vested (subject to the individual’s Continuous Service (as defined in the 2022 Plan) on such vesting date). This vesting schedule will also apply to employees who have served in their roles for at least two years before the grant date. |
(B) | Time-based vesting will occur in accordance with the following schedule (subject to the individual’s Continuous Service (as defined in the 2022 Plan) on each such vesting date): one-forty eighth (1/48th) of the total number of RSUs (rounded down, except for the final scheduled vesting installment) will satisfy time-based vesting on the last day of each calendar month beginning with the month in which the Vesting Commencement Date occurs and over a period of 48 months. This vesting schedule will also apply to employees who have served in their roles for less than two years as of the grant date. |
(C) | In the event of a Change in Control (as defined in the 2022 Plan), 100% of the then unvested shares subject to the RSUs shall vest immediately prior to the consummation of the Change in Control. |
(D) | In the event of a Change in Control (as defined in the 2022 Plan), 50% of the then unvested shares subject to the RSUs shall vest immediately prior to the consummation of the Change in Control with such acceleration to be applied on a pro-rata basis with respect to each remaining vesting tranche. |
(E) | Time-based vesting will occur in accordance with the following schedule (subject to the individual’s Continuous Service (as defined in the 2022 Plan) on each such vesting date): one-forty eighth (1/48th) of the total number of RSUs (rounded down, except for the final scheduled vesting installment) will satisfy time-based vesting on the last day of each calendar month beginning with the month in which the Vesting Commencement Date occurs and over a period of 48 months. |
Name |
Cash(1) |
Stock Awards ($)(2) |
Option Awards ($) |
All Other Compensation |
Total ($) |
|||||||||||||||
Peter Pace |
$ | — | $ | — | $ | — | — | — | ||||||||||||
Alissa Fitzgerald |
$ | — | $ | — | $ | — | — | — | ||||||||||||
Ray Johnson |
$ | — | $ | — | $ | — | — | — | ||||||||||||
Cathy McCarthy |
$ | — | $ | 1,076,250 | $ | — | — | $ | 1,076,250 |
(1) | None of the non-employee directors received cash compensation for their service as a director during the fiscal year ended December 31, 2021. |
(2) | This column reflects the aggregate grant date fair value of the restricted stock units granted to the director during fiscal year 2021 under the 2013 Plan. The aggregate grant date fair value is computed in accordance with ASC Topic 718 for stock-based compensation transactions. Assumptions used in the calculation of these amounts are included in the notes to our financial statements included elsewhere in this prospectus. In accordance with ASC Topic 718, recognition of compensation expense is deferred until consummation of the Business Combination. This amount does not reflect the actual economic value that may be realized by the director. |
Name |
Shares Underlying Options Outstanding (Vested) at Fiscal Year End |
Shares Underlying Options Outstanding (Unvested) at Fiscal Year End |
Unvested Stock Awards at Fiscal Year End |
|||||||||
Peter Pace |
141,370 | 153,750 | — | |||||||||
Alissa Fitzgerald |
126,731 | 168,388 | — | |||||||||
Ray Johnson |
78,800 | 216,320 | — | |||||||||
Cathy McCarthy |
— | — | 295,120 |
• | arrange for the assumption or substitution of a stock award by a surviving or acquiring corporation; |
• | terminate the stock awards; |
• | accelerate the vesting of the stock award and, to the extent the administrator determines, provide for termination if not exercised (if applicable) at or before the effective time of the merger or change in control; |
• | terminate or cancel or arrange for the termination or cancellation of the stock award, to the extent not vested or not exercised before the effective time of the transaction; or |
• | terminate the Award in exchange for an amount of cash and/or property equal to the amount that would have been attained upon the exercise of such Award or realization of the participant’s rights as of the date of the occurrence of the transaction or the replacement of such award with other rights or property selected by the administrator in its sole discretion; |
• | the amounts involved exceeded or will exceed $120,000; and |
• | any of our directors, executive officers or holders of more than 5% of the company’s capital stock, or any member of the immediate family of, or person sharing the household with, the foregoing persons, had or will have a direct or indirect material interest. |
• | the risks, costs, and benefits to us; |
• | the impact on a director’s independence in the event the related person is a director, immediate family member of a director or an entity with which a director is affiliated; |
• | the terms of the transaction; |
• | the availability of other sources for comparable services or products; and |
• | the terms available to or from, as the case may be, unrelated third parties. |
• | each person known by the Company to be the beneficial owner of more than 5% of outstanding shares of common stock; |
• | each of the Company’s named executive officers and directors; |
• | all executive officers and directors of the Company as a group. |
Name of Beneficial Owner (1) |
Number of Shares of Common Stock Beneficially Owned |
% of Ownership |
||||||
Directors and Named Executive Officers |
||||||||
Chad Rigetti (2) |
7,035,559 | 6.0 | % | |||||
Taryn Naidu (3) |
858,026 | * | ||||||
Brian Sereda (4) |
418 | * | ||||||
Gen. Peter Pace (5) |
295,120 | * | ||||||
David Cowan (6) |
— | — | ||||||
Alissa Fitzgerald (7) |
206,873 | * | ||||||
Ray Johnson (8) |
188,212 | * | ||||||
Cathy McCarthy |
— | — | ||||||
Michael Clifton (9)(10) |
62,500 | * | ||||||
H. Gail Sandford |
— | — | ||||||
All executive officers and directors after the business combination as a group (13 persons) |
9,150,792 | 7.7 | % | |||||
Five Percent Holders |
||||||||
Supernova Partners II LLC (10) |
12,868,000 | 10.9 | % | |||||
Entities affiliated with Bessemer Venture Partners (11) |
21,582,218 | 19.0 | % | |||||
AVG Entities (12) |
7,597,642 | 6.7 | % | |||||
Insurance Company of the West (13) |
9,178,816 | 8.1 | % |
* | Less than 1% |
(1) | Unless otherwise noted, the mailing address of each of those listed in the table above is 775 Heinz Avenue, Berkeley, CA, 94710. |
(2) | Consists of 4,144,913 shares of common stock held by Dr. Rigetti, and 2,890,646 shares of common stock issuable upon the exercise or settlement of options or restricted stock unit awards held by Dr. Rigetti which are exercisable or vest within 60 days of the Closing Date. |
(3) | Consists of 204,960 shares of common stock held by Mr. Naidu or his affiliated entity AlphaNuma LLC at Closing, and 653,066 shares of common stock issuable upon the exercise or settlement of options, Rigetti assumed warrants or restricted stock unit awards which are exercisable or vest within 60 days of the Closing Date. |
(4) | Consists of 418 shares of common stock issuable upon the settlement restricted stock unit awards held by Mr. Sereda which vest within 60 days of the Closing Date. |
(5) | Consists of 295,120 shares of common stock held by Gen. Pace. |
(6) | David Cowan, a member of the Rigetti Board, is a partner at Bessemer Venture Partners. Mr. Cowan disclaims beneficial ownership interest of the securities held by the Bessemer Entities (as defined below) referred to in footnote 11 below, except to the extent of his pecuniary interest, if any, in such securities through an indirect interest in the Bessemer Entities. |
(7) | Consists of 206,873 shares of common stock issuable upon the exercise or settlement of options or restricted stock unit awards held by Ms. Fitzgerald which are exercisable or vest within 60 days of the Closing Date. |
(8) | Consists of 22,788 shares of common stock held by Mr. Johnson, and 165,424 shares of common stock issuable upon the exercise or settlement of options or restricted stock unit awards held by Mr. Johnson which are exercisable or vest within 60 days of the Closing Date. |
(9) | Consists of 62,500 shares of common stock purchased in the PIPE Financing. |
(10) | Supernova Sponsor holds 8,418,000 shares of common stock and 4,450,000 shares underlying private placement warrants held by Supernova Sponsor, which are exercisable for shares of common stock commencing 30 days after the closing of the Business Combination. Supernova Sponsor is governed by a board of managers consisting of four managers: Spencer M. Rascoff, Alexander M. Klabin, Robert D. Reid and Michael S. Clifton. Each manager has one vote, and the approval of a majority of the managers is required to approve any action of Supernova Sponsor. Under the so-called “rule of three,” if voting and dispositive decisions regarding an entity’s securities are made by three or more individuals, and a voting or dispositive decision requires the approval of at least a majority of those individuals, then none of the individuals is deemed a beneficial owner of the entity’s securities. Based upon the foregoing analysis, no director of Supernova Sponsor exercises voting or dispositive control over any of the securities held by Supernova Sponsor, even those in which he or she directly holds a pecuniary interest. Accordingly, none of them will be deemed to have or share beneficial ownership of such shares. Includes 2,479,000 Sponsor Vesting Shares that became unvested and subject to forfeiture as of the Closing and will only vest if, during the five year period following the Closing, the volume weighted average price of common stock equals or exceeds $12.50 for any twenty trading days within a period of thirty consecutive trading days, and (ii) 580,273 Sponsor Vesting Shares held by the Sponsor Holders became unvested and subject to forfeiture as of the Closing and will only vest if, during the five year period following the Closing, the volume weighted average price of common stock equals or exceeds $15.00 for any twenty trading days within a period of thirty consecutive trading days. Any such shares held by the Sponsor Holders that remain unvested after the fifth anniversary of the Closing will be forfeited. The address for Supernova Sponsor is 4301 50th Street NW, Suite 300 PMB 1044, Washington, D.C. 20016. |
(11) | Consists of (i) 9,481,710 shares of common stock held by Bessemer Venture Partners X Institutional L.P., or Bessemer Institutional, and 10,100,508 shares of common stock held by Bessemer Venture Partners X L.P., or Bessemer X, and together with Bessemer Institutional, the Bessemer Entities, and (ii) 968,400 shares of common stock purchased by Bessemer Institutional and 1,031,600 shares of common stock purchased by Bessemer X in the PIPE Financing. Deer X & Co. L.P., or Deer X L.P., is the general partner of the Bessemer Entities. Deer X & Co. Ltd., or Deer X Ltd., is the general partner of Deer X L.P. Adam Fisher, Robert P. Goodman, David Cowan, Jeremy Levine, Byron Deeter, Ethan Kurzweil, Alex Ferrara, Brian Feinstein and Stephen Kraus are the directors of Deer X Ltd. and hold the voting and dispositive power for the Bessemer Entities. Investment and voting decisions with respect to the securities held by the Bessemer Entities are made by the directors of Deer X Ltd. acting as an investment committee. Mr. Cowan disclaims beneficial ownership interest of the securities of the Company held by the Bessemer Entities except to the extent of his pecuniary interest, if any, in such securities through an indirect interest in the Bessemer Entities. The address for the Bessemer Entities is c/o Bessemer Venture Partners, 1865 Palmer Avenue, Suite 104, Larchmont, NY 10538. |
(12) | Consists of (i) 772,613 shares of common stock held by AVG - BIV Rigetti Trust1 2020, 906,446 shares of common stock held by AVG - BIV Rigetti Trust2 2020, 5,344,241 shares of common stock held by AVG - BIV Rigetti Trust3 2020 and 29,429 shares of common stock held by AVGF-BIV 2 Rigetti 2017, LLC, (ii) 100,000 shares of common stock purchased by AVG - BIV Rigetti Trust3 2020 in the PIPE Financing and (iii) 444,913 of common stock issuable upon exercise of Rigetti assumed warrants held by AVG - BIV Rigetti Trust1 2020, AVG - BIV Rigetti Trust2 2020 and AVG - BIV Rigetti Trust3 2020 that are exercisable as of or within 60 days of the Closing Date. |
(13) | Consists of (i) 8,678,816 shares of common stock held by Insurance Company of the West and (ii) 500,000 shares of common stock purchased by Insurance Company of the West in the PIPE Financing. |
Shares of Common Stock |
Warrants (1) to Purchase Common Stock |
|||||||||||||||||||||||||||||||
Name |
Number Beneficially Owned Prior to Offering |
Number Registered for Sale Hereby |
Number Beneficially Owned After Offering |
Percent Owned After Offering |
Number Beneficially Owned Prior to Offering |
Number Registered For Sale Hereby |
Number Beneficially Owner After Offering |
Percent Owner After Offering |
||||||||||||||||||||||||
75 & Sunny LP (2) |
165,000 | 165,000 | — | — | — | — | — | — | ||||||||||||||||||||||||
Alissa Fitzgerald (3) |
295,119 | 295,119 | — | — | — | — | — | |||||||||||||||||||||||||
Alpha Intelligence Capital Fund I (4) |
2,970,197 | 200,000 | 2,770,197 | * | — | — | — | — | ||||||||||||||||||||||||
Alumni Ventures - Rigetti Trust 2022 (5) |
100,000 | 100,000 | — | — | — | — | — | — | ||||||||||||||||||||||||
Alyeska Master Fund, LP (6) |
474,017 | 300,000 | 174,017 | * | — | — | — | — | ||||||||||||||||||||||||
Ancient 1604 LLC (7) |
136,250 | 136,250 | — | — | — | — | — | — | ||||||||||||||||||||||||
Asset Management Exchange CCF - AMX CCF Lansdowne Partners Developed Markets Long Only (8) |
105,988 | 105,988 | — | — | — | — | — | — | ||||||||||||||||||||||||
AVG - BIV Rigetti Trust1 2020 (9) |
860,629 | 860,629 | — | — | — | — | — | — | ||||||||||||||||||||||||
AVG - BIV Rigetti Trust2 2020 (10) |
1,022,123 | 1,022,123 | — | — | — | — | — | — | ||||||||||||||||||||||||
AVG - BIV Rigetti Trust3 2020 (11) |
5,585,461 | 5,585,461 | — | — | — | — | — | — | ||||||||||||||||||||||||
AVGF-BIV 2 Rigetti 2017, LLC(12) |
29,429 | 29,429 | — | — | — | — | — | — | ||||||||||||||||||||||||
Bessemer Venture Partners X Institutional L.P. (13) |
10,450,110 | 10,450,110 | — | — | — | — | — | — | ||||||||||||||||||||||||
Bessemer Venture Partners X L.P. (14) |
11,132,108 | 11,132,108 | — | — | — | — | — | — | ||||||||||||||||||||||||
Brian Sereda (15) |
1,055,564 | 1,055,564 | — | — | — | — | — | — | ||||||||||||||||||||||||
Campbell Pension Plans Master Retirement Trust (16) |
11,587 | 11,587 | — | — | — | — | — | — | ||||||||||||||||||||||||
Canada Life Global Growth Equity Fund (T. Rowe Price) (17) |
10,052 | 10,052 | — | — | — | — | — | — | ||||||||||||||||||||||||
Cathy McCarthy (18) |
295,120 | 295,120 | — | — | — | — | — | — | ||||||||||||||||||||||||
Chad T. Rigetti (19) |
10,847,174 | 10,847,174 | — | — | — | — | — | — | ||||||||||||||||||||||||
Coronation Global Opportunities Fund (20) |
128,516 | 128,516 | — | — | — | — | — | — | ||||||||||||||||||||||||
Damien Hooper-Campbell (21) |
34,500 | 34,500 | — | — | — | — | — | — | ||||||||||||||||||||||||
Data Collective III, L.P. (22) |
1,673,615 | 1,673,615 | — | — | — | — | — | — | ||||||||||||||||||||||||
David Rivas (23) |
625,168 | 625,168 | — | — | — | — | — | — | ||||||||||||||||||||||||
DCVC Opportunity Fund II, L.P. (24) |
2,038,265 | 2,038,265 | — | — | — | — | — | — | ||||||||||||||||||||||||
DEE STREET GLOBAL EQUITY FUND (25) |
54,458 | 54,458 | — | — | — | — | — | — | ||||||||||||||||||||||||
Delaware Public Employees’ Retirement System (26) |
271,109 | 271,109 | — | — | — | — | — | — | ||||||||||||||||||||||||
Dr. Ray O. Johnson (27) |
317,908 | 317,908 | — | — | — | — | — | — | ||||||||||||||||||||||||
Equipsuper Pty Ltd as Trustee for Equipsuper Superannuation Fund (28) |
203,459 | 203,459 | — | — | — | — | — | — | ||||||||||||||||||||||||
Franklin Templeton Investment Funds - Franklin Technology Fund (29) |
1,500,000 | 1,500,000 | — | — | — | — | — | — | ||||||||||||||||||||||||
Gregg Renfrew (30) |
34,500 | 34,500 | — | — | — | — | — | — |
Shares of Common Stock |
Warrants (1) to Purchase Common Stock |
|||||||||||||||||||||||||||||||
Name |
Number Beneficially Owned Prior to Offering |
Number Registered for Sale Hereby |
Number Beneficially Owned After Offering |
Percent Owned After Offering |
Number Beneficially Owned Prior to Offering |
Number Registered For Sale Hereby |
Number Beneficially Owner After Offering |
Percent Owner After Offering |
||||||||||||||||||||||||
HKJC Investment Trust Fund - Equity Series Trust (31) |
125,169 | 125,169 | — | — | — | — | — | — | ||||||||||||||||||||||||
In-Q-Tel, (32) |
195,858 | 1,000 | 194,858 | * | — | — | — | — | ||||||||||||||||||||||||
Insurance Company of the West (33) |
9,178,816 | 9,178,816 | — | — | — | — | — | — | ||||||||||||||||||||||||
Jim Lanzone (34) |
34,500 | 34,500 | — | — | — | — | — | — | ||||||||||||||||||||||||
Katie Curnutte (35) |
34,500 | 34,500 | — | — | — | — | — | — | ||||||||||||||||||||||||
Kenneth Fox (36) |
34,500 | 34,500 | — | — | — | — | — | — | ||||||||||||||||||||||||
Keysight Technologies, Inc. (37) |
2,951,220 | 2,951,220 | — | — | — | — | — | — | ||||||||||||||||||||||||
Lansdowne Developed Markets Long Only Master Fund Limited (38) |
770,276 | 770,276 | — | — | — | — | — | — | ||||||||||||||||||||||||
Lansdowne DM Long Only Cayman Master L.P. (39) |
304,608 | 304,608 | — | — | — | — | — | — | ||||||||||||||||||||||||
Lansdowne DMLO Davies Street LP (40) |
381,130 | 381,130 | — | — | — | — | — | — | ||||||||||||||||||||||||
Lansdowne ICAV - Lansdowne Developed Markets Long Only Fund (41) |
74,916 | 74,916 | — | — | — | — | — | — | ||||||||||||||||||||||||
Leslie Enterprises LP (42) |
1,004,110 | 25,000 | 979,110 | * | — | — | — | — | ||||||||||||||||||||||||
Mandy Birch (43) |
389,385 | 389,385 | — | — | — | — | — | — | ||||||||||||||||||||||||
Michael Clifton (44) |
62,500 | 62,500 | — | — | — | — | — | — | ||||||||||||||||||||||||
Michael Harburn (45) |
834,920 | 834,920 | — | — | — | — | — | — | ||||||||||||||||||||||||
Nimble Ventures, LLC (46) |
3,256,298 | 3,256,298 | — | — | — | — | — | — | ||||||||||||||||||||||||
Northgate CommsTech Innovations Partners, L.P. (47) |
4,266,442 | 4,266,442 | — | — | — | — | — | — | ||||||||||||||||||||||||
Palantir Technologies Inc. (48) |
1,000,000 | 1,000,000 | — | — | — | — | — | — | ||||||||||||||||||||||||
Peter Pace (49) |
295,120 | 295,120 | — | — | — | — | — | — | ||||||||||||||||||||||||
Public Service Pension Plan Fund (50) |
129,884 | 129,884 | — | — | — | — | — | — | ||||||||||||||||||||||||
Rajeev Singh (51) |
34,500 | 34,500 | — | — | — | — | — | — | ||||||||||||||||||||||||
Rick Danis (52) |
648,408 | 648,408 | — | — | — | — | — | — | ||||||||||||||||||||||||
Robert Gelfond (53) |
539,554 | 50,000 | 489,554 | * | — | — | — | — | ||||||||||||||||||||||||
Robert Reid (54) |
136,250 | 136,250 | — | — | — | — | — | — | ||||||||||||||||||||||||
Robert Rigetti (55) |
162,989 | 50,000 | 112,989 | * | — | — | — | — | ||||||||||||||||||||||||
Supernova Partners II LLC (56) |
8,418,000 | 8,418,000 | — | — | 4,450,000 | 4,450,000 | — | — | ||||||||||||||||||||||||
T. Rowe Price Global Equity Fund (57) |
1,026,678 | 1,026,678 | — | — | — | — | — | — | ||||||||||||||||||||||||
T. Rowe Price Global Growth Equity Pool (58) |
219,751 | 219,751 | — | — | — | — | — | — | ||||||||||||||||||||||||
T. Rowe Price Global Growth Equity Trust (59) |
191,249 | 191,249 | — | — | — | — | — | — | ||||||||||||||||||||||||
T. Rowe Price Global Growth Stock Fund (60) |
358,875 | 358,875 | — | — | — | — | — | — | ||||||||||||||||||||||||
Taryn Naidu (61) |
1,747,915 | 1,747,915 | — | — | — | — | — | — | ||||||||||||||||||||||||
Teachers’ Pension Plan Fund (62) |
77,356 | 77,356 | — | — | — | — | — | — | ||||||||||||||||||||||||
Trinity Capital Inc. (63) |
833,132 | 833,132 | — | — | — | — | — | |||||||||||||||||||||||||
Trust U/W Carl M. Loeb FBO Arthur Loeb (64) |
12,500 | 12,500 | — | — | — | — | — | — | ||||||||||||||||||||||||
Trust U/W Carl M. Loeb FBO Elisabeth Levin (65) |
12,500 | 12,500 | — | — | — | — | — | — | ||||||||||||||||||||||||
Virginia Retirement System (66) |
244,749 | 244,749 | — | — | — | — | — | — | ||||||||||||||||||||||||
Witan Investment Trust PLC (67) |
249,214 | 249,214 | — | — | — | — | — | — |
* | Less than one percent. |
(1) | Represents the private placement warrants. |
(2) | Consists of shares of common stock issued in the PIPE Financing. The managing partner of 75 & Sunny LP is Spencer Racoff, who was a member of the Supernova Board prior to the Business Combination. |
(3) | Consists of 295,119 shares of common stock issuable upon exercise of options. Ms. Fitzgerald is a member of the Board. |
(4) | Consists of 200,000 shares of common stock issued in the PIPE Financing, 2,547,739 shares of common stock held of record and 222,458 shares issuable upon exercise of Rigetti assumed warrants. |
(5) | Consists of shares of common stock issued in the PIPE Financing. |
(6) | Alyeska Investment Group, L.P., the investment manager of Alyeska Master Fund, L.P. (“Master Fund”), has voting and investment control of the shares held by the Master Fund. Anand Parekh is the Chief Executive Officer of Alyeska Investment Group, L.P. and may be deemed to be the beneficial owner of such shares. Mr. Parekh, however, disclaims any beneficial ownership of the shares held by the Master Fund. The registered address of Alyeska Master Fund, L.P. is at c/o Maples Corporate Services Limited, P.O. Box 309, Ugland House, South Church Street George Town, Grand Cayman, KY1-1104, Cayman Islands. Alyeska Investment Group, L.P. is located at 77 W. Wacker, Suite 700, Chicago IL 60601. |
(7) | Consists of shares of common stock issued in the PIPE Financing. Alexander Klabin is the manager of Klabin Descendants Delaware Trust LLC, which is the sole member of Ancient 1604 LLC. Mr. Klabin was a member of the Supernova Board prior to the Business Combination. |
(8) | Consists of shares of common stock issued in the PIPE Financing. |
(9) | Consists of 2,772,613 shares of common stock held of record and 88,016 shares issuable upon exercise of Rigetti assumed warrants. |
(10) | Consists of 906,446 shares of common stock held of record and 115,677 shares issuable upon exercise of Rigetti assumed warrants. |
(11) | Consists of 5,344,241 shares of common stock held of record and 241,220 shares issuable upon exercise of Rigetti assumed warrants. |
(12) | Consists of 29,429 shares of common stock held of record. |
(13) | Consists of 9,481,710 shares of common stock held of record and 968,400 shares of common stock purchased in the PIPE Financing. Deer X & Co. L.P., or Deer X L.P., is the general partner of Bessemer Venture Partners X Institutional L.P., or Bessemer Institutional. Deer X & Co. Ltd., or Deer X Ltd., is the general partner of Deer X L.P. Adam Fisher, Robert P. Goodman, David Cowan, Jeremy Levine, Byron Deeter, Ethan Kurzweil, Alex Ferrara, Brian Feinstein and Stephen Kraus are the directors of Deer X Ltd. and hold the voting and dispositive power for Bessemer Institutional. Investment and voting decisions with respect to the securities held by Bessemer Institutional are made by the directors of Deer X Ltd. acting as an investment committee. Mr. Cowan disclaims beneficial ownership interest of the securities of the Company held by Bessemer Institutional except to the extent of his pecuniary interest, if any, in such securities through an indirect interest in Bessemer Institutional. The address for Bessemer Institutional is c/o Bessemer Venture Partners, 1865 Palmer Avenue, Suite 104, Larchmont, NY 10538. |
(14) | Consists of 10,100,508 shares of common stock held of record and 1,031,600 shares of common stock purchased in the PIPE Financing. Deer X & Co. L.P., or Deer X L.P., is the general partner of Bessemer Venture Partners X L.P., or Bessemer X. Deer X & Co. Ltd., or Deer X Ltd., is the general partner of Deer X L.P. Adam Fisher, Robert P. Goodman, David Cowan, Jeremy Levine, Byron Deeter, Ethan Kurzweil, Alex Ferrara, Brian Feinstein and Stephen Kraus are the directors of Deer X Ltd. and hold the voting and dispositive power for Bessemer X. Investment and voting decisions with respect to the securities held by Bessemer X are made by the directors of Deer X Ltd. acting as an investment committee. Mr. Cowan disclaims beneficial ownership interest of the securities of the Company held by Bessemer X except to the extent of his pecuniary interest, if any, in such securities through an indirect interest in Bessemer X. The address for Bessemer X is c/o Bessemer Venture Partners, 1865 Palmer Avenue, Suite 104, Larchmont, NY 10538. |
(15) | Consists 1,055,564 shares issuable upon settlement of restricted stock units. Mr. Sereda serves as the Chief Financial Officer of Rigetti. |
(16) | Consists of shares of common stock issued in the PIPE Financing. |
(17) | Consists of shares of common stock issued in the PIPE Financing. |
(18) | Ms. McCarthy is a member of the Board. Consists of 295,120 shares issuable upon vesting and settlement of RSUs. |
(19) | Mr. Rigetti is the founder and Chief Executive Officer of Rigetti. Consists of 4,144,913 shares of common stock held of record, 3,219,251 shares issuable upon vesting and settlement of RSUs and 3,483,010 shares issuable upon exercise of warrants. |
(20) | Consists of shares of common stock issued in the PIPE Financing. |
(21) | The selling securityholder was a member of the Supernova Board prior to the Business Combination. |
(22) | Consists of 50,000 shares of common stock issued in the PIPE Financing, 1,470,533 shares of common stock held of record and 153,062 shares issuable upon exercise of Rigetti assumed warrants. |
(23) | Consists of 241,814 shares of common stock issuable upon vesting and settlement of RSUs and 383,354 shares issuable upon exercise of options. Mr. Rivas is an executive officer of the Company. |
(24) | Consists of 50,000 shares of common stock issued in the PIPE Financing, 1,807,640 shares of common stock held of record and 180,625 shares issuable upon exercise of Rigetti assumed warrants. |
(25) | Consists of shares of common stock issued in the PIPE Financing. |
(26) | Consists of shares of common stock issued in the PIPE Financing. |
(27) | Dr. Johnson is a member of the Board. Consists of 22,788 shares of common stock and 295,120 shares issuable upon exercise of options. |
(28) | Consists of shares of common stock issued in the PIPE Financing. |
(29) | Consists of shares of common stock issued in the PIPE Financing. |
(30) | Consists of Founder Shares. The selling securityholder was a member of the Supernova Board prior to the Business Combination. |
(31) | Consists of shares of common stock issued in the PIPE Financing. |
(32) | Consists of 1,000 shares of common stock issued in the PIPE Financing, 177,458 shares of common stock held of record and 17,400 shares issuable upon exercise of Rigetti assumed warrants. |
(33) | Consists of 500,000 shares of common stock issued in the PIPE Financing and 8,678,816 shares of common stock held of record. |
(34) | Consists of Founder Shares. The selling securityholder was a member of the Supernova Board prior to the Business Combination. |
(35) | Consists of Founder Shares. The selling securityholder was a member of the Supernova Board prior to the Business Combination. |
(36) | Consists of Founder Shares. The selling securityholder was a member of the Supernova Board prior to the Business Combination. |
(37) | Consists of shares of common stock issued in the PIPE Financing. |
(38) | Consists of shares of common stock issued in the PIPE Financing. |
(39) | Consists of shares of common stock issued in the PIPE Financing. |
(40) | Consists of shares of common stock issued in the PIPE Financing. |
(41) | Consists of shares of common stock issued in the PIPE Financing. |
(42) | Consists of 25,000 shares of common stock issued in the PIPE Financing and 979,110 shares of common stock held of record. |
(43) | Ms. Birch is a former employee of the Company. Consists of 147,341 shares of common stock held of record, 19,078 shares of common stock issuable upon vesting and settlement of restricted stock units and 222,966 shares of common stock issuable upon exercise of options. |
(44) | Mr. Clifton is a member of the Board. |
(45) | Mr. Harburn is an executive officer of the Company. Consists of 480,329 shares of common stock issuable upon vesting and settlement of RSUs and 354,591 shares of common stock issuable upon exercise of options. |
(46) | Consists of 3,145,069 shares of common stock held of record and 111,229 shares of common stock issuable upon exercise of Rigetti assumed warrants. |
(47) | Consists of 350,000 PIPE Shares and 3,471,526 shares of common stock held of record and 444,916 shares of common stock issuable upon exercise of Rigetti assumed warrants. |
(48) | Consists of shares of common stock issued in the PIPE Financing. |
(49) | The selling securityholder is a member of the Board. |
(50) | Consists of shares of common stock issued in the PIPE Financing. |
(51) | Consists of Founder Shares. The selling securityholder was a member of the Supernova Board prior to the Business Combination. |
(52) | Consists of 260,932 shares of common stock issuable upon vesting and settlement of RSUs and 387,476 shares of common stock issuable upon exercise of options. Mr. Danis is an executive officer of the Company. |
(53) | Consists of 50,000 shares of common stock issued in the PIPE Financing, 433,940 shares of common stock held of record and 55,614 shares of common stock issuable upon exercise of Rigetti assumed warrants. |
(54) | Consists of Founder Shares. The selling securityholder was a member of the Supernova Board prior to the Business Combination. |
(55) | Consists of 50,000 shares of common stock issued in the PIPE Financing, 101,867 shares of common stock held of record and 11,122 shares of common stock issuable upon exercise of Rigetti assumed warrants. |
(56) | Consists of 8,418,000 Founder Shares and 4,450,000 private placement warrants. Supernova Partners II LLC is governed by a board of managers consisting of four managers: Spencer M. Rascoff, Alexander M. Klabin, Robert D. Reid and Michael S. Clifton. As a result, each of Messrs. Rascoff, Klabin, Reid, and Clifton may be deemed to share beneficial |
ownership of the securities owned by Supernova Partners II LLC. However, each manager of Supernova Partners LLC has one vote, and the approval of a majority of the manager is required to approve any action of Supernova Partners LLC. Mr. Clifton is a member of the Board. Includes 2,479,000 Sponsor Vesting Shares that became unvested and subject to forfeiture as of the Closing and will only vest if, during the five year period following the Closing, the volume weighted average price of common stock equals or exceeds $12.50 for any twenty trading days within a period of thirty consecutive trading days, and (ii) 580,273 Sponsor Vesting Shares held by the Sponsor Holders became unvested and subject to forfeiture as of the Closing and will only vest if, during the five year period following the Closing, the volume weighted average price of common stock equals or exceeds $15.00 for any twenty trading days within a period of thirty consecutive trading days. Any such shares held by the Sponsor Holders that remain unvested after the fifth anniversary of the Closing will be forfeited. The address for Supernova Sponsor is 4301 50th Street NW, Suite 300 PMB 1044, Washington, D.C. 20016. |
(57) | Consists of shares of common stock issued in the PIPE Financing. |
(58) | Consists of shares of common stock issued in the PIPE Financing. |
(59) | Consists of shares of common stock issued in the PIPE Financing. |
(60) | Consists of shares of common stock issued in the PIPE Financing. |
(61) | Consists of 199,075 shares of common stock held of record, 716,281 shares of common stock issuable upon exercise of options, 804,429 shares of common stock issuable upon settlement of restricted stock units, and 22,245 shares issuable upon exercise of Rigetti assumed warrants. Also includes 5,885 shares held by AlphaNuma LLC, of which Mr. Naidu is the sole member. Mr. Naidu serves as the Chief Operating Officer of Rigetti. |
(62) | Consists of shares of common stock issued in the PIPE Financing. |
(63) | Consists of 50,000 shares of common stock issued in the PIPE Financing and 783,132 shares of common stock issuable upon exercise of Rigetti assumed warrants. |
(64) | Consists of shares of common stock issued in the PIPE Financing. |
(65) | Consists of shares of common stock issued in the PIPE Financing. |
(66) | Consists of shares of common stock issued in the PIPE Financing. |
(67) | Consists of shares of common stock issued in the PIPE Financing. |
• | in whole and not in part; |
• | at a price of $0.01 per warrant; |
• | upon a minimum of 30 days’ prior written notice of redemption to each warrant holder; and |
• | if, and only if, the closing price of the shares of common stock equals or exceeds $18.00 per share (as adjusted for adjustments to the number of shares issuable upon exercise or the exercise price of a warrant as described under the heading “— Anti-dilution Adjustments |
• | in whole and not in part; |
• | at $0.10 per warrant; |
• | upon a minimum of 30 days’ prior written notice of redemption provided |
• | if, and only if, the closing price of shares of common stock equals or exceeds $10.00 per public share (as adjusted for adjustments to the number of shares issuable upon exercise or the exercise price of a |
warrant as described under the heading “— Anti-dilution Adjustments |
Fair Market Value of Common Stock |
||||||||||||||||||||||||||||||||||||
Redemption Date (period to expiration of warrants) |
≤ | 10.00 |
11.00 |
12.00 |
13.00 |
14.00 |
15.00 |
16.00 |
17.00 |
≥ | 18.00 |
|||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||
60 months |
0.261 | 0.281 | 0.297 | 0.311 | 0.324 | 0.337 | 0.348 | 0.358 | 0.361 | |||||||||||||||||||||||||||
57 months |
0.257 | 0.277 | 0.294 | 0.310 | 0.324 | 0.337 | 0.348 | 0.358 | 0.361 | |||||||||||||||||||||||||||
54 months |
0.252 | 0.272 | 0.291 | 0.307 | 0.322 | 0.335 | 0.347 | 0.357 | 0.361 | |||||||||||||||||||||||||||
51 months |
0.246 | 0.268 | 0.287 | 0.304 | 0.320 | 0.333 | 0.346 | 0.357 | 0.361 | |||||||||||||||||||||||||||
48 months |
0.241 | 0.263 | 0.283 | 0.301 | 0.317 | 0.332 | 0.344 | 0.356 | 0.361 | |||||||||||||||||||||||||||
45 months |
0.235 | 0.258 | 0.279 | 0.298 | 0.315 | 0.330 | 0.343 | 0.356 | 0.361 | |||||||||||||||||||||||||||
42 months |
0.228 | 0.252 | 0.274 | 0.294 | 0.312 | 0.328 | 0.342 | 0.355 | 0.361 | |||||||||||||||||||||||||||
39 months |
0.221 | 0.246 | 0.269 | 0.290 | 0.309 | 0.325 | 0.340 | 0.354 | 0.361 | |||||||||||||||||||||||||||
36 months |
0.213 | 0.239 | 0.263 | 0.285 | 0.305 | 0.323 | 0.339 | 0.353 | 0.361 | |||||||||||||||||||||||||||
33 months |
0.205 | 0.232 | 0.257 | 0.280 | 0.301 | 0.320 | 0.337 | 0.352 | 0.361 | |||||||||||||||||||||||||||
30 months |
0.196 | 0.224 | 0.250 | 0.274 | 0.297 | 0.316 | 0.335 | 0.351 | 0.361 | |||||||||||||||||||||||||||
27 months |
0.185 | 0.214 | 0.242 | 0.268 | 0.291 | 0.313 | 0.332 | 0.350 | 0.361 | |||||||||||||||||||||||||||
24 months |
0.173 | 0.204 | 0.233 | 0.260 | 0.285 | 0.308 | 0.329 | 0.348 | 0.361 | |||||||||||||||||||||||||||
21 months |
0.161 | 0.193 | 0.223 | 0.252 | 0.279 | 0.304 | 0.326 | 0.347 | 0.361 | |||||||||||||||||||||||||||
18 months |
0.146 | 0.179 | 0.211 | 0.242 | 0.271 | 0.298 | 0.322 | 0.345 | 0.361 | |||||||||||||||||||||||||||
15 months |
0.130 | 0.164 | 0.197 | 0.230 | 0.262 | 0.291 | 0.317 | 0.342 | 0.361 | |||||||||||||||||||||||||||
12 months |
0.111 | 0.146 | 0.181 | 0.216 | 0.250 | 0.282 | 0.312 | 0.339 | 0.361 | |||||||||||||||||||||||||||
9 months |
0.090 | 0.125 | 0.162 | 0.199 | 0.237 | 0.272 | 0.305 | 0.336 | 0.361 | |||||||||||||||||||||||||||
6 months |
0.065 | 0.099 | 0.137 | 0.178 | 0.219 | 0.259 | 0.296 | 0.331 | 0.361 | |||||||||||||||||||||||||||
3 months |
0.034 | 0.065 | 0.104 | 0.150 | 0.197 | 0.243 | 0.286 | 0.326 | 0.361 | |||||||||||||||||||||||||||
0 months |
— | — | 0.042 | 0.115 | 0.179 | 0.233 | 0.281 | 0.323 | 0.361 |
• | before such date, the board of directors of the corporation approved either the business combination or the transaction that resulted in the stockholder becoming an interested stockholder; |
• | upon completion of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction began, excluding for purposes of determining the voting stock outstanding, but not the outstanding voting stock owned by the interested stockholder, those shares owned (1) by persons who are directors and also officers and (2) employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or |
• | on or after such date, the business combination is approved by the board of directors and authorized at an annual or special meeting of the stockholders, and not by written consent, by the affirmative vote of at least 66 2/3% of the outstanding voting stock that is not owned by the interested stockholder. |
• | any merger or consolidation involving the corporation and the interested stockholder; |
• | any sale, transfer, pledge or other disposition of 10% or more of the assets of the corporation involving the interested stockholder; |
• | subject to certain exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder; |
• | any transaction involving the corporation that has the effect of increasing the proportionate share of the stock or any class or series of the corporation beneficially owned by the interested stockholder; or |
• | the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits by or through the corporation. |
• | providing for a classified board of directors with staggered, three-year terms; |
• | the ability of the Board to issue up to 10,000,000 shares of preferred stock, including “blank check” preferred stock, with any rights, preferences and privileges as they may designate, including the right to approve an acquisition or other change of control; |
• | provide that the authorized number of directors may be changed only by resolution of the Board; |
• | provide that, subject to the rights of the holders of any series of preferred stock, any individual director or directors may be removed only with cause by the affirmative vote of the holders of at least 66 2/3% of the voting power of all of the then-outstanding shares of our capital stock entitled to vote generally in the election of directors, voting together as a single class; |
• | provide that all vacancies, including newly created directorships, may, except as otherwise required by law, be filled by the affirmative vote of a majority of directors then in office, even if less than a quorum; |
• | require that any action to be taken by our stockholders must be effected at a duly called annual or special meeting of stockholders and not be taken by written consent or electronic transmission; |
• | provide that stockholders seeking to present proposals before a meeting of stockholders or to nominate candidates for election as directors at a meeting of stockholders must provide advance notice in writing, and also specify requirements as to the form and content of a stockholder’s notice; |
• | provide that special meetings of our stockholders may be called by the chairperson of the Board, the chief executive officer or by the Board pursuant to a resolution adopted by a majority of the total number of authorized directors; and |
• | not provide for cumulative voting rights, therefore allowing the holders of a majority of the shares of common stock entitled to vote in any election of directors to elect all of the directors standing for election, if they should so choose. |
• | 1% of the total number of our common stock then outstanding; or |
• | the average weekly reported trading volume of our common stock during the four calendar weeks preceding the filing of a notice on Form 144 with respect to the sale. |
• | the issuer of the securities that was formerly a shell company has ceased to be a shell company; |
• | the issuer of the securities is subject to the reporting requirements of Section 13 or 15(d) of the Exchange Act; |
• | the issuer of the securities has filed all Exchange Act reports and material required to be filed, as applicable, during the preceding 12 months (or such shorter period that the issuer was required to file such reports and materials), other than Form 8-K reports; and |
• | at least one year has elapsed from the time that the issuer filed current Form 10 type information with the SEC reflecting its status as an entity that is not a shell company. |
• | an individual who is a citizen or resident of the United States; |
• | a corporation, or an entity treated as a corporation for U.S. federal income tax purposes, created or organized in the United States or under the laws of the United States or of any state thereof or the District of Columbia; |
• | an estate, the income of which is subject to U.S. federal income tax regardless of its source; or |
• | a trust if (a) a U.S. court can exercise primary supervision over the trust’s administration and one or more U.S. persons have the authority to control all of the trust’s substantial decisions or (b) the trust has a valid election in effect under applicable U.S. Treasury Regulations to be treated as a U.S. person. |
• | the gain is effectively connected with the conduct of a trade or business by the non-U.S. Holder within the United States (and, if an applicable tax treaty so requires, is attributable to a U.S. permanent establishment or fixed base maintained by the non-U.S. Holder); |
• | the non-U.S. Holder is an individual who is present in the United States for 183 days or more in the taxable year of disposition and certain other conditions are met; or |
• | we are or have been a “United States real property holding corporation” for U.S. federal income tax purposes at any time during the shorter of the five-year period ending on the date of disposition or the period that the non-U.S. Holder held our common stock or warrants and, in the case where shares of our common stock are regularly traded on an established securities market, (i) the non-U.S. Holder is disposing of our common stock and has owned, directly or constructively, more than 5% of our common stock at any time within the shorter of the five-year period preceding the disposition or such Non-U.S. Holder’s holding period for the shares of our common stock or (ii) in the case where our warrants are regularly traded on an established securities market, the non-U.S. Holder is disposing of our warrants and has owned, directly or constructively, more than 5% of our warrants at any time within the shorter of the five-year period preceding the disposition or such Non-U.S. Holder’s holding period for the shares of our warrants. There can be no assurance that our common stock or warrants will be treated as regularly traded or not regularly traded on an established securities market for this purpose. |
• | purchases by a broker-dealer as principal and resale by such broker-dealer for its own account pursuant to this prospectus; |
• | ordinary brokerage transactions and transactions in which the broker solicits purchasers; |
• | block trades in which the broker-dealer so engaged will attempt to sell the shares as agent but may position and resell a portion of the block as principal to facilitate the transaction; |
• | an over-the-counter distribution in accordance with the rules of Nasdaq; |
• | through trading plans entered into by a selling securityholder pursuant to Rule 10b5-1 under the Exchange Act, that are in place at the time of an offering pursuant to this prospectus and any applicable prospectus supplement hereto that provide for periodic sales of their securities on the basis of parameters described in such trading plans; |
• | short sales; |
• | distribution to employees, members, limited partners or stockholders of the selling securityholders; |
• | through the writing or settlement of options or other hedging transaction, whether through an options exchange or otherwise; |
• | by pledge to secured debts and other obligations; |
• | delayed delivery arrangements; |
• | to or through underwriters or broker-dealers; |
• | in “at the market” offerings, as defined in Rule 415 under the Securities Act, at negotiated prices, at prices prevailing at the time of sale or at prices related to such prevailing market prices, including sales made directly on a national securities exchange or sales made through a market maker other than on an exchange or other similar offerings through sales agents; |
• | in privately negotiated transactions; |
• | in options transactions; |
• | through a combination of any of the above methods of sale; or |
• | any other method permitted pursuant to applicable law. |
Page |
||||
RIGETTI HOLDINGS, INC. |
||||
F-3 |
||||
Audited Consolidated Financial Statements: |
||||
F-4 |
||||
F-5 |
||||
F-6 |
||||
F-7 |
||||
F-8 |
||||
F-9 |
||||
SUPERNOVA PARTNERS ACQUISITION COMPANY II, LTD. |
||||
F-43 | ||||
Audited Consolidated Financial Statements |
||||
F-44 | ||||
F-45 | ||||
F-46 | ||||
F-47 | ||||
F-48 |
December 31, |
January 31, |
|||||||
2021 |
2021 |
|||||||
Assets |
||||||||
Current assets: |
||||||||
Cash |
$ | 11,728,516 | $ | 22,202,388 | ||||
Accounts receivable |
1,542,540 | 479,374 | ||||||
Prepaid expenses and other current assets |
1,350,690 | 1,035,703 | ||||||
Deferred offering costs |
3,448,470 | — | ||||||
|
|
|
|
|||||
Total current assets |
18,070,216 | 23,717,465 | ||||||
Property and equipment, net |
22,497,484 | 20,140,872 | ||||||
Restricted cash |
317,134 | 317,134 | ||||||
Other assets |
164,341 | 129,363 | ||||||
Goodwill |
5,377,255 | 5,377,255 | ||||||
|
|
|
|
|||||
Total assets |
$ | 46,426,430 | $ | 49,682,089 | ||||
|
|
|
|
|||||
Liabilities, redeemable convertible preferred stock and stockholders’ deficit |
||||||||
Current liabilities: |
||||||||
Accounts payable |
$ | 1,970,998 | $ | 1,107,924 | ||||
Accrued expenses and other current liabilities |
4,035,615 | 1,603,299 | ||||||
Deferred revenue - current |
984,976 | 491,827 | ||||||
Debt - current portion |
1,290,538 | — | ||||||
|
|
|
|
|||||
Total current liabilities |
8,282,127 | 3,203,050 | ||||||
Debt - net of current portion |
23,500,494 | — | ||||||
Derivative warrant liabilities |
4,354,707 | — | ||||||
Other liabilities |
294,632 | 381,300 | ||||||
|
|
|
|
|||||
Total liabilities |
36,431,960 | 3,584,350 | ||||||
Commitments and contingencies (Note 6) |
||||||||
Redeemable convertible preferred stock, par value $0.000001 per share. 102,891,847 shares authorized at December 31, 2021 and January 31, 2021, respectively; and 98,726,505 shares issued and outstanding at December 31, 2021 and January 31, 2021, respectively (aggregate liquidation preference of $89,524,504 at December 31, 2021) |
81,523,141 | 81,523,141 | ||||||
Stockholders’ deficit: |
||||||||
Common stock, par value $0.000001 per share. 170,333,338 shares authorized at December 31, 2021 and January 31, 2021, respectively; 23,153,127 and 21,071,085 of shares issued and outstanding at December 31, 2021 and January 31, 2021, respectively |
23 | 21 | ||||||
Additional paid-in capital |
135,550,822 | 133,407,584 | ||||||
Accumulated other comprehensive gain |
51,815 | 56,825 | ||||||
Accumulated deficit |
(207,131,331 | ) | (168,889,832 | ) | ||||
|
|
|
|
|||||
Total stockholders’ deficit |
(71,528,671 | ) | (35,425,402 | ) | ||||
|
|
|
|
|||||
Total liabilities, redeemable convertible preferred stock and stockholders’ deficit |
$ | 46,426,430 | $ | 49,682,089 | ||||
|
|
|
|
11 Months Ended |
Year Ended |
|||||||
December 31, |
January 31, |
|||||||
2021 |
2021 |
|||||||
Revenue |
$ | 8,196,306 | $ | 5,542,598 | ||||
Cost of revenue |
1,623,336 | 1,491,610 | ||||||
|
|
|
|
|||||
Total gross profit |
6,572,970 | 4,050,988 | ||||||
Operating expenses: |
||||||||
Research and development |
26,927,599 | 24,099,335 | ||||||
General and administrative |
11,299,068 | 13,157,735 | ||||||
Sales and marketing |
2,474,968 | 1,885,565 | ||||||
|
|
|
|
|||||
Total operating expenses |
40,701,635 | 39,142,635 | ||||||
|
|
|
|
|||||
Loss from operations |
(34,128,665 | ) | (35,091,647 | ) | ||||
|
|
|
|
|||||
Other (expense) income , net: |
||||||||
Gain on extinguishment of debt |
— | 8,913,532 | ||||||
Change in fair value of warrant liability |
(1,664,133 | ) | — | |||||
Interest expense |
(2,465,135 | ) | (51,666 | ) | ||||
Interest income |
9,852 | 60,154 | ||||||
Other income |
6,582 | 42,131 | ||||||
|
|
|
|
|||||
Total other (expense) income, net |
(4,112,834 | ) | 8,964,151 | |||||
Net loss before provision for income taxes |
||||||||
Provision for income taxes |
||||||||
|
|
|
|
|||||
Net loss |
$ | (38,241,499 | ) | $ | (26,127,496 | ) | ||
|
|
|
|
|||||
Net loss per share attribute to common stockholders - basic and diluted |
$ | (1.74 | ) | $ | (1.26 | ) | ||
Weighted average shares used in computing net loss per share attributable to common stockholders – basic and diluted |
21,941,997 | 20,719,085 |
11 Months Ended |
Year Ended |
|||||||
December 31, |
January 31, |
|||||||
2021 |
2021 |
|||||||
Net loss |
$ | (38,241,499 | ) | $ | (26,127,496 | ) | ||
Other comprehensive loss: |
||||||||
Foreign currency translation (loss) gain |
(5,010 | ) | 72,136 | |||||
|
|
|
|
|||||
Comprehensive loss |
$ | (38,246,509 | ) | $ | (26,055,360 | ) | ||
|
|
|
|
Additional Paid-In Capital |
Accumulated Other Comprehensive Gain (Loss) |
Accumulated Deficit |
Total Stockholders’ Deficit |
|||||||||||||||||||||||||||||
Redeemable Convertible Preferred Stock |
Common Stock |
|||||||||||||||||||||||||||||||
Shares |
Amount |
Shares |
Amount |
|||||||||||||||||||||||||||||
Balance, January 31, 2020 |
14,154,064 | $ | 120,793,893 | 8,165,828 | $ | 8 | $ | 14,364,973 | $ | (15,311 | ) | $ | (142,762,336 | ) | $ | (128,412,666 | ) | |||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
Conversion of Series B/A Preferred Stock to Common Stock upon Equity Restructuring |
(14,154,064 | ) | (120,793,893 | ) | 3,538,484 | 4 | 120,793,889 | — | — | 120,793,893 | ||||||||||||||||||||||
Issuance of Common Stock upon Modification of Convertible Notes |
— | — | 6,874,309 | 7 | 1,443,598 | — | — | 1,443,605 | ||||||||||||||||||||||||
Issuance of Series C Preferred Stock, Net |
59,575,811 | 52,786,276 | — | — | — | — | — | — | ||||||||||||||||||||||||
Issuance of Common Stock Warrants to Investors |
— | — | — | — | 1,236,600 | — | — | 1,236,600 | ||||||||||||||||||||||||
Issuance of Series C-1 Preferred Stock to Participating Series B/A Preferred Stock Holders |
11,415,620 | 7,734,083 | — | — | (7,734,083 | ) | — | — | (7,734,083 | ) | ||||||||||||||||||||||
Issuance of Series C, C-1, Common Stock and Warrants upon Conversion of Notes |
26,131,870 | 19,812,252 | 2,036,617 | 2 | 489,875 | — | — | 489,877 | ||||||||||||||||||||||||
Issuance of Series C and C-1 upon Conversion of SAFE |
1,603,204 | 1,190,530 | — | — | — | — | — | — | ||||||||||||||||||||||||
Issuance of Common Stock Warrants to Customer |
— | — | — | — | 154,330 | — | — | 154,330 | ||||||||||||||||||||||||
Issuance of Common Stock upon Exercise of Common Stock Warrants |
— | — | 70,000 | — | 14,980 | — | — | 14,980 | ||||||||||||||||||||||||
Issuance of Common Stock upon Exercise of Stock Options |
— | — | 238,576 | — | 51,384 | — | — | 51,384 | ||||||||||||||||||||||||
Issuance of Common Stock upon Release of Acquisition Escrow |
— | — | 147,271 | — | — | — | — | — | ||||||||||||||||||||||||
Stock-Based Compensation |
— | — | — | — | 2,592,038 | — | — | 2,592,038 | ||||||||||||||||||||||||
Foreign Currency Translation Gain (Loss) |
— | — | — | — | — | 72,136 | 72,136 | |||||||||||||||||||||||||
Net Loss |
— | — | — | — | — | — | (26,127,496 | ) | (26,127,496 | ) | ||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
Balance, January 31, 2021 |
98,726,505 | $ | 81,523,141 | 21,071,085 | $ | 21 | $ | 133,407,584 | $ | 56,825 | $ | (168,889,832 | ) | $ | (35,425,402 | ) | ||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
Issuance of Common Stock upon Exercise of Stock Options |
1,785,242 | 1 | 374,900 | 374,901 | ||||||||||||||||||||||||||||
Issuance of Common Stock upon Exercise of Common Stock Warrants |
296,800 | 1 | 2,967 | 2,968 | ||||||||||||||||||||||||||||
Stock-Based Compensation |
— | — | — | — | 1,765,371 | — | — | 1,765,371 | ||||||||||||||||||||||||
Foreign Currency Translation Gain (Loss) |
— | — | — | — | — | (5,010 | ) | (5,010 | ) | |||||||||||||||||||||||
Net Loss |
— | — | — | — | — | — | (38,241,499 | ) | (38,241,499 | ) | ||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
Balance, December 31, 2021 |
98,726,505 | $ | 81,523,141 | 23,153,127 | $ | 23 | $ | 135,550,822 | $ | 51,815 | $ | (207,131,331 | ) | $ | (71,528,671 | ) | ||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
11 Months Ended |
Year Ended |
|||||||
December 31, |
January 31, |
|||||||
2021 |
2021 |
|||||||
Cash flows from operating activities |
||||||||
Net loss |
$ | (38,241,499 | ) | $ | (26,127,496 | ) | ||
Adjustments to reconcile net loss to net cash used in operating activities: |
||||||||
Depreciation and amortization |
4,651,129 | 4,299,263 | ||||||
Stock-based compensation |
1,765,371 | 2,592,038 | ||||||
Gain on extinguishment of debt |
— | (8,913,532 | ) | |||||
Change in fair value of derivative warrant liabilities |
1,664,133 | — | ||||||
Change in fair value of forward contract agreement liabilities |
230,000 | — | ||||||
Amortization of debt issuance costs |
512,755 | — | ||||||
Amortization of debt commitment fee asset |
94,405 | — | ||||||
Accretion of debt end of term liabilities |
121,585 | — | ||||||
Changes in operating assets and liabilities: |
||||||||
Accounts receivable |
(1,063,166 | ) | (290,399 | ) | ||||
Prepaid expenses and other current assets |
(314,988 | ) | 244,932 | |||||
Other assets |
(34,978 | ) | (2,248 | ) | ||||
Deferred revenue |
493,149 | (1,659,856 | ) | |||||
Accounts payable |
(388,574 | ) | (1,995,037 | ) | ||||
Accrued expenses and other current liabilities |
1,553,984 | 1,403,772 | ||||||
Other liabilities |
(86,666 | ) | 381,300 | |||||
|
|
|
|
|||||
Net cash used in operating activities |
(29,043,360 | ) | (30,067,263 | ) | ||||
|
|
|
|
|||||
Cash flows from investing activities |
||||||||
Purchases of property and equipment |
(7,007,742 | ) | (4,400,432 | ) | ||||
|
|
|
|
|||||
Net cash used in investing activities |
(7,007,742 | ) | (4,400,432 | ) | ||||
|
|
|
|
|||||
Cash flows from financing activities |
||||||||
Proceeds from issuance of convertible notes |
— | 2,200,000 | ||||||
Proceeds from issuance of debt and warrants |
27,000,000 | — | ||||||
Payments on debt issuance costs |
(247,140 | ) | — | |||||
Payments on deferred offering costs |
(1,548,489 | ) | — | |||||
Proceeds from issuance of preferred stock and warrants, gross |
— | 54,022,876 | ||||||
Proceeds from issuance of common stock upon exercise of stock options |
374,901 | 51,384 | ||||||
Proceeds from issuance of common stock upon exercise of common stock warrants |
2,968 | 14,980 | ||||||
|
|
|
|
|||||
Net cash provided by financing activities |
25,582,240 | 56,289,240 | ||||||
|
|
|
|
|||||
Effect of changes in exchange rate on cash and restricted cash |
(5,010 | ) | 72,136 | |||||
Net (decrease) increase in cash and restricted cash |
(10,473,872 | ) | 21,893,681 | |||||
Cash and restricted cash at beginning of period |
22,519,522 | 625,841 | ||||||
|
|
|
|
|||||
Cash and restricted cash at end of period |
$ | 12,045,650 | $ | 22,519,522 | ||||
|
|
|
|
|||||
Supplemental disclosure of cash flow information: |
||||||||
Cash paid for interest |
$ | 1,488,890 | $ | 51,666 | ||||
Supplemental disclosure of non-cash financing activity: |
||||||||
Deferred offering costs in accounts payable and accrued expenses |
$ | 1,899,981 | $ | — | ||||
Fair value of loan and security agreement warrant liability |
$ | 2,690,574 | $ | — | ||||
Conversion of redeemable convertible preferred stock to common stock upon equity recapitalization |
$ | — | $ | 120,793,893 | ||||
Conversion of convertible notes to redeemable convertible preferred stock and warrants |
$ | — | $ | 19,874,439 | ||||
Issuance of redeemable convertible preferred stock upon equity recapitalization |
$ | — | $ | 7,734,083 | ||||
Issuance of common stock in connection with debt modification |
$ | — | $ | 1,443,605 | ||||
Conversion of SAFE to redeemable convertible preferred stock |
$ | — | $ | 1,190,530 | ||||
Conversion of convertible notes to common stock |
$ | — | $ | 427,690 | ||||
Issuance of warrants to customer |
$ | — | $ | 154,330 |
1. |
DESCRIPTION OF BUSINESS |
2. |
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES |
December 31, |
January 31, |
|||||||
2021 |
2021 |
|||||||
Cash |
11,728,516 | 22,202,388 | ||||||
Restricted cash |
317,134 | 317,134 | ||||||
|
|
|
|
|||||
Total cash and restricted cash |
$ | 12,045,650 | $ | 22,519,522 | ||||
|
|
|
|
• | Identify the contract with a customer |
• | Identify the performance obligations in the contract |
• | Determine the transaction price |
• | Allocate the transaction price to the performance obligations in the contract |
• | Recognize revenue when (or as) performance obligations are satisfied |
December 31, |
January 31, |
|||||||
Customer |
2021 |
2021 |
||||||
Customer A |
29 | % | * | |||||
Customer B |
20 | % | 32 | % | ||||
Customer C |
17 | % | 15 | % | ||||
Customer D |
16 | % | * | |||||
Customer E |
15 | % | 31 | % |
* | Customer accounted for less than 10% of revenue in the respective year |
11 Months Ended December 31, |
||||||||
2021 |
2020 |
|||||||
(Unaudited) | ||||||||
Revenue |
$ | 8,196,306 | $ | 5,105,824 | ||||
Cost of revenue |
1,623,336 | 1,344,916 | ||||||
|
|
|
|
|||||
Total gross profit |
6,572,970 | 3,760,908 | ||||||
Operating expenses: |
||||||||
Research and development |
26,927,599 | 22,843,637 | ||||||
General and administrative |
11,299,068 | 10,613,190 | ||||||
Sales and marketing |
2,474,968 | 1,947,447 | ||||||
|
|
|
|
|||||
Total operating expenses |
40,701,635 | 35,404,274 | ||||||
|
|
|
|
|||||
Loss from operations |
(34,128,665 | ) | (31,643,366 | ) | ||||
|
|
|
|
|||||
Other income (expense), net: |
||||||||
Gain on extinguishment of debt |
— | 8,913,532 | ||||||
Change in fair value of warrant liability |
(1,664,133 | ) | — | |||||
Interest expense |
(2,465,135 | ) | (51,666 | ) | ||||
Interest Income |
9,852 | 58,644 | ||||||
Other income |
6,582 | 71,737 | ||||||
|
|
|
|
|||||
Total other income (expense), net |
(4,112,834 | ) | 8,992,247 | |||||
Net loss before provision for income taxes |
||||||||
Provision for income taxes |
||||||||
|
|
|
|
|||||
Net loss |
$ |
(38,241,499 |
) |
$ |
(22,651,119 |
) | ||
|
|
|
|
|||||
Net loss per share attribute to common stockholders—basic and diluted |
$ | (1.74) | $ | (1.09) | ||||
Weighted average shares used in computing net loss per share attributable to common stockholders – basic and diluted |
21,941,997 | 20,687,611 |
3. |
REVENUE RECOGNITION |
11 Months Ended |
Year Ended |
|||||||
December 31, |
January 31, |
|||||||
2021 |
2021 |
|||||||
Type of Goods or Service |
||||||||
Collaborative research and other professional services |
$ | 5,849,267 | $ | 2,919,507 | ||||
Access to quantum computing systems |
2,347,039 | 2,380,091 | ||||||
Quantum computing components |
— | 243,000 | ||||||
|
|
|
|
|||||
$ | 8,196,306 | $ | 5,542,598 | |||||
|
|
|
|
|||||
Timing of Revenue Recognition |
||||||||
Revenue recognized at a point in time |
$ | — | $ | 243,000 | ||||
Revenue recognized over time |
8,196,306 | 5,299,598 | ||||||
|
|
|
|
|||||
$ | 8,196,306 | $ | 5,542,598 | |||||
|
|
|
|
December 31, |
January 31, |
|||||||
2021 |
2021 |
|||||||
Trade receivables, net |
$ | 961,370 | $ | 327,301 | ||||
Unbilled receivables |
$ | 581,170 | $ | 152,073 | ||||
Deferred revenue - current |
$ | (984,976 | ) | $ | (491,827 | ) |
11 Months Ended |
Year Ended |
|||||||
December 31, |
January 31, |
|||||||
2021 |
2021 |
|||||||
Balance at beginning of period |
$ | (491,827 | ) | $ | (2,151,683 | ) | ||
Deferral of revenue |
(904,502 | ) | (364,545 | ) | ||||
Recognition of deferred revenue |
411,353 | 2,024,401 | ||||||
|
|
|
|
|||||
Balance at end of period |
$ | (984,976 | ) | $ | (491,827 | ) | ||
|
|
|
|
4. |
FAIR VALUE MEASUREMENTS |
Fair Value Hierarchy |
||||||||||||
Level 1 |
Level 2 |
Level 3 |
||||||||||
At December 31, 2021 |
||||||||||||
Liabilities: |
||||||||||||
Derivative warrant liabilities |
$ | — | $ | — | $ | 4,354,707 | ||||||
Forward warrant agreement |
— | — | 230,000 | |||||||||
Debt - net of current portion |
— | — | ||||||||||
|
|
|
|
|
|
|||||||
Total Liabilities |
$ |
— |
$ |
— | $ |
4,584,707 |
||||||
|
|
|
|
|
|
Convertible Notes |
Simple agreement for future equity |
Derivative Warrant Liabilities |
Forward Warrant Agreement |
|||||||||||||
Balance - January 31, 2020 |
$ | 26,892,459 | $ | 1,882,397 | $ | — | $ | — | ||||||||
Issuances |
— | — | — | — | ||||||||||||
Settlement |
(26,892,459 | ) | (1,882,397 | ) | — | — | ||||||||||
Loss on change in fair value |
— | — | — | — | ||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Balance - January 31, 2021 |
$ |
— |
$ |
— |
$ |
— |
$ |
— |
||||||||
|
|
|
|
|
|
|
|
|||||||||
Issuances |
$ | — | $ | — | $ | 2,690,574 | $ | 400,000 | ||||||||
Settlement |
— | — | — | — | ||||||||||||
Loss (gain) on change in fair value |
— | — | 1,664,133 | (170,000 | ) | |||||||||||
|
|
|
|
|
|
|
|
|||||||||
Balance - December 31, 2021 |
$ |
— |
$ |
— |
$ |
4,354,707 |
$ |
230,000 |
||||||||
|
|
|
|
|
|
|
|
5. |
SUPPLEMENTAL FINANCIAL STATEMENTS INFORMATION |
December 31, |
January 31, |
|||||||
2021 |
2021 |
|||||||
Quantum computing fridges |
$ | 17,189,904 | $ | 14,251,579 | ||||
Process equipment |
16,169,598 | 12,747,756 | ||||||
Leasehold improvements |
4,296,620 | 4,077,646 | ||||||
IT hardware |
2,427,681 | 1,999,082 | ||||||
Furniture and other assets |
1,246,068 | 1,246,067 | ||||||
|
|
|
|
|||||
Total property and equipment |
$ | 41,329,871 | $ | 34,322,130 | ||||
Less: Accumulated depreciation and amortization |
(18,832,387 | ) | (14,181,258 | ) | ||||
|
|
|
|
|||||
Property and equipment - net |
$ | 22,497,484 | $ | 20,140,872 | ||||
|
|
|
|
December 31, |
January 31, |
|||||||
2021 |
2021 |
|||||||
Interest - notes payable |
$ | 247,500 | $ | — | ||||
Other current liability - forward warrant agreement |
230,000 | — | ||||||
Payroll and other payroll costs |
962,399 | 739,893 | ||||||
Property and other taxes |
570,852 | 451,545 | ||||||
Subscription Fee |
555,832 | — | ||||||
Professional fees and other |
820,699 | 411,861 | ||||||
Deferred offering costs |
648,333 | — | ||||||
|
|
|
|
|||||
$ | 4,035,615 | $ | 1,603,299 | |||||
|
|
|
|
6. |
COMMITMENTS AND CONTINGENCIES |
Years Ending December 31, |
||||
2022 |
$ | 1,807,759 | ||
2023 |
901,316 | |||
2024 |
928,355 | |||
2025 |
956,206 | |||
2026 |
81,262 | |||
|
|
|||
Total minimum future lease payments |
$ | 4,674,898 | ||
|
|
7. |
FINANCING ARRANGEMENTS |
December 31, 2021 |
||||
Outstanding principal amount - stated value |
$ | 27,000,000 | ||
Add: Accrued final payment fee |
121,585 | |||
Less: Unamortized deferred financing costs |
(170,058 | ) | ||
Less: Unamortized debt discount |
(2,160,495 | ) | ||
|
|
|||
Total debt |
$ | 24,791,032 | ||
|
|
|||
Debt - current portion |
$ | 1,290,538 | ||
Debt - net of current portion |
23,500,494 | |||
|
|
|||
Total debt |
$ | 24,791,032 | ||
|
|
Total |
||||
2022 | $ | 1,290,538 | ||
2023 | 8,750,354 | |||
2024 | 11,084,382 | |||
2025 | 5,874,726 | |||
|
|
|||
$ | 27,000,000 | |||
|
|
8. |
REDEEMABLE CONVERTIBLE PREFERRED STOCK |
9. |
COMMON STOCK |
Class A Common Stock |
Class B Common Stock |
|||||||
Series C Preferred Stock |
69,223,658 | — | ||||||
Series C-1 Preferred Stock |
— | 3,687,836 | ||||||
Common Stock Warrants |
10,817,831 | — | ||||||
Stock-Based Awards - Options Outstanding |
14,572,344 | — | ||||||
Stock-Based Awards - RSUs Outstanding |
6,846,961 | — | ||||||
Stock-Based Awards - Options Available for Future Grant |
4,954,141 | — | ||||||
|
|
|
|
|||||
Total |
106,414,935 |
3,687,836 |
||||||
|
|
|
|
10. |
Warrants |
Warrant Class |
Shares |
Issuance Date |
Strike Price per Share |
Expiration Date |
||||||||||||
Common Stock Warrants |
995,099 | May 18, 2021 | $ | 0.214 | May 18, 2031 |
Valuation Assumption - Common Stock Warrants |
Initial Recognition |
December 31, 2021 |
||||||
Stock price |
$ | 2.87 | $ | 4.44 | ||||
Strike price |
$ | 0.21 | $ | 0.21 | ||||
Volatility (annual) |
51.90 | % | 105.10 | % | ||||
Risk-free rate |
1.65 | % | 1.51 | % | ||||
Estimated time to expiration (years) |
10 | 9 | ||||||
Dividend yield |
0.00 | % | 0.00 | % |
Valuation Assumptions |
Initial Recognition |
|||
Stock Price |
$ | 0.21 | ||
Strike Price |
$ | 0.01 | ||
Volatility (annual) |
51.50 | % | ||
Risk-free rate |
1.55 | % | ||
Estimated time to expiration (years) |
10 | |||
Dividend yield |
0.00 | % |
Valuation Assumptions |
Initial Recognition |
|||
Stock Price |
$ | 0.21 | ||
Strike Price |
$ | 0.91 | ||
Volatility (annual) |
45.00 | % | ||
Risk-free rate |
1.29 | % | ||
Estimated time to expiration (years) |
10 | |||
Dividend yield |
0.00 | % |
December 31, 2021 |
January 31, 2021 | |||||
Vested Customer warrants |
1,362,461 | 1,021,845 | ||||
Unvested Customer warrants |
2,043,695 | 2,384,311 | ||||
|
|
| ||||
3,406,156 | 3,406,156 | |||||
|
|
|
11. FORWARD WARRANT AGREEMENT |
Key Valuation Assumptions | ||
Holding period (in years) |
0.50 - 1.13 | |
Risk free rate |
0.19% - 0.43% | |
Probability of occurring the contingency |
50% - 100% | |
Underlying value per share |
$10.29 |
12. |
EQUITY PLANS |
Number of Options |
Weighted-Average Exercise Price |
Average Remaining Contractual Term (In Years) |
||||||||||
Outstanding - January 31, 2021 |
17,008,770 | $ | 0.27 | 9.0 | ||||||||
Granted |
62,500 | $ | 0.21 | |||||||||
Exercised |
(1,785,242 | ) | $ | 0.21 | ||||||||
Forfeited |
(713,684 | ) | $ | 0.21 | ||||||||
|
|
|
|
|
|
|||||||
Outstanding - December 31, 2021 |
14,572,344 | $ | 0.28 | 8.1 | ||||||||
|
|
|
|
|
|
|||||||
Exercisable - December 31, 2021 |
7,797,387 | $ | 0.31 | 7.9 |
11 Months Ended December 31, |
Year Ended January 31, |
|||||||
2021 |
2021 |
|||||||
Research and development |
$ | 975,136 | $ | 894,141 | ||||
Selling, general, and administrative expenses |
790,235 | 1,697,897 | ||||||
|
|
|
|
|||||
Total stock-based compensation expense |
$ | 1,765,371 | $ | 2,592,038 | ||||
|
|
|
|
December 31, |
January 31, | |||
2021 |
2021 | |||
Expected volatility |
46.8% | 41.2% - 43.1% | ||
Weighted-average risk-free interest rate |
1.07% | 0.3% - 0.6% | ||
Expected dividend yield |
0% | 0% | ||
Expected term (in years) |
6.1 years | 5.0 - 6.3 years | ||
Exercise price |
$0.21 | $ 0.21 |
13. |
NET LOSS PER SHARE |
December 31, |
January 31, |
|||||||
2021 |
2021 |
|||||||
Net Loss |
$ | (38,241,499 | ) | $ | (26,127,496 | ) | ||
Basic and diluted shares |
||||||||
Weighted-average Class A Common Stock outstanding |
21,941,997 | 20,719,085 | ||||||
Loss per share for Class A Common Stock |
||||||||
— Basic |
$ | (1.74 | ) | $ | (1.26 | ) | ||
— Diluted |
$ | (1.74 | ) | $ | (1.26 | ) |
December 31, |
January 31, |
|||||||
2021 |
2021 |
|||||||
Convertible Series C Preferred Stock |
69,223,658 | 69,223,658 | ||||||
Common Stock Warrants |
10,817,831 | 3,406,156 | ||||||
Stock Options |
14,572,344 | 17,008,770 | ||||||
Restricted Stock Units |
6,846,961 | — | ||||||
|
|
|
|
|||||
101,460,794 | 89,638,584 | |||||||
|
|
|
|
December 31, |
January 31, |
|||||||
2021 |
2021 |
|||||||
Convertible Series C-1 Preferred Stock |
29,502,847 | 29,502,847 | ||||||
|
|
|
|
|||||
29,502,847 | 29,502,847 | |||||||
|
|
|
|
14. |
INCOME TAXES |
December 31, |
January 31, |
|||||||
2021 |
2021 |
|||||||
Domestic |
$ | (36,787,312 | ) | $ | (25,222,388 | ) | ||
Foreign |
(1,454,187 | ) | (905,108 | ) | ||||
|
|
|
|
|||||
$(38,241,499) | $(26,127,496) | |||||||
|
|
|
|
December 31, |
January 31, |
|||||||
2021 |
2021 |
|||||||
Deferred Tax Assets: |
||||||||
Net operating loss carryforwards |
$ | 46,552,853 | $ | 38,650,103 | ||||
Accruals and reserves |
146,603 | 96,320 | ||||||
Stock-based compensation |
744,300 | 278,581 | ||||||
Research and development credits |
10,986 | 10,986 | ||||||
Intangible assets |
32,324 | 35,516 | ||||||
|
|
|
|
|||||
Gross deferred assets |
47,487,066 | 39,071,506 | ||||||
Valuation allowance |
(46,066,606 | ) | (38,051,098 | ) | ||||
|
|
|
|
|||||
Net Deferred Tax Assets |
1,420,460 | 1,020,408 | ||||||
Deferred Tax Liabilities: |
||||||||
Property and equipment |
$ | (1,420,460 | ) | $ | (1,020,408 | ) | ||
|
|
|
|
|||||
Total Deferred Tax Liabilities |
(1,420,460 | ) | (1,020,408 | ) | ||||
|
|
|
|
|||||
Total Net Deferred Tax Assets |
$ | — | $ | — | ||||
|
|
|
|
11 Months Ended December 31, 2021 |
Year Ended January 31, 2021 |
|||||||
Component |
Rate Impact |
Rate Impact |
||||||
Total pre-tax book income |
21 | % | 22 | % | ||||
State and local income taxes |
0 | % | 0 | % | ||||
Permanent differences |
-1 | % | -2 | % | ||||
Rate differential |
0 | % | 0 | % | ||||
Return to provision true up |
1 | % | -11 | % | ||||
Change in valuation allowance |
-21 | % | -9 | % | ||||
|
|
|
|
|||||
Total: |
0 | % | 0 | % | ||||
|
|
|
|
Beginning balance at February 1, 2021 |
$ | 4,672,209 | ||
Current year increase(decrease) |
— | |||
Prior year adjustment - increase(decrease) |
— | |||
|
|
|||
Ending balance at December 31, 2021 |
$ | 4,672,209 | ||
|
|
15. |
SEGMENTS |
11 Months Ended December 31, |
Year Ended January 31, |
|||||||
2021 |
2021 |
|||||||
United States |
$ | 5,826,004 | $ | 5,108,847 | ||||
United Kingdom |
2,370,302 | 412,747 | ||||||
Australia |
— | 21,004 | ||||||
|
|
|
|
|||||
$ | 8,196,306 | $ | 5,542,598 | |||||
|
|
|
|
16. |
SUBSEQUENT EVENTS |
• | On March 1, 2022, pursuant to the Merger Agreement, Supernova filed a notice of deregistration with the Cayman Islands Registrar of Companies, together with the necessary accompanying documents, and filed a certificate of incorporation and a certificate of corporate domestication with the Secretary of State of the State of Delaware, under which Supernova was domesticated and continues as a Delaware corporation, changing its name to “Rigetti Computing, Inc.” |
• | As a result of and upon the effective time of the Domestication, among other things, (1) each then issued and outstanding Supernova Class A ordinary share converted automatically, on a one-for-one one-for-one one-fourth of one New Rigetti Warrant. No fractional shares were issued upon exercise of the New Rigetti. |
• | On the Closing Date, pursuant to the Merger Agreement, New Rigetti consummated the merger transaction contemplated by the Merger Agreement, following approval at the Extraordinary General Meeting on February 28, 2022, whereby (i) the First Merger occurred and (ii) immediately following the consummation of the Fist Merger, the Second Merger occurred. |
• | Immediately prior to the effective time of the First Merger, all shares of Legacy Rigetti Preferred Stock converted into shares of Legacy Rigetti Common Stock in accordance with the Amended and Restated Certificate of Incorporation of Legacy Rigetti (the “Legacy Rigetti Preferred Stock Conversion”). |
• | Each share of Legacy Rigetti Common Stock (including Legacy Rigetti Common Stock resulting from the Legacy Rigetti Preferred Stock Conversion) that was issued and outstanding immediately prior to the First Merger was cancelled and converted into 78,959,579 shares of New Rigetti Common Stock. |
• | Each warrant to purchase Legacy Rigetti Common Stock converted into a warrant to purchase shares of New Rigetti Common Stock subject to the same terms and conditions as were applicable to the original Legacy Rigetti warrants, and with an exercise price and number of shares of New Rigetti Common Stock purchasable based on the Exchange Ratio and other terms contained in the Merger Agreement. |
• | Each option to purchase Legacy Rigetti Common Stock converted Into An Option To Purchase Shares Of New Rigetti Common Stock Subject To The Same Terms And Conditions As Were Applicable To The Original Legacy Rigetti Options, And With An Exercise Price And Number Of Shares Of New Rigetti Common Stock Purchasable Based On The Exchange Ratio And Other Terms Contained In The Merger Agreement. |
• | Each Restricted Share Of Legacy Rigetti Common Stock Was Exchanged For Restricted Shares Of New Rigetti Common Stock Subject To The Same Terms And Conditions As Were Applicable To The Original Legacy Restricted Shares, And With The Number Of Shares Of New Rigetti Common Stock Based On The Exchange Ratio And Other Terms Contained In The Merger Agreement. |
• | Each Legacy Rigetti Restricted Stock Unit Award Converted Into A Restricted Stock Unit Award To Receive Shares Of New Rigetti Common Stock Subject To The Same Terms And Conditions As Were Applicable To The Original Legacy Restricted Stock Unit Awards, And With The Number Of Shares Of New Rigetti Common Stock To Which The Restricted Stock Unit Award Relates Based On The Exchange Ratio And Other Terms Contained In The Merger Agreement. |
• | The issuance and sale of (i) 10,251,000 shares of New Rigetti Common Stock for a purchase price of $10.00 per share and (ii) 4,390,244 shares of New Rigetti Common Stock for a purchase price of $10.25 per share, generated aggregate gross proceeds of $147.5 million in PIPE Financing pursuant to the Subscription Agreements. |
• | Pursuant to the Sponsor Support Agreement, at the Closing (i) 2,479,000 shares of New Rigetti Common Stock held by the Sponsor (the “Promote Sponsor Vesting Shares”) became subject to vesting and are considered unvested and will only vest if, during the five year period following the Closing, the volume weighted average price of New Rigetti Common Stock equals or exceeds $12.50 for any twenty trading days within a period of thirty consecutive trading days, and (ii) 580,273 shares of New Rigetti Common Stock held by the Sponsor (“Sponsor Redemption-Based Vesting Shares”) became subject to vesting and considered unvested and will only vest if, during the five year period following the Closing, the volume weighted average price of New Rigetti Common Stock equals or exceeds $15.00 for any twenty trading days within a period of thirty consecutive trading days (collectively, the Promote Sponsor Vesting Shares and Sponsor |
Redemption-Based Vesting Shares, “Sponsor Earn Out Shares”). Any Sponsor Earn Out Shares that remain unvested after the fifth anniversary of the Closing will be forfeited. |
• | In connection with the execution of the Merger Agreement, Legacy Rigetti entered into a warrant subscription agreement with a strategic partner, Ampere, for the purchase of a warrant for an aggregate purchase price (including amounts from exercise) of $10,000,000. At the Closing, the warrant agreement was assumed by New Rigetti as a result of the Mergers. The warrant provides for the purchase of an aggregate of 1,000,000 shares of New Rigetti Common Stock at an exercise price of $0.0001. Ampere is required to pay $5.0 million no later than (i) the Closing or (ii) June 30, 2022, and upon such payment the warrant will vest and be exercisable by Ampere with respect to 500,000 shares of New Rigetti Common Stock pursuant to the terms of the warrant. No such purchase or payment has been made as of the Closing Date regarding this first $5.0 million. Ampere is required to pay an additional $5.0 million no later than the second anniversary of the date of the warrant subscription agreement, and upon such payment, the warrant will vest and be exercisable by Ampere with respect to the remaining 500,000 shares of New Rigetti Common Stock pursuant to the terms of the warrant. |
December 31, 2021 |
December 31, 2020 |
|||||||
Assets |
||||||||
Current assets: |
||||||||
Cash |
$ | 532,436 | $ | — | ||||
Prepaid expenses – current |
235,399 | 10,309 | ||||||
Total current assets |
767,835 | 10,309 | ||||||
Deferred offering costs |
— | 33,000 | ||||||
Prepaid expenses – long term |
35,683 | — | ||||||
Investments held in Trust Account |
345,019,271 | — | ||||||
Total Assets |
$ |
345,822,789 |
$ |
43,309 |
||||
Liabilities, Class A Ordinary Shares Subject to Possible Redemption and Shareholders’ Equity (Deficit) |
||||||||
Current liabilities: |
||||||||
Accounts payable |
$ | 314,094 | $ | — | ||||
Accrued expenses |
3,922,625 | 33,000 | ||||||
Total current liabilities |
4,236,719 | 33,000 | ||||||
Deferred underwriting commissions |
12,075,000 | — | ||||||
Derivative warrant liabilities |
30,987,750 | — | ||||||
Total Liabilities |
47,299,469 | 33,000 | ||||||
Commitments and Contingencies (Note 5) |
||||||||
Class A ordinary shares subject to possible redemption, $0.0001 par value; 34,500,000 and -0- |
345,000,000 | — | ||||||
Shareholders’ Equity (Deficit) |
||||||||
Preference shares, $0.0001 par value; 5,000,000 shares authorized; no shares issued or outstanding |
— | — | ||||||
Class A ordinary shares, $0.0001 par value; 500,000,000 shares authorized; no non-redeemable shares issued or outstanding |
— | — | ||||||
Class B ordinary shares, $0.0001 par value; 50,000,000 shares authorized; 8,625,000 shares issued and outstanding as of December 31, 2021 and December 31, 2020 |
863 | 863 | ||||||
Additional paid-in capital |
— | 24,137 | ||||||
Accumulated deficit |
(46,477,543 | ) | (14,691 | ) | ||||
Total Shareholders’ Equity (Deficit) |
(46,476,680 | ) | 10,309 | |||||
Total Liabilities, Class A Ordinary Shares Subject to Possible Redemption and Shareholders’ Equity (Deficit) |
$ |
345,822,789 |
$ |
43,309 |
||||
For the Year Ended December 31, 2021 |
For the Period from December 22, 2020 (inception) through December 31, 2020 |
|||||||
General and administrative expenses |
$ | 4,904,921 | $ | 14,691 | ||||
|
|
|
|
|||||
Loss from operations |
(4,904,921 | ) | (14,691 | ) | ||||
Other income (expense) |
||||||||
Change in fair value of derivative warrant liabilities |
(17,782,000 | ) | — | |||||
Offering costs associated with derivative warrant liabilities |
(502,450 | ) | — | |||||
Income from investments held in Trust Account |
19,271 | — | ||||||
|
|
|
|
|||||
Net loss |
$ | (23,170,100 | ) | $ | (14,691 | ) | ||
|
|
|
|
|||||
Weighted average number of Class A ordinary shares, basic and diluted |
28,639,726 | — | ||||||
|
|
|
|
|||||
Basic and diluted net loss per share, Class A |
$ | (0.62 | ) | $ | — | |||
|
|
|
|
|||||
Weighted average number of Class B ordinary shares, basic |
8,433,904 | 7,500,000 | ||||||
|
|
|
|
|||||
Weighted average number of Class B ordinary shares, diluted |
8,625,000 | 7,500,000 | ||||||
|
|
|
|
|||||
Basic net loss per share, Class B |
$ | (0.62 | ) | $ | (0.00 | ) | ||
|
|
|
|
|||||
Diluted net loss per share, Class B |
$ | (0.62 | ) | $ | (0.00 | ) | ||
|
|
|
|
Ordinary Shares |
Additional Paid-in Capital |
Accumulated Deficit |
Total Shareholders’ Equity (Deficit) |
|||||||||||||||||||||||||
Class A |
Class B |
|||||||||||||||||||||||||||
Shares |
Amount |
Shares |
Amount |
|||||||||||||||||||||||||
Balance - December 31, 2020 |
— |
$ |
— |
8,625,000 |
$ |
863 |
$ |
24,137 |
$ |
(14,691 |
) |
$ |
10,309 |
|||||||||||||||
Sale of private placement warrants to Sponsor in private placement, less allocation to derivative warrant liabilities |
— | — | — | — | 4,405,500 | — | 4,405,500 | |||||||||||||||||||||
Accretion of Class A ordinary shares to redemption amount |
— | — | — | — | (4,429,637 | ) | (23,292,752 | ) | (27,722,389 | ) | ||||||||||||||||||
Net loss |
— | — | — | — | — | (23,170,100 | ) | (23,170,100 | ) | |||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
Balance - December 31, 2021 |
— |
$ |
— |
8,625,000 |
$ |
863 |
$ |
— |
$ |
(46,477,543 |
) |
$ |
(46,476,680 |
) | ||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Ordinary Shares |
Additional Paid-in Capital |
Total Shareholders’ Equity (Deficit) |
||||||||||||||||||||||||||
Class A |
Class B |
Accumulated Deficit |
||||||||||||||||||||||||||
Shares |
Amount |
Shares |
Amount |
|||||||||||||||||||||||||
Balance - December 22, 2020 (inception) |
— |
$ |
— |
$ |
— |
$ |
— |
$ |
— |
$ |
— |
$ |
— |
|||||||||||||||
Issuance of Class B ordinary shares to Sponsor (1)(2) |
— | — | 8,625,000 | 863 | 24,137 | — | 25,000 | |||||||||||||||||||||
Net loss |
— | — | — | — | — | (14,691 | ) | (14,691 | ) | |||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
Balance - December 31, 2020 |
— |
$ |
— |
8,625,000 |
$ |
863 |
$ |
24,137 |
$ |
(14,691 |
) |
$ |
10,309 |
|||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Year Ended December 31, 2021 |
For the Period from December 22, 2020 (inception) through December 31, 2020 |
|||||||
Cash Flows from Operating Activities: |
||||||||
Net loss |
$ | (23,170,100 | ) | $ | (14,691 | ) | ||
Adjustments to reconcile net loss to cash used in operating activities: |
||||||||
Change in fair value of derivative warrant liabilities |
17,782,000 | — | ||||||
Offering costs associated with derivative liabilities |
502,450 | — | ||||||
Income from investments held in Trust Account |
(19,271 | ) | — | |||||
Changes in operating assets and liabilities: |
||||||||
Prepaid expenses |
(260,773 | ) | 14,691 | |||||
Accounts payable |
314,094 | — | ||||||
Accrued expenses |
3,889,625 | — | ||||||
|
|
|
|
|||||
Net cash used in operating activities |
(961,975 | ) | — | |||||
|
|
|
|
|||||
Cash Flows from Investing Activities: |
||||||||
Cash deposited in Trust Account |
(345,000,000 | ) | — | |||||
|
|
|
|
|||||
Net cash used in investing activities |
(345,000,000 | ) | — | |||||
|
|
|
|
|||||
Cash Flows from Financing Activities: |
||||||||
Proceeds from note payable to related party |
275,000 | — | ||||||
Repayment of note payable to related party |
(275,000 | ) | — | |||||
Proceeds received from initial public offering, gross |
345,000,000 | — | ||||||
Proceeds received from private placement |
8,900,000 | — | ||||||
Offering costs paid |
(7,405,589 | ) | — | |||||
|
|
|
|
|||||
Net cash provided by financing activities |
346,494,411 | — | ||||||
|
|
|
|
|||||
Net change in cash |
532,436 | — | ||||||
Cash - beginning of the period |
— | — | ||||||
|
|
|
|
|||||
Cash - end of the period |
$ |
532,436 |
$ |
— |
||||
|
|
|
|
|||||
Supplemental disclosure of noncash financing activities: |
||||||||
Offering costs included in accrued expenses |
$ | — | $ | 33,000 | ||||
Prepaid expenses paid by Sponsor in exchange for issuance of Class B ordinary shares |
$ | — | $ | 25,000 | ||||
Deferred underwriting commissions |
$ | 12,075,000 | $ | — | ||||
Accretion of Class A ordinary shares to redemption amount |
$ | 27,722,389 | $ | — |
• |
Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets; |
• |
Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and |
• |
Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. |
For the Year Ended December 31, 2021 |
For the Period from December 22, 2020 (inception) through December 31, 2020 |
|||||||||||||||
Class A |
Class B |
Class A |
Class B |
|||||||||||||
Basic and diluted net loss per ordinary share: |
||||||||||||||||
Numerator: |
||||||||||||||||
Allocation of net loss - basic and diluted |
$ | (17,899,119 | ) | $ | (5,270,981 | ) | $ | — | $ | (14,691 | ) | |||||
Denominator: |
||||||||||||||||
Basic and diluted weighted average ordinary shares outstanding |
28,639,726 | 8,433,904 | — | 7,500,000 | ||||||||||||
Diluted weighted average ordinary shares outstanding |
28,639,726 | 8,625,000 | — | 7,500,000 | ||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Basic and diluted net loss per ordinary share |
$ | (0.62 | ) | $ | (0.62 | ) | $ | — | $ | (0.00 | ) | |||||
|
|
|
|
|
|
|
|
|||||||||
Diluted net loss per ordinary share |
$ | (0.62 | ) | $ | (0.62 | ) | $ | — | $ | (0.00 | ) | |||||
|
|
|
|
|
|
|
|
• | in whole and not in part; |
• | at a price of $0.01 per warrant; |
• | upon a minimum of 30-days’ prior written notice of redemption; and |
• | if, and only if, the last reported sale price (the “closing price”) of Class A ordinary shares equals or exceeds $18.00 per share (as adjusted) for any 20 trading days within a 30-trading day period ending on the third trading day prior to the date on which the Company sends the notice of redemption to the warrant holders. |
• | in whole and not in part; |
• | at a price of $0.10 per warrant; |
• | upon a minimum of 30-days’ prior written notice of redemption provided that holders will be able to exercise their warrants on a cashless basis prior to redemption and receive that number of shares determined by reference to an agreed table based on the redemption date and the fair market value of Class A ordinary shares; |
• | if, and only if, the closing price of Class A ordinary shares equals or exceeds $10.00 per Public Share (as adjusted) for any 20 trading days within the 30-trading day period ending three trading days before the Company sends the notice of redemption to the warrant holders; |
• | if the closing price of the Class A ordinary shares for any 20 trading days within a 30-trading day period ending on the third trading day prior to the date on which the Company sends the notice of redemption to the warrant holders is less than $18.00 per Public Share (as adjusted), the Private Placement Warrants must also be concurrently called for redemption on the same terms as the outstanding Public Warrants, as described above. |
Gross proceeds |
$ | 345,000,000 | ||
Less: |
||||
Amount allocated to Public Warrants |
(8,711,250 | ) | ||
Class A ordinary shares issuance costs |
(19,011,139 | ) | ||
Plus: |
||||
Accretion of carrying value to redemption value |
27,722,389 | |||
Class A ordinary shares subject to possible redemption |
$ | 345,000,000 | ||
Description |
Quoted Prices in Active Markets (Level 1) |
Significant Other Observable Inputs (Level 2) |
Significant Other Unobservable Inputs (Level 3) |
|||||||||
Assets: |
||||||||||||
Investments held in Trust Account - money market fund |
$ | 345,019,271 | $ | — | $ | — | ||||||
Liabilities: |
||||||||||||
Derivative warrant liabilities - Public warrants |
$ | 20,441,250 | $ | — | $ | — | ||||||
Derivative warrant liabilities - Private placement warrants |
$ | — | $ | — | $ | 10,546,500 |
December 31, 2021 |
Initial Measurement |
|||||||
Exercise price |
$ | 11.50 | $ | 11.50 | ||||
Stock price |
$ | 10.29 | $ | 9.75 | ||||
Volatility |
29.9 | % | 16.0 | % | ||||
Term (years) |
5.16 | 5.33 | ||||||
Risk-free rate |
1.28 | % | 0.94 | % |
Derivative liabilities as of January 1, 2021 |
$ | — | ||
Issuance of Public Warrants - Level 3 |
8,711,250 | |||
Issuance of Private Warrants - Level 3 |
4,494,500 | |||
Change in fair value of derivative liabilities - Level 3 |
6,397,000 | |||
Transfer of Public Warrants to Level 1 Measurement |
(9,056,250 | ) | ||
|
|
|||
Derivative liabilities as of December 31, 2021 - Level 3 |
$ | 10,546,500 | ||
|
|
Item 13. |
Other Expenses of Issuance and Distribution. |
Amount |
||||
SEC registration fee |
$ | 72,881 | ||
Accountants’ fees and expenses |
100,000 | |||
Legal fees and expenses |
200,000 | |||
Printing fees |
50,000 | |||
Miscellaneous |
2,119 | |||
|
|
|||
Total expenses |
$ | 425,000 | ||
|
|
Item 14. |
Indemnification of Directors and Officers. |
• | for any transaction from which the director derives an improper personal benefit; |
• | for any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law; |
• | for any unlawful payment of dividends or redemption of shares; or |
• | for any breach of a director’s duty of loyalty to the corporation or its stockholders. |
Item 15. |
Recent Sales of Unregistered Securities . |
Item 16. |
Exhibits and Financial Statement Schedules . |
Incorporated by Reference |
||||||||||||||||||
Exhibit No. |
Description |
Schedule/ Form |
File No. |
Exhibit |
Filing Date |
|||||||||||||
10.28# |
Amended & Restated Employment Agreement, dated February 2, 2022, between Rigetti Holdings, Inc. and Mike Harburn. | S-4/A |
333-260692 |
10.28 | February 8, 2022 | |||||||||||||
10.29# |
Amended & Restated Employment Agreement, dated February 2, 2022, between Rigetti Holdings, Inc. and Rick Danis. | S-4/A |
333-260692 |
10.29 | February 8, 2022 | |||||||||||||
10.30#* |
Executive Employment Agreement, dated March 14, 2022, between Rigetti Computing, Inc. and Greg Peters. | |||||||||||||||||
16.1 |
Letter from Marcum LLP to the SEC. | 8-K |
001-40140 |
16.1 | March 7, 2022 | |||||||||||||
21.1 |
List of Subsidiaries of Rigetti Computing, Inc. | 8-K |
001-40140 |
21.1 | March 7, 2022 | |||||||||||||
23.1* |
Consent of BDO USA LLP | |||||||||||||||||
23.2* |
Consent of Marcum LLP | |||||||||||||||||
23.3* |
Consent of Cooley LLP (included in Exhibit 5.1) | |
||||||||||||||||
24.1* |
Power of Attorney (included on signature pages) | |||||||||||||||||
101.INS* |
XBRL Instance Document | |||||||||||||||||
101.SCH* |
XBRL Taxonomy Extension Schema Document | |
||||||||||||||||
101.CAL* |
XBRL Taxonomy Extension Calculation Linkbase Document | |
||||||||||||||||
101.DEF* |
XBRL Taxonomy Extension Definition Linkbase Document | |
||||||||||||||||
101.LAB* |
XBRL Taxonomy Extension Label Linkbase Document | |
||||||||||||||||
101.PRE* |
XBRL Taxonomy Extension Presentation Linkbase Document | |||||||||||||||||
104* |
Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) | |||||||||||||||||
107* |
Filing Fee Table |
* | Filed herewith. |
+ | The schedules and exhibits to this agreement have been omitted pursuant to Item 601(a)(5) of Regulation S-K. A copy of any omitted schedule and/or exhibit will be furnished to the SEC upon request. |
# | Indicates management contract or compensatory plan or arrangement. |
Item 17. |
Undertakings . |
(a) | The undersigned registrant hereby undertakes as follows: |
(1) | To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement: |
(i) | To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933; |
(ii) | To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20 percent change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement; |
(iii) | To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement. |
(2) | That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. |
(3) | To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering. |
(4) | That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser: |
(i) | Each prospectus filed by the registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the date the filed prospectus was deemed part of and included in the registration statement; and |
(ii) | Each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5) or (b)(7) as part of a registration statement in reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii) or (x) for the purpose of providing the information required by Section 10(a) of the Securities Act shall be deemed to be part of and included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. Provided, however, that no statement made in a registration |
statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date. |
(5) | That, for the purpose of determining any liability under the Securities Act of 1933 to any purchaser in the initial distribution of the securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser: |
(i) | Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424; |
(ii) | Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant; |
(iii) | The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or our securities provided by or on behalf of the undersigned registrant; and |
(iv) | Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser. |
(b) | Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the undersigned pursuant to the foregoing provisions, or otherwise, the undersigned has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the undersigned of expenses incurred or paid by a director, officer or controlling person of the undersigned in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the undersigned will, unless in the opinion of our counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue. |
RIGETTI COMPUTING, INC. | ||
By: | /s/ Chad Rigetti | |
Chad Rigetti | ||
Chief Executive Officer |
Signature |
Title |
Date | ||
/s/ Chad Rigetti |
Chief Executive Officer and Director | March 23, 2022 | ||
Chad Rigetti | (Principal Executive Officer) | | ||
/s/ Brian Sereda |
Chief Financial Officer | March 23, 2022 | ||
Brian Sereda | (Principal Financial Officer and Principal Accounting Officer) | | ||
/s/ Michael Clifton |
Director | March 23, 2022 | ||
Michael Clifton | ||||
/s/ David Cowan |
Director | March 23, 2022 | ||
David Cowan | |
| ||
/s/ Alissa Fitzgerald |
Director | March 23, 2022 | ||
Alissa Fitzgerald | |
| ||
/s/ Ray Johnson |
Director | March 23, 2022 | ||
Ray Johnson | |
|
Signature |
Title |
Date | ||
/s/ Cathy McCarthy |
Director | March 23, 2022 | ||
Cathy McCarthy | |
| ||
/s/ Gen. Peter Pace |
Chairman of the Board of Directors | March 23, 2022 | ||
Gen. Peter Pace | |
| ||
/s/ H. Gail Sandford |
Director | March 23, 2022 | ||
H. Gail Sandford | |
|
Exhibit 5.1
Rupa Briggs
+1 212 479 6525
rbriggs@cooley.com
March 23, 2022
Rigetti Computing, Inc.
775 Heinz Avenue
Berkeley, CA, 94710
Re: Rigetti Computing, Inc. Registration Statement on Form S-1
Ladies and Gentlemen:
We have acted as counsel to Rigetti Computing, Inc., a Delaware corporation (the Company), and you have requested our opinion in connection with the filing of a Registration Statement on Form S-1 (the Registration Statement) with the Securities and Exchange Commission, including a related prospectus included in the Registration Statement (the Prospectus), covering the registration of (a) the issuance of shares of common stock, $0.0001 par value per share (Common Stock), of the Company upon the exercise of warrants issued or assumed by the Company, and (b) the resale of Common Stock and warrants held by certain stockholders and holders of outstanding warrants of the Company, as follows:
(i) | the issuance of up to 19,354,059 shares of Common Stock as follows: |
| up to 4,450,000 shares of Common Stock (the Private Warrant Shares) issuable upon the exercise of certain outstanding warrants (the Private Warrants) by the holders thereof; |
| up to 8,624,972 shares of Common Stock (the Public Warrant Shares and, together with the Private Warrant Shares, the Warrant Shares) issuable upon the exercise of certain outstanding warrants (together with the Private Warrants, the Warrants) by the holders thereof; and |
| up to 6,279,087 shares of Common Stock (the Assumed Warrant Shares) issuable upon the exercise of warrants initially issued by Rigetti Holdings, Inc. (Legacy Rigetti) and assumed by the Company and converted into warrants to purchase Common Stock (the Assumed Warrants) pursuant to that certain Agreement and Plan of Merger, dated October 6, 2021, as amended on December 23, 2021 and January 10, 2022, by and among by and among Supernova Partners Acquisition Company II, Ltd., Supernova Merger Sub, Inc., Supernova Romeo Merger Sub, LLC and Legacy Rigetti (the Merger Agreement). |
(ii) | the resale of up to 96,941,181 shares of Common Stock (the Selling Stockholder Shares as follows: |
| 14,641,244 shares of Common Stock issued in connection with a private placement pursuant to subscription agreements entered into on October 6, 2021 and December 23, 2021 (the Subscription Agreements); |
| up to 8,625,000 shares of common stock (the Founder Shares) originally issued in a private placement to Supernova Partners II LLC (Supernova Sponsor) pursuant to that certain Sponsor Agreement, dated as of October 6, 2021, by and among Supernova Sponsor, Supernova and Legacy Rigetti, as amended and modified from time to time (the Sponsor Agreement) in connection with the Supernova initial public offering, including 3,059,273 Founder Shares subject to vesting and forfeiture (the Sponsor Vesting Shares); |
| up to 4,450,000 Private Warrant Shares; |
| up to 2,446,716 Assumed Warrant Shares; |
| up to 6,226,065 shares of Common Stock (the Option Shares) issuable upon exercise of outstanding options that were initially granted by Legacy Rigetti and assumed by the Company and converted into options to purchase Common Stock pursuant to the Merger Agreement; |
| up to 6,288,369 shares of Common Stock (the RSU Shares) issuable upon the settlement of restricted stock units assumed by the Company and converted into restricted stock units with respect to Common Stock. |
| 54,263,787 shares of Common Stock issued pursuant to the Merger Agreement; and |
(iii) | the resale of up to 4,450,000 Private Warrants (the Resale Warrants). |
The Warrants were issued pursuant to a Warrant Agreement, dated March 1, 2021, between the Company and American Stock Transfer & Trust Company, LLC, as warrant agent (Warrant Agreement).
In connection with this opinion, we have examined and relied upon (a) the Registration Statement and the Prospectus, (b) the Companys certificate of incorporation and bylaws, each as currently in effect, (c) the Warrant Agreement, (d) the Subscription Agreements, (e) the Sponsor Agreement; (f) the Merger Agreement and (g) originals or copies certified to our satisfaction of such opinions, records, documents, certificates, memoranda and other instruments as in our judgment are necessary or appropriate to enable us to render the opinion expressed below. We have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals, the conformity to originals of all documents submitted to us as copies, the accuracy, completeness and authenticity of certificates of public officials and the due authorization, execution and delivery of all documents by all persons other than the Company where due authorization, execution and delivery are prerequisites to the effectiveness thereof. As to certain factual matters, we have relied upon a certificate of an officer of the Company and have not independently verified such matters.
We note that the Company was initially incorporated under the laws of the Cayman Islands and was domesticated as a corporation in the State of Delaware in accordance with Section 388 of the DGCL (the Domestication). We have assumed all matters determinable under the laws of the Cayman Islands, including without limitation that (i) immediately prior to the Domestication, the Company was duly organized, validly existing and in good standing under the laws of the Cayman Islands, (ii) the Company had full power, authority and legal right to domesticate in the State of Delaware pursuant to Section 388, (iii) the laws of the Cayman Islands permitted the Company to domesticate in the State of Delaware pursuant to Section 388, (iv) the discontinuation of the Company from the Cayman Islands was duly authorized by all necessary corporate action as provided in its governing documents and was duly effected in accordance with Cayman Islands law, (v) any and all consents, approvals and authorizations from applicable Cayman Island governmental authorities required to authorize and permit the Company to domesticate in the State of Delaware pursuant to Section 388 were obtained, and (vi) the issued and outstanding ordinary shares of the Company as an exempted company incorporated under the laws of the Cayman Islands immediately prior to the Domestication were validly issued, fully paid and nonassessable, and (vii) all share issuances and documents related thereto that were authorized by the Company prior to the Domestication, including those to be effected pursuant to or in connection with the Warrants, the Subscription Agreements, the Sponsor Agreement and the Merger Agreement were done in accordance with the applicable governing documents of the Company as a Cayman Islands exempted company and the laws of the Cayman Islands.
Rupa Briggs Cooley LLP 55 Hudson Yards New York, NY 10001-2157
t: (212) 479-6000 f: (212) 479-6000 cooley.com
Our opinion is expressed only with respect to the General Corporation Law of the State of Delaware and the laws of the State of New York. We express no opinion to the extent that any other laws are applicable to the subject matter hereof and express no opinion and provide no assurance as to compliance with any federal or state securities law, rule or regulation.
With respect to the Warrants, the Warrant Shares, the Assumed Warrants and the Assumed Warrant Shares, we express no opinion to the extent that future issuances of securities of the Company, including the Warrant Shares and the Assumed Warrant Shares and/or antidilution adjustments to outstanding securities of the Company, including the Warrants and the Assumed Warrants, may cause the number of Warrant Shares issuable upon exercise of the Warrants or the number of Assumed Warrant Shares issuable upon exercise of the Assumed Warrants to be greater than the number of shares of Common Stock that then remain authorized but unissued. Further, we have assumed the exercise prices of the Warrants and the Assumed Warrants will not be adjusted to an amount below the par value per share of Common Stock.
With regard to our opinion concerning the Resale Warrants constituting valid and binding obligations of the Company:
(i) Our opinion is subject to, and may be limited by, (a) applicable bankruptcy, reorganization, insolvency, moratorium, fraudulent conveyance, debtor and creditor, and similar laws which relate to or affect creditors rights generally, and (b) general principles of equity (including, without limitation, concepts of materiality, reasonableness, good faith and fair dealing) regardless of whether considered in a proceeding in equity or at law.
(ii) Our opinion is subject to the qualification that the availability of specific performance, an injunction or other equitable remedies is subject to the discretion of the court before which the request is brought.
(iii) We express no opinion as to any provision of the Warrants that: (a) provides for liquidated damages, buy-in damages, monetary penalties, prepayment or make-whole payments or other economic remedies to the extent such provisions may constitute unlawful penalties, (b) relates to advance waivers of claims, defenses, rights granted by law, or notice, opportunity for hearing, evidentiary requirements, statutes of limitations, trial by jury, or procedural rights, (c) restricts non-written modifications and waivers, (d) provides for the payment of legal and other professional fees where such payment is contrary to law or public policy, (e) relates to exclusivity, election or accumulation of rights or remedies, (f) authorizes or validated conclusive or discretionary determinations, or (g) provides that provisions of the Warrants are severable to the extent an essential part of the agreed exchange is determined to be invalid and unenforceable.
(iv) We express no opinion as to whether a state court outside of the State of New York or a federal court of the United States would give effect to the choice of New York law provided for in the Warrants.
On the basis of the foregoing, and in reliance thereon, we are of the opinion that:
1. | The Warrant Shares and the Assumed Warrant Shares, when issued and paid for upon exercise of the Warrants or the Assumed Warrants, as applicable, in accordance with the terms of the Warrants or the Assumed Warrants, as applicable, will be validly issued, fully paid and nonassessable. |
2. | The Resale Warrants constitute valid and binding obligations of the Company. |
3. | The Selling Stockholder Shares, other than any Private Warrant Shares, Sponsor Vesting Shares, Assumed Warrant Shares, Option Shares or RSU Shares included in the Selling Stockholder Shares, are validly issued, fully paid and nonassessable. Any Private Warrant Shares, Assumed Warrant Shares, Option Shares or RSU Shares included in the Selling Stockholder Shares, when issued and, if applicable, paid for in accordance with the terms of the Private Warrants, the Assumed Warrants, the Stock Options or the RSUs, will be validly issued, fully paid and nonassessable. The Sponsor Vesting Shares have been validly issued and are nonassessable and, when the conditions to vesting stated in the Sponsor Agreement have been satisfied, will be fully paid and no longer subject to forfeiture. |
Rupa Briggs Cooley LLP 55 Hudson Yards New York, NY 10001-2157
t: (212) 479-6000 f: (212) 479-6000 cooley.com
Our opinion is limited to the matters stated herein and no opinion is implied or may be inferred beyond the matters expressly stated. Our opinion is based on these laws as in effect on the date hereof, and we disclaim any obligation to advise you of facts, circumstances, events or developments which hereafter may be brought to our attention and which may alter, affect or modify the opinion expressed herein.
We hereby consent to the filing of this opinion as an exhibit to the Registration Statement and to the reference to our firm under the caption Legal Matters in the Prospectus.
[signature page follows]
Rupa Briggs Cooley LLP 55 Hudson Yards New York, NY 10001-2157
t: (212) 479-6000 f: (212) 479-6000 cooley.com
Very truly yours,
COOLEY LLP | ||
By: | /s/ Rupa Briggs | |
Rupa Briggs |
Rupa Briggs Cooley LLP 55 Hudson Yards New York, NY 10001-2157
t: (212) 479-6000 f: (212) 479-6000 cooley.com
Exhibit 10.30
EXECUTIVE EMPLOYMENT AGREEMENT
This EXECUTIVE EMPLOYMENT AGREEMENT dated as of March 14, 2022 (Agreement) is by and between Greg Peters (Executive) and RIGETTI COMPUTING, INC. (the Company).
WHEREAS, Executive is employed by the Company as its Chief Revenue Officer;
WHEREAS, the Company desires to employ Executive on and following the Effective Date (as defined below) and provide Executive with certain compensation and benefits in return for Executives services, and Executive agrees to be employed by the Company in such capacity and to receive the compensation and benefits on the terms and conditions set forth herein; and
NOW, THEREFORE, in consideration of the mutual promises and covenants contained herein, the parties agree to the following:
1. Employment by the Company.
1.1 Contingent on Transaction. The effective date (Effective Date) of the employment terms in this Agreement shall be contingent upon and concurrent with the Closing Date as defined in that certain Agreement and Plan of Merger, dated October 6, 2021, by and among the Company, Supernova Partners Acquisition Company II, Ltd., Supernova Merger Sub, Inc. and Supernova Romeo Merger Sub, LLC (the Merger Agreement) and, contingent on occurrence of the Closing Date, the terms of this Agreement shall supersede and replace the prior offer letter in effect between Company and Executive as of the Effective Date. If the transactions contemplated by the Merger Agreement do not close, this Agreement shall have no effect and shall terminate as of the termination of the Merger Agreement, and neither the Company nor the Executive shall have obligations hereunder. Capitalized terms used herein and not otherwise defined shall have the meanings set forth in the Merger Agreement.
1.2 Position. Subject to the terms set forth herein, the Company agrees to employ Executive in the position of Chief Revenue Officer, and Executive hereby accepts such continued employment on the terms and conditions set forth in this Agreement.
1.3 Duties. As Chief Revenue Officer, Executive will report to the Chief Executive Officer of the Company (the CEO), performing such duties as are normally associated with the position and such duties as are assigned from time to time, subject to the oversight and direction of the CEO. During calendar year 2022, Executive shall be permitted to work remotely within the United States at Executives discretion. Executive shall make such business trips to such places as may be reasonably necessary or advisable for the efficient operations of the Company.
1.4 Company Policies and Benefits. The employment relationship between the parties shall also be subject to the Companys personnel policies and procedures as they may be interpreted, adopted, revised or deleted from time to time in the Companys sole discretion. Executive will be eligible to participate on the same basis as similarly situated employees in the Companys benefit plans in effect from time to time during Executives employment. All matters of eligibility for coverage or benefits under any benefit plan shall be determined in accordance with the provisions of such plan. The Company reserves the right to change, alter, or terminate any benefit plan in its sole discretion. Notwithstanding the foregoing, in the event that the terms of this Agreement differ from or are in conflict with the Companys general employment policies or practices, this Agreement shall control.
1
1.5 Vacation. While this Agreement is in effect, Executive shall also receive unlimited paid time off subject to the Companys vacation policies and procedures as in effect or amended from time to time.
1.6 Indemnification. Subject to applicable law, Executive will be provided indemnification to the maximum extent permitted by the Companys Certificate of Incorporation or Bylaws, all as amended, including, if applicable, any directors and officers insurance policies, with such indemnification to be on terms determined by the Board or any of its committees. Such indemnification shall be documented in an Indemnification Agreement provided after the Closing Date subject to approval by the Board.
2. Compensation.
2.1 Salary. Executive shall receive for Executives services to be rendered under this Agreement an initial base salary of $334,000 on an annualized basis, subject to review and adjustment by the Company in its sole discretion, payable subject to standard federal and state payroll withholding requirements in accordance with the Companys standard payroll practices (Base Salary).
2.2 Annual Bonus. While this Agreement is in effect, Executive shall be eligible for a discretionary annual cash bonus of a target amount equal to 25% of Base Salary (Target Amount), subject to review and adjustment by the Company in its reasonable discretion, payable subject to standard federal and state payroll withholding requirements. Whether or not Executive earns any bonus will be dependent upon (a) Executives continuous performance of services to the Company through the last date of the applicable performance period, unless otherwise provided for in this Agreement; and (b) the actual achievement by Executive and the Company of the applicable performance targets and goals set by the Board or its Compensation Committee. The annual period over which performance is measured for purposes of this bonus is January 1 through December 31. The Board or its Compensation Committee will determine in its reasonable discretion the extent to which Executive and the Company have achieved the performance goals upon which the bonus is based and the amount of the bonus, which could be above or below the Target Amount (and may be zero). The bonus, if awarded, will be paid no later than March 15 of the calendar year immediately following the calendar year for which the bonus is being measured.
2.3 Equity.
(a) Subject to the approval of the Board or the Compensation Committee of the Board (Compensation Committee), on the effective date of the Companys first filing of an S-8 registration statement with the U.S. Securities and Exchange Commission that occurs following the Closing Date, the Company will grant Executive restricted stock units to acquire 350,000 (the Initial RSU Award). To be eligible for the Initial RSU Award, Executive must still be employed by the Company when the Board or the Compensation Committee grants
2
the Initial RSU Award. The Initial RSU Award will be subject to the terms and conditions of that certain 2022 Equity Incentive Plan (the Plan) and a restricted stock unit award agreement in a form approved by the Company. The Initial RSU Award will vest in accordance with the following schedule: one fourth (1/4th) of the total number of Initial RSU Awards (rounded down) will satisfy time-based vesting on the one-year anniversary of the vesting commencement date and thereafter one-forty eighth (1/48th) of the total number of Initial RSU Awards (rounded down, except for the final scheduled vesting installment) will satisfy time-based vesting each month following the vesting commencement date over a period of four years.
(b) Subject to the approval of the Board or the Compensation Committee, Executive will be eligible for an annual refresh restricted stock unit grant to acquire 102,200 shares of Company common stock (the Refresh RSU Award). To be eligible for the Refresh RSU Award, Executive must still be employed by the Company when the Board or the Compensation Committee grants the Refresh RSU Award. The Refresh RSU Award will be subject to the terms and conditions of the Plan and a restricted stock unit award agreement in a form approved by the Company. The Refresh RSU Award will vest in accordance with the following schedule: one-forty eighth (1/48th) of the total number of Refresh RSU Awards (rounded down, except for the final scheduled vesting installment) will satisfy time-based vesting each month following the vesting commencement date over a period of four years. In the event of a Change in Control (as defined in the Plan), 100% of the then unvested shares subject to the Refresh RSU Award shall vest immediately prior to the consummation of the Change in Control, subject to Executives Continuous Service through such date. In the event that Executive is terminated for Cause, as defined below, the Refresh RSU Award will cease to vest as of the date of termination and the Executive will have no further right, title or interest in the Refresh RSU Award.
(c) Executive is also eligible to receive restricted stock units to acquire shares of Company common stock (the PSU Awards), if certain performance-based milestones established by the Company are satisfied in the future and provided that Executive has remained continuously employed by the Company through the date that the Board or the Compensation Committee grants such PSU Awards. The PSU Awards, if granted, will be issued subject to the terms and conditions of the Plan and a restricted stock unit award agreement in a form satisfactory to the Company and shall vest in accordance with the terms therein.
(d) Executive will also be eligible to receive awards of stock options, restricted stock, restricted stock units or other equity awards pursuant to any plans or arrangements the Company may have in effect from time to time. The Board or a committee of the Board shall determine in its discretion whether Executive shall be granted any such equity awards and the terms of any such award in accordance with the terms of any applicable plan or arrangement that may be in effect from time to time.
2.4 Expense Reimbursement. The Company will reimburse Executive for reasonable business expenses in accordance with the Companys standard expense reimbursement policy, as the same may be modified by the Company from time to time. For the avoidance of doubt, to the extent that any reimbursements payable to Executive are subject to the provisions of Section 409A of the Code: (a) any such reimbursements will be paid no later than December 31 of the year following the year in which the expense was incurred, (b) the amount of expenses reimbursed in one year will not affect the amount eligible for reimbursement in any subsequent year, and (c) the right to reimbursement under this Agreement will not be subject to liquidation or exchange for another benefit.
3
2.5 Healthcare Reimbursement. The Company will reimburse Executive for healthcare expenses for healthcare provided outside the Company provided plan in the amount of $1,250 per month (which includes healthcare cost plus tax gross-up).
3. Confidential Information and Invention Assignment Obligations. As a condition of continued employment, Executive agrees to execute and abide by a Confidential Information and Invention Assignment Agreement attached as Exhibit A (Proprietary Information Agreement), which may be amended by the parties from time to time without regard to this Agreement. The Proprietary Information Agreement contains provisions that are intended by the parties to survive and do survive termination of this Agreement.
4. Outside Activities during Employment. During the term of Executives employment with the Company, Executive will work on a full-time basis for the Company and will devote Executives best efforts and substantially all of Executives business time and attention to the business of the Company. Except with the prior written consent of the CEO, including consent given to Executive prior to the signing of this Agreement as set forth on Exhibit B, Executive will not, while employed by the Company, undertake or engage in any other employment, occupation or business enterprise that would interfere with Executives responsibilities and the performance of Executives duties hereunder except for (i) reasonable time devoted to volunteer services for or on behalf of such religious, educational, non-profit and/or other charitable organization as Executive may wish to serve, (ii) reasonable time devoted to activities in the non-profit and business communities consistent with Executives duties; and (iii) such other activities as may be specifically approved by the Board, and such approval shall not be unreasonably withheld. This restriction shall not, however, preclude Executive (x) from owning less than one percent (1%) of the total outstanding shares of a publicly traded company, or (y) from employment or service in any capacity with Affiliates of the Company. As used in this Agreement, Affiliates means an entity under common management or control with the Company.
5. No Conflict with Existing Obligations. Executive represents that Executives performance of all the terms of this Agreement does not and will not breach any agreement or obligation of any kind made prior to Executives employment by the Company, including agreements or obligations Executive may have with prior employers or entities for which Executive has provided services. Executive has not entered into, and Executive agrees that Executive will not enter into, any agreement or obligation, either written or oral, in conflict herewith.
6. Termination of Employment. The parties acknowledge that Executives employment relationship with the Company is at-will, meaning either the Company or Executive may terminate Executives employment at any time, with or without cause or advance notice. The provisions in this Section govern the amount of compensation, if any, to be provided to Executive upon termination of employment and do not alter Executives at-will status.
4
6.1 Termination by the Company without Cause or for Good Reason.
(a) The Company shall have the right to terminate Executives employment with the Company pursuant to this Section 6.1 at any time, in accordance with Section 6.6, without Cause (as defined in Section 6.3(b) below) by giving notice as described in Section 7.1 of this Agreement. A termination pursuant to Section 6.5 below is not a termination without Cause for purposes of receiving the benefits described in Sections 6.1 or Section 6.2.
(b) If the Company terminates Executives employment at any time without Cause or Executive terminates employment with the Company for Good Reason and provided that such termination constitutes a separation from service (as defined under Treasury Regulation Section 1.409A-1(h), without regard to any alternative definition thereunder, a Separation from Service), then Executive shall be entitled to receive the Accrued Obligations (defined below). If Executive complies with the obligations in Section 6.1(c) below, Executive shall also be eligible to receive the following Severance Benefits:
(i) The Company will pay Executive an amount equal to Executives then current Base Salary for twelve (12) months, less all applicable withholdings and deductions, paid in equal installments on the Companys normal payroll schedule following the termination date, with the first payment beginning on the Severance Pay Commencement Date (as defined in Section 6.1(c) below), and the remaining installments occurring on the Companys regularly scheduled payroll dates thereafter; provided that on the Severance Pay Commencement Date, the Company will pay in a lump sum the aggregate amount of the cash severance payments that the Company would have paid Executive through such date had the payments commenced on the effective date of termination through the Severance Pay Commencement Date.
(ii) If Executive timely elects continued coverage under COBRA for Executive and Executives covered dependents under the Companys group health plans following such termination, then the Company shall pay the COBRA premiums necessary to continue Executives and Executives covered dependents health insurance coverage in effect for Executive (and Executives covered dependents) on the termination date until the earliest of: (i) twelve (12) months following the termination date (the COBRA Severance Period); (ii) the date when Executive becomes eligible for substantially equivalent health insurance coverage in connection with new employment or self-employment; or (iii) the date Executive ceases to be eligible for COBRA continuation coverage for any reason, including plan termination (such period from the termination date through the earlier of (i)-(iii), (the COBRA Payment Period). Notwithstanding the foregoing, if at any time the Company determines that its payment of COBRA premiums on Executives behalf would result in a violation of applicable law (including, but not limited to, the 2010 Patient Protection and Affordable Care Act, as amended by the 2010 Health Care and Education Reconciliation Act), then in lieu of paying COBRA premiums pursuant to this Section, the Company shall pay Executive on the last day of each remaining month of the COBRA Payment Period, a fully taxable cash payment equal to the COBRA premium for such month, subject to applicable tax withholding (such amount, the Special Severance Payment), for the remainder of the COBRA Payment Period. Nothing in this Agreement shall deprive Executive of Executives rights under COBRA or ERISA for benefits under plans and policies arising under Executives employment by the Company.
5
(c) Executive will be paid all of the Accrued Obligations on the Companys first payroll date after Executives date of termination from employment or earlier if required by law. Executive shall receive the Severance Benefits pursuant to Section 6.1(b) or the Change in Control Severance Benefits (defined below) pursuant to 6.2(a) of this Agreement, as applicable, if: (i) Executive executes and does not revoke a separation agreement containing an effective, general release of claims in favor of the Company and its affiliates and representatives but no other post-employment obligations other than an obligation to continue to abide and be bound by any post-employment obligations set forth in agreements previously entered into with the Company or its affiliates, such as this Agreement or any proprietary rights agreement), in a form acceptable to the Company (the Release) and the Release is enforceable and effective as provided in the Release on or before the date that is the sixtieth (60th) day following the effective date of termination (such 60th day, the Severance Pay Commencement Date); (ii) if Executive holds any other positions with the Company, Executive resigns such position(s) to be effective no later than the date of Executives termination date (or such other date as requested by the Board); (iii) Executive returns all Company property on or before the Severance Pay Commencement Date; (iv) Executive complies with Executives post-termination obligations under this Agreement and the Proprietary Information Agreement; and (v) Executive complies with the terms of the Release.
(d) For purposes of this Agreement, Accrued Obligations are (i) Executives accrued but unpaid salary through the date of termination, (ii) any unreimbursed business expenses incurred by Executive payable in accordance with the Companys standard expense reimbursement policies, and (iii) benefits owed to Executive under any qualified retirement plan or health and welfare benefit plan in which Executive was a participant in accordance with applicable law and the provisions of such plan.
(e) The Severance Benefits provided to Executive pursuant to this Section 6.1 are in lieu of, and not in addition to, any benefits to which Executive may otherwise be entitled under any Company severance plan, policy or program.
(f) For purposes of this Agreement, Good Reason shall mean the occurrence of any of the following events without Executives consent: (i) a material reduction in Executives Base Salary, other than a reduction applied in a similar proportional amount to all similarly situated executives; (ii) a material breach of this Agreement by the Company; (iii) a material reduction in the Executives duties, authority and responsibilities relative to the Executives duties, authority, and responsibilities in effect immediately prior to such reduction; (iv) a material change in Executives reporting relationship, other than such change made directly in connection with organizational changes resulting from a Change in Control; or (v) the relocation of Executives principal place of employment, without Executives consent, in a manner that lengthens Executives one-way commute distance by twenty-five (25) or more miles from Executives then-current principal place of employment immediately prior to such relocation; not to include a requirement to return to in-person work as set forth in Section 1.3, in which circumstance Good Reason will not apply; provided, however, that, any such termination by Executive shall only be deemed for Good Reason pursuant to this definition if: (1) Executive gives the Company written notice of Executives intent to terminate for Good Reason within thirty (30) days following the first occurrence of the condition(s) that Executive believes constitute(s) Good Reason, which notice shall describe such condition(s); (2) the Company fails to remedy such condition(s) within thirty (30) days following receipt of the written notice (the Cure Period); and (3) Executive voluntarily terminates employment within thirty (30) days following the end of the Cure Period, or the parties agree in writing to extend such Cure Period.
6
6.2 Termination by the Company without Cause or for Good Reason Coincident with a Change in Control. If Executives employment by the Company is terminated by the Company or any successor entity without Cause (and not due to Disability or death) or by Executive for Good Reason, in either case, within three (3) months prior to or within twelve (12) months following the effective date of a Change in Control (as defined in the Plan), and, in either case, provided that such termination constitutes a Separation from Service, without regard to any alternative definition thereunder, then in addition to paying or providing Executive with the Accrued Obligations, and subject to compliance with Section 6.1(c), the following additional benefits shall be provided in lieu of, and not in addition to, the Severance Benefits provided for in Section 6.1(b) (the Change in Control Severance Benefits):
(a) The Company will pay Executive a lump sum equal to Executives then current annual Base Salary, less all applicable withholdings and deductions, paid on the Severance Pay Commencement Date.
(b) If Executive timely elects continued coverage under COBRA for Executive and Executives covered dependents under the Companys group health plans following such termination, then the Company shall pay the COBRA premiums necessary to continue Executives and Executives covered dependents health insurance coverage in effect for Executive (and Executives covered dependents) on the termination date during the COBRA Payment Period. Notwithstanding the foregoing, if at any time the Company determines that its payment of COBRA premiums on Executives behalf would result in a violation of applicable law (including, but not limited to, the 2010 Patient Protection and Affordable Care Act, as amended by the 2010 Health Care and Education Reconciliation Act), then in lieu of paying COBRA premiums pursuant to this Section, the Company shall pay Executive on the last day of each remaining month of the COBRA Payment Period, the Special Severance Payment, for the remainder of the COBRA Payment Period. Nothing in this Agreement shall deprive Executive of Executives rights under COBRA or ERISA for benefits under plans and policies arising under Executives employment by the Company.
(c) The Company will pay a bonus equivalent to a pro rata share of Executives full Target Amount, for the portion of the performance year completed when Executives termination occurs. This bonus will be payable subject to standard federal and state payroll withholding requirements in a lump sum payment on the Severance Pay Commencement Date.
(d) Notwithstanding the terms of any equity plan or award agreement to the contrary, the time-based vesting conditions applicable to 100% of Executives then outstanding stock options and/or other equity awards subject to time-based vesting requirements as of Executives termination date shall be accelerated as of the date of termination, and, with respect to any performance-based equity awards, and unless otherwise provided by the applicable award agreement, any performance-based vesting objectives will be deemed achieved at the higher of target or actual performance.
7
6.3 Termination by the Company for Cause.
(a) The Company shall have the right to terminate Executives employment with the Company at any time, in accordance with Section 6.6, for Cause by giving notice as described in Section 7.1 of this Agreement. In the event Executives employment is terminated at any time for Cause, Executive will not receive Severance Benefits, Change in Control Severance Benefits, or any other severance compensation or benefits, except that, pursuant to the Companys standard payroll policies, the Company shall pay to Executive the Accrued Obligations.
(b) Cause for termination shall mean that the Company has determined in its sole discretion that Executive has engaged in any of the following: (i) Executives material breach of any covenant or condition under this Agreement or any other agreement between the parties; (ii) Executives material act constituting dishonesty or fraudulent conduct in connection with Executives duties to the Company; (iii) any conduct which constitutes a felony or a crime of moral turpitude under applicable law; (iv) material violation of any Company policy; (v) refusal to follow or implement a clear and reasonable directive of Company, or any act of willful or intentional misconduct in relation to the Executives duties to the Company; (vi) repeated or willful failure by Executive to perform Executives duties in a manner satisfactory to the Company; or (vii) Executives breach of fiduciary duty to the Company; provided that Sections 6.3(b)(i), (iv) and (vi) shall only provide the basis for a Cause termination if the Executive has not cured such breach, violation or conduct, to the extent curable, after the expiration of ten (10) days following the Company providing Executive with written notice of such basis for Cause.
6.4 Resignation by Executive.
(a) Executive may resign from Executives employment with the Company at any time, in accordance with Section 6.6, by giving notice as described in Section 7.1.
(b) In the event Executive resigns from Executives employment with the Company for any reason other than Good Reason in accordance with Sections 6.1 or 6.2, Executive will not receive Severance Benefits, Change in Control Severance Benefits, or any other severance compensation or benefits, except that, pursuant to the Companys standard payroll policies, the Company shall pay to Executive the Accrued Obligations.
6.5 Termination by Virtue of Death or Disability of Executive.
(a) In the event of Executives death while employed pursuant to this Agreement, all obligations of the parties hereunder shall terminate, in accordance with Section 6.6, and the Company shall, pursuant to the Companys standard payroll policies, pay to Executives legal representatives all Accrued Obligations.
(b) Subject to applicable state and federal law, the Company shall at all times have the right, upon written notice to Executive, and in accordance with Section 6.6, to terminate Executives employment based on Executives Disability. Termination by the Company of Executives employment based on Disability shall mean termination because Executive is unable due to a physical or mental condition to perform the essential functions of Executives
8
position with or without reasonable accommodation for 180 days in the aggregate during any twelve (12) month period or based on the written certification by two licensed physicians of the likely continuation of such condition for such period. This definition shall be interpreted and applied consistent with the Americans with Disabilities Act, the Family and Medical Leave Act, and other applicable federal, state or local law. In the event Executives employment is terminated by the Company based on Executives Disability or Executive voluntarily resigns due to such Disability, Executive will not receive Severance Benefits, Change in Control Severance Benefits, or any other severance compensation or benefit, except that, pursuant to the Companys standard payroll policies, the Company shall pay to Executive the Accrued Obligations.
6.6 Notice; Effective Date of Termination.
(a) Termination of Executives employment pursuant to this Agreement shall be effective on the earliest of:
(i) immediately after the Company gives notice to Executive of Executives termination, with or without Cause, unless pursuant to Section 6.3(b)(i), if curable, or Section 6.3(b)(vi), in which case ten (10) days after notice if not cured or unless the Company specifies a later date, in which case, termination shall be effective as of such later date;
(ii) immediately upon the Executives death;
(iii) ten (10) days after the Company gives notice to Executive of Executives termination on account of Executives Disability, unless the Company specifies a later date, in which case, termination shall be effective as of such later date, provided that Executive has not returned to the full-time performance of Executives duties prior to such date;
(iv) ten (10) days after the Executive gives written notice to the Company of Executives resignation, provided that the Company may set a termination date at any time between the date of notice and the date of resignation, in which case the Executives resignation shall be effective as of such other date. Executive will receive compensation through any required notice period; or
(v) for a termination for Good Reason, immediately upon Executives full satisfaction of the requirements of Section 6.1(f).
(b) In the event of a termination for Cause, written confirmation shall specify the subsection(s) of the definition of Cause relied on to support the decision to terminate.
6.7 Cooperation with Company after Termination of Employment. Following termination of Executives employment for any reason, Executive agrees to provide reasonable cooperation to the Company in connection with its actual or contemplated defense, prosecution, or investigation of any claims or demands by or against third parties, or other matters arising from events, acts, or failures to act that occurred during the period of Executives employment by the Company. Such cooperation includes, without limitation, making Executive available to the Company upon reasonable notice, without subpoena, to provide complete, truthful and accurate information in witness interviews, depositions and trial testimony. The Company will reimburse Executive for reasonable out-of-pocket expenses Executive incurs in connection with
9
any such cooperation (excluding forgone wages, salary, or other compensation) and will make reasonable efforts to accommodate Executives scheduling needs and for more than de minimis service, the parties will agree on a mutually agreeable per diem rate. In addition, in the event Executive is receiving Severance Benefits or Change in Control Severance Benefits, for twelve (12) months after Executives employment with the Company ends for any reason, Executive agrees to reasonably cooperate with the Company in all matters relating to the transition of Executives work and responsibilities on behalf of the Company, including, but not limited to, any present, prior or subsequent relationships and the orderly transfer of any such work and institutional knowledge to such other persons as may be designated by the Company. Such transition assistance described in the previous sentence shall not be subject to additional compensation, and the Company will make reasonable efforts to accommodate Executives scheduling needs.
6.8 Application of Section 409A. It is intended that all of the severance payments payable under this Agreement satisfy, to the greatest extent possible, the exemptions from the application of Section 409A of the Code and the regulations and other guidance thereunder and any state law of similar effect (collectively, Section 409A) provided under Treasury Regulations Sections 1.409A-1(b)(4) and 1.409A-1(b)(9), and this Agreement will be construed in a manner that complies with Section 409A. If not so exempt, this Agreement (and any definitions hereunder) will be construed in a manner that complies with Section 409A, and incorporates by reference all required definitions and payment terms. No severance payments will be made under this Agreement unless Executives termination of employment constitutes a separation from service (as defined under Treasury Regulation Section 1.409A-1(h)). For purposes of Section 409A (including, without limitation, for purposes of Treasury Regulations Section 1.409A-2(b)(2)(iii)), Executives right to receive any installment payments under this Agreement (whether severance payments or otherwise) shall be treated as a right to receive a series of separate payments and, accordingly, each installment payment hereunder shall at all times be considered a separate and distinct payment. If the Company determines that the severance benefits provided under this Agreement constitutes deferred compensation under Section 409A and if Executive is a specified employee of the Company, as such term is defined in Section 409A(a)(2)(B)(i) of the Code at the time of Executives Separation from Service, then, solely to the extent necessary to avoid the incurrence of the adverse personal tax consequences under Section 409A, the timing of the Severance will be delayed as follows: on the earlier to occur of (a) the date that is six months and one day after Executives Separation from Service, and (b) the date of Executives death (such earlier date, the Delayed Initial Payment Date), the Company will (i) pay to Executive a lump sum amount equal to the sum of the severance benefits that Executive would otherwise have received through the Delayed Initial Payment Date if the commencement of the payment of the severance benefits had not been delayed pursuant to this Section 6.8 and (ii) commence paying the balance of the severance benefits in accordance with the applicable payment schedule set forth in Section 6. No interest shall be due on any amounts deferred pursuant to this Section 6.8. To the extent that any Severance Benefits are deferred compensation under Section 409A of the Code, and are not otherwise exempt from the application of Section 409A, then, if the period during which Executive may consider and sign the Release spans two calendar years, the payment of any such Severance Benefit will not be made or begin until the later calendar year.
10
6.9 Section 280G. Notwithstanding any other provision of this Agreement to the contrary, if payments made or benefits provided pursuant to this Agreement or otherwise from the Company or any person or entity are considered parachute payments under Section 280G of the Code after the application of all exemptions available under Code Section 280G(b)(5)(A), then such parachute payments will be limited to the greatest amount that may be paid to Executive under Section 280G of the Code without causing any loss of deduction to the Company Group under such section, but only if, by reason of such reduction, the net after tax benefit to Executive will exceed the net after tax benefit if such reduction were not made. Net after tax benefit for purposes of this Agreement will mean the sum of (i) the total amounts payable to the Executive under this Agreement, plus (ii) all other payments and benefits which the Executive receives or then is entitled to receive from the Company or otherwise that would constitute a parachute payment within the meaning of Section 280G of the Code, less (iii) the amount of federal, state and local taxes payable with respect to the foregoing calculated at the maximum marginal income tax rate for each year in which the foregoing will be paid to Executive (based upon the rate in effect for such year as set forth in the Code at the time of termination of Executives employment), less (iv) the amount of excise taxes imposed with respect to the payments and benefits described in (i) and (ii) above by Section 4999 of the Code. The determination as to whether and to what extent payments are required to be reduced in accordance with this Section 6.9 will be made at the Companys expense by a nationally recognized certified public accounting firm or other professional services firm, in either case, as may be designated by the Company prior to a change in control (the Firm). In the event of any mistaken underpayment or overpayment under this Agreement, as determined by the Firm, the amount of such underpayment or overpayment will forthwith be paid to Executive or refunded to the Company, as the case may be, with interest at one hundred twenty (120%) of the applicable Federal rate provided for in Section 7872(f)(2) of the Code. Any reduction in payments required by this Section 6.9 will occur in the following order: (1) any cash severance, (2) cancellation of equity awards being taken into account at full value that were granted contingent on a change in ownership or control within the meaning of 280G of the Code in the reverse order of date of grant of the awards (that is, the most recently granted equity awards will be cancelled first); (3) any other cash amount payable to Executive, (4) any benefit valued as a parachute payment, (5) the acceleration of vesting of any equity awards that are options, and (6) the acceleration of vesting of any other equity awards. Within any such category of payments and benefits, a reduction will occur first with respect to amounts that are not deferred compensation within the meaning of Section 409A and then with respect to amounts that are. In the event that acceleration of compensation from equity awards is to be reduced, such acceleration of vesting will be canceled, subject to the immediately preceding sentence, in the reverse order of the date of grant.
7. General Provisions.
7.1 Notices. Any notices hereunder must be in writing and shall be deemed effectively given: (a) upon personal delivery to the party to be notified, (b) when sent by electronic mail if sent during normal business hours of the recipient, and if not, then on the next business day, (c) five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (d) one (1) business day after timely deposit for next-business-day delivery with a nationally recognized overnight courier, specifying next-business-day delivery, with written verification of receipt. All communications shall be sent to the Company at its primary office location, or to legal@rigetti.com, and to Executive at either Executives address as listed on the Company payroll records, or Executives Company-issued email address, or at such other address as the Company or Executive may designate by ten (10) days advance written notice to the other.
11
7.2 Severability. Whenever possible, each provision of this Agreement will be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability will not affect any other provision or any other jurisdiction, but this Agreement will be reformed, construed and enforced in such jurisdiction as if such invalid, illegal or unenforceable provisions had never been contained herein.
7.3 Survival. Provisions of this Agreement which by their terms must survive the termination of this Agreement in order to effectuate the intent of the parties will survive any such termination for such period as may be appropriate under the circumstances.
7.4 Waiver. If either party should waive any breach of any provisions of this Agreement, it shall not thereby be deemed to have waived any preceding or succeeding breach of the same or any other provision of this Agreement.
7.5 Complete Agreement. This Agreement constitutes the entire agreement between Executive and the Company with regard to the subject matter hereof. This Agreement is the complete, final, and exclusive embodiment of their agreement with regard to this subject matter and supersedes any prior oral discussions or written communications and agreements, including the Prior Agreement. This Agreement is entered into without reliance on any promise or representation other than those expressly contained herein, and it cannot be modified or amended except in writing signed by Executive and an authorized officer of the Company. The parties have entered into a separate Proprietary Information Agreement and have or may enter into separate agreements related to equity. These separate agreements govern other aspects of the relationship between the parties, have or may have provisions that survive termination of Executives employment under this Agreement, may be amended or superseded by the parties without regard to this Agreement and are enforceable according to their terms without regard to the enforcement provision of this Agreement.
7.6 Counterparts. This Agreement may be executed in separate counterparts, any one of which need not contain signatures of more than one party, but all of which taken together will constitute one and the same Agreement. The parties agree that facsimile and scanned image copies of signatures, including DocuSign, will suffice as original signatures.
7.7 Withholding Taxes. The Company will be entitled to withhold from any payment due to Executive hereunder any amounts required to be withheld by applicable tax laws or regulations.
7.8 Headings. The headings of the sections hereof are inserted for convenience only and shall not be deemed to constitute a part hereof nor to affect the meaning thereof.
7.9 Successors and Assigns. The Company shall assign this Agreement and its rights and obligations hereunder in whole, but not in part, to any Company or other entity with or into which the Company may hereafter merge or consolidate or to which the Company may transfer all or substantially all of its assets, if in any such case said Company or other entity shall by operation of law or expressly in writing assume all obligations of the Company hereunder as fully as if it had been originally made a party hereto, but may not otherwise assign this Agreement or its rights and obligations hereunder. Executive may not assign or transfer this Agreement or any rights or obligations hereunder, other than to Executives estate upon Executives death.
12
7.10 Choice of Law. All questions concerning the construction, validity and interpretation of this Agreement will be governed by the laws of the State of California.
7.11 Dispute Resolution. The parties recognize that litigation in federal or state courts or before federal or state administrative agencies of disputes arising out of the Executives employment with the Company or out of this Agreement, or the Executives termination of employment or termination of this Agreement, may not be in the best interests of either the Executive or the Company, and may result in unnecessary costs, delays, complexities, and uncertainty. Except where prohibited by law, the parties agree that any dispute between the parties arising out of or relating to the negotiation, execution, performance or termination of this Agreement or the Executives employment, including, but not limited to, any claim arising out of this Agreement, claims under Title VII of the Civil Rights Act of 1964, as amended, the Civil Rights Act of 1991, the Age Discrimination in Employment Act of 1967, the Americans with Disabilities Act of 1990, Section 1981 of the Civil Rights Act of 1966, as amended, the Family Medical Leave Act, the Executive Retirement Income Security Act, and any similar federal, state or local law, statute, regulation, or any common law doctrine, whether that dispute arises during or after employment, shall be settled by binding arbitration in accordance with the National Rules for the Resolution of Employment Disputes of the American Arbitration Association. The location for the arbitration shall be in Alameda County, California. Any award made by such panel shall be final, binding and conclusive on the parties for all purposes, and judgment upon the award rendered by the arbitrators may be entered in any court having jurisdiction thereof. The arbitrators fees and expenses and all administrative fees and expenses associated with the filing of the arbitration shall be borne by the Company; provided however, that at the Executives option, Executive may voluntarily pay up to one-half the costs and fees. The parties acknowledge and agree that their obligations to arbitrate under this Section survive the termination of this Agreement and continue after the termination of the employment relationship between Executive and the Company. The parties each further agree that the arbitration provisions of this Agreement shall provide each party with its exclusive remedy, and each party expressly waives any right it might have to seek redress in any other forum, except as otherwise expressly provided in this Agreement. By election arbitration as the means for final settlement of all claims, the parties hereby waive their respective rights to, and agree not to, sue each other in any action in a Federal, State or local court with respect to such claims, but may seek to enforce in court an arbitration award rendered pursuant to this Agreement. The parties specifically agree to waive their respective rights to a trial by jury, and further agree that no demand, request or motion will be made for trial by jury.
[SIGNATURES TO FOLLOW ON NEXT PAGE]
13
IN WITNESS WHEREOF, the parties have duly executed this Agreement as of the date first above written.
RIGETTI HOLDINGS, INC. | ||
By: | /s/ Chad Rigetti | |
Name: Chad Rigetti | ||
Title: CEO |
EXECUTIVE |
/s/ Greg Peters |
Greg Peters |
[SIGNATURE PAGE TO EXECUTIVE EMPLOYMENT AGREEMENT]
Exhibit B
Approved Activities
15
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
Rigetti Computing, Inc.
Berkeley, California
We hereby consent to the use in the Prospectus constituting a part of this Registration Statement of our report dated March 7, 2022, relating to the consolidated financial statements of Rigetti Holdings, Inc., which is contained in that Prospectus.
We also consent to the reference to us under the caption Experts in the Prospectus.
/s/ BDO USA, LLP
Spokane, Washington
March 23, 2022
Exhibit 23.2
INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRMS CONSENT
We consent to the inclusion in this Registration Statement of Rigetti Computing, Inc. on Form S-1 of our report dated February 23, 2022, with respect to our audits of the consolidated financial statements of Supernova Partners Acquisition Company II, Ltd. as of December 31, 2021 and 2020, and for the year ended December 31, 2021 and for the period from December 22, 2020 (inception) through December 31, 2020, which includes an explanatory paragraph as to the Companys ability to continue as a going concern, which report appears in the Prospectus, which is part of this Registration Statement. We also consent to the reference to our Firm under the heading Experts in such Prospectus.
We were dismissed as auditors on March 7, 2022 and, accordingly, we have not performed any audit or review procedures with respect to any financial statements appearing in such Prospectus for the periods after the date of our dismissal.
/s/ Marcum LLP
Marcum LLP
Costa Mesa, CA
March 23, 2022
Exhibit 107
Calculation of Filing Fee Tables
Form S-1
(Form Type)
Rigetti Computing, Inc.
(Exact Name of Registrant as Specified in its Charter)
Table 1: Newly Registered and Carry Forward Securities
Security Type
|
Security Class Title
|
Fee Calculation or Carry Forward Rule
|
Amount Registered (1)
|
Proposed Maximum Offering Price Per Unit
|
Maximum Aggregate Offering Price
|
Fee Rate
|
Amount of Registration Fee
| |||||||||
Fees to Be Paid
|
Equity
|
Common Stock, par value $0.0001 per share |
457(g) |
13,074,972 (2) |
$11.50 (6) |
$150,362,178.00 |
0.0000927 |
$13,938.58 | ||||||||
Fees to Be Paid
|
Equity
|
Common Stock, par value $0.0001 per share |
457(c) |
6,279,087 (3) |
$6.16 (7) |
$38,679,175.92 |
0.0000927 |
$3,585.56 | ||||||||
Fees to Be Paid
|
Equity
|
Common Stock, par value $0.0001 per share |
457(c) |
96,941,181 (4) |
$6.16 (7) |
$597,157,675.00 |
0.0000927 |
$55,356.52 | ||||||||
Fees to Be Paid
|
Equity
|
Warrants to purchase shares of common stock |
457(i) |
4,450,000 (5) |
(8) |
(8) |
|
(8) | ||||||||
Total Offering Amounts
|
$786,199,028.88 |
|||||||||||||||
Total Fees Previously Paid
|
|
|||||||||||||||
Total Fee Offsets
|
|
|||||||||||||||
Net Fee Due
|
$72,880.65 |
(1) | In the event of a stock split, stock dividend or other similar transaction involving the registrants common stock, in order to prevent dilution, the number of shares of common stock registered hereby shall be automatically increased to cover the additional shares of common stock in accordance with Rule 416(a) under the Securities Act. |
(2) | Consists of up to 13,074,972 shares of common stock, consisting of up to: (i) 4,450,000 shares of common stock that may be issued upon the exercise of 4,450,000 warrants (the private placement warrants) originally issued in a private placement in connection with the initial public offering of Supernova Partners Acquisition Company II, Ltd. (Supernova), by the holders thereof, at an exercise price of $11.50 per share, subject to adjustment, and (ii) 8,624,972 shares of common stock that may be issued upon the exercise of 8,624,972 warrants (the public warrants), originally issued in the initial public offering of Supernova, by holders thereof, at an exercise price of $11.50 per share, subject to adjustment. |
(3) | Consists of up to 6,279,087 shares of common stock that may be issued upon the exercise of warrants assumed by Rigetti Computing, Inc. and converted into warrants to purchase common stock (the Rigetti assumed warrants) in connection with the Business Combination, at a weighted average exercise price of $0.6628 per share. |
(4) | Consists of up to 96,941,181 shares of common stock being registered for resale by the selling securityholders named in this registration statement consisting of up to: (i) 14,641,244 shares of common stock purchased by subscribers in a private placement pursuant to separate subscription agreements, (ii) 8,625,000 shares of common stock (the founder shares) originally issued in a private placement to Supernova Partners II LLC in connection with the initial public offering of Supernova, (iii) 4,450,000 shares of common stock issuable upon exercise of the private placement warrants, (iv) 2,446,716 shares of common stock issuable pursuant to the exercise of Rigetti assumed warrants, (v) 6,226,065 shares of common stock issuable upon exercise of outstanding options, (vi) 6,288,369 shares of common stock issuable in connection with the vesting and settlement of outstanding restricted stock units, and (vii) 54,263,787 shares of common stock issued in connection with the Business Combination. |
(5) | Represents the resale of 4,450,000 private placement warrants. |
(6) | Calculated pursuant to Rule 457(g) under the Securities Act, based on the $11.50 exercise price per share of common stock issuable upon exercise of the public warrants and private placement warrants. |
(7) | Estimated solely for the purpose of calculating the registration fee in accordance with Rule 457(c) under the Securities Act. The price per share and aggregate offering price are based on the average of the high and low prices of the registrants common stock on March 16, 2022, as reported on the Nasdaq Capital Market. |
(8) | In accordance with Rule 457(g), the entire registration fee for the private placement warrants is allocated to the shares of common stock underlying the private placement warrants, and no separate fee is payable for the private placement warrants. |